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Abstract
The detection of the infectious agents responsible for prion diseases remains problematic. 
The unusual nature of this infectious agent means that it is not inactivated by standard 
decontamination and sterilisation processes and there is evidence of transmission through 
blood transfusion. There is an urgent requirement for an assay to provide reliable 
validation of novel decontamination processes and a sensitive test for screening of blood 
donations and diagnosis of patients.
This research project aimed to address these problems, by the development of a novel 
ultra-sensitive detection method based on a thermostable adenylate kinase (tAK) antibody 
label coupled to ATP-bioluminescence. Utilisation of thermostability of AK enabled 
inclusion of background reducing heat steps within the format therefore enabling detection 
of specific antigen within a background of proteins.
The thesis describes development o f the methodology from  initial model assay to 
identification and production o f a suitable recombinant tAK. An attempt to produce 
sensitive anti-prion polyclonal antiserum is also described. Finally, the use of the 
monoclonal antibody 6H4 (Prionics) labelled with tAK via a cleavable linker to establish 
limits of detection of the assay is described and established as 15 pg.mL"1 of rec PrP using 
a fully optimised assay (670 fM). Sensitive detection of rec PrP within relevant biological 
substrates was also shown, along with some detection of infectious BSE (301V) MBH. 
There was also some evidence o f detection on the surface of surgical grade stainless steel.
The use of this AK-ELISA is discussed within current scientific knowledge and 
specifically the continuing lack of available sensitive assay. The sensitivity achieved using
this assay format was ultimately not sufficient to address this requirement, however the 
developed detection methodology has the flexibility to be coupled to new emerging 
technologies or disease specific antibodies, to provide an immediate increase in sensitivity 
in answer to this continuing need.
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1 Literature Review
1.1 Transmissible spongiform encephalopathies (TSEs)
Transmissible spongiform encephalopathies (TSEs) are a family of related 
neurodegenerative disorders which affect numerous animal species in addition to humans. 
The animal forms of disease include Bovine Spongiform Encephalopathy (BSE) in cattle, 
Feline Spongiform Encephalopathy (FSE) in cats, Mink Spongiform Encephalopathy, 
scrapie in sheep and Chronic Wasting Disease in deer. The human forms of these diseases 
include Creutzfeldt-Jakob disease (CJD), Kuru, Gerstmann-Straussler-Scheinker disease 
(GSS) and fatal familial insomnia (FFI) and all these disorders are invariably fatal and 
associated with a range of clinical and pathological presentations (Collinge 2001; Prusiner 
1998; reviewed by Wadsworth & Collinge 2007). The human forms of these diseases have 
a diverse range of clinical presentation however they all exhibit long incubation periods of 
months or in some instances years without any symptoms of infection or immune response.
1.1.1 Prions
It has been widely accepted that TSEs are caused by a unique infectious agent, which has 
no nucleic acid and appears composed only of protein and which has been termed a prion. 
The prion hypothesis was proposed originally by Stanley Prusiner (Prusiner 1982), but 
there is still considerable debate surrounding this theory (Chesebro 2003). This group of 
diseases are associated with the formation of a protease resistant form (PrPSc) of a normal 
cellular protein (PrPc), which is a 30-35 kDa glycoprotein found in most cells (Collinge 
2001; Prusiner 1998). The normal form of the cellular protein PrPc has a structure mainly
composed o f alpha-helices with a lesser beta-pleated sheet content. The abnormal form 
PrPSc is characterised by the presence of a large p-sheet content and which results in the 
aggregation of the abnormal prion protein in the brain leading to spongiform changes 
(Prusiner 1998).
The prion hypothesis proposes that it is this abnormal protein molecule that is the 
infectious agent and is able to cause conversion of PrPc to the abnormal PrPSc. TSEs are 
associated with increased resistance of the protein molecule to protease digestion which 
results in a characteristic banding pattern on SDS-PAGE and Western blotting analysis. 
The resulting distinctive patterns can be used to differentiate between different strains of 
disease. The use of Western blot technique confirms immunoreactivity of the material after 
protease digestion and therefore verifies the presence of the putative disease associated 
isoform PrPSc. PrPc protein is encoded by a single gene and it has been found that a 
polymorphism at codon 129 for methionine or valine has been associated with differing 
susceptibility to prion diseases (Bishop et al., 2006). Methionine homozygosity is 
associated with reduced incubation period o f many forms of CJD in general and very 
specifically with variant CJD (vCJD). These diseases are relatively rare and affect 
approximately one person per million of the population and the human forms of the disease 
can be categorised as sporadic, inherited, or acquired in presentation (Prusiner 1998).
1.1.2 Sporadic CJD
Sporadic CJD (sCJD) is the most common of the human forms and approximately 85% of 
cases fall into this category with an occurrence rate at about 1 -2 cases per million of the 
population (reviewed by Wadsworth & Collinge 2007). The onset of the sporadic form of 
the disease is generally between the ages of 45-75 with the median age of death occurring
at 68 years and the clinical presentation tends to be associated with a rapid progression and 
short duration of ~5 months, although atypical forms of the disease with longer duration of 
illness have been recognised. The origins of this form of CJD are unclear and no specific 
mutation has been associated with it (Prusiner 1997) and there are a number of different 
hypotheses. Spontaneous mutation of normal PrPc to the abnormal isoform PrPSc has been 
suggested (Prusiner 1989). Other theories have centred round the possibility of horizontal 
transmission of infection from human or animal sources (Gajdusek 1977), however no 
convincing evidence for this has been found.
1.1.3 Inherited CJD
Inherited CJD is the cause of approximately 15% of cases of CJD in humans and is 
associated with a known genetic mutation in the PRNP gene. Although the exact nature of 
the pathogenesis is currently unknown, it is thought to be caused by an increased tendency 
of the normal protein PrPc to convert to the abnormal PrPSc form (Brown et al., 1987). This 
has not been completely accepted (Wadsworth & Collinge, 2007). The inherited diseases 
GSS, FFI and CJD have different clinical features and duration of illness.
1.1.4 Acquired CJD
Acquired human CJD includes Kuru, variant CJD (vCJD) and iatrogenic CJD. Kuru is an
acquired form of prion disease associated with the practice of ritualistic cannibalism which
took place in Papua New Guinea. The disease had reached epidemic levels in the 1950s
and 60s before the practice of cannibalism ended. Epidemiological analysis of the
progression o f this disease both during and post epidemic has revealed incubation periods
of up to 50 years and this has raised the possibility of potentially long asymptomatic
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phases in the case of other prion diseases such as vCJD (Collinge et al., 2006; Wadsworth 
& Collinge, 2007).
Another example of an acquired CJD is iatrogenic CJD, which occurs in cases of disease 
transmission resulting from medical treatment (Brown, Preece & Will, 1992). Iatrogenic 
CJD is not a distinct strain as such but represents surgical transmission of sCJD and 
inherited CJD. Transmission o f sporadic CJD has been reported due to transplantation of 
ocular tissue (Tullo et al., 2006) and also associated with transplantation of dura mater 
grafts (Lang et al., 1995). Surveillance studies in the UK identified seven cases of 
iatrogenic CJD associated with dura mater grafts in the period between 1970-2003 (Heath 
et a l, 2006). Iatrogenic CJD has also been reported as a result of the use of human growth 
hormone which was derived from cadavers (Brown, 1998). A review of iatrogenic cases of 
CJD (Brown et al., 2006) notes that cases are declining now due to changes in practice 
following the discovery of this potential route of infection, although there are still 
occasional occurrences which are perhaps due to extended incubation periods.
1.1.5 Variant CJD
A variant form of CJD was identified in the UK in the 1990s linked to a younger age of 
onset and is thought to be associated with consumption of BSE contaminated meat 
products. This was subsequently shown to be derived from the same strain on experimental 
analysis (Bruce et al., 1997; Collinge et al., 1996). This disease differed from sporadic and 
inherited CJD in its clinical presentation and young median age of onset of ~26 years. The 
appearance of this new strain of human disease has raised widespread concerns of a 
potential public health threat. In addition, the long incubation periods and unusual stability 
of the infectious agent, which is resistant to the usual methods of decontamination and
sterilisation, has raised the possibility that a proportion of the population could potentially 
be harbouring this disease unknowingly and could result in iatrogenic presentations 
through surgery, blood donation and organ transplantation etc. An additional feature 
specific to vCJD is the presence of lymphoreticular accumulation of disease associated 
PrPSc in spleen, tonsil, appendix and lymph nodes. This is different to other forms of CJD 
in which disease associated PrPSc accumulation has been demonstrated only in the central 
nervous system (Hilton et al, 2004). This may potentially increase the possibility of 
iatrogenic transmission of vCJD via tissues such as tonsil and spleen.
Initially there were widespread fears that this disease was going to reach epidemic levels, 
however to date, the total number of deaths from definite or probable vCJD is 163 (March, 
2008) with a further 3 cases incubating disease (The National Creutzfeldt-Jakob Disease 
Surveillance Unit (NCJDSU) 2008) which in terms of numbers affected this is relatively 
low and the numbers appear to be declining after a peak around 2002-3. This has resulted 
in speculation that the vCJD “epidemic” is coming to an end and therefore this disease no 
longer poses a risk to public health. However some recent retrospective prevalence studies 
looking at archived pathological tonsil and appendix specimens have raised the possibility 
that there a number of people with sub clinical manifestations incubating the disease 
unknowing and that the prevalence in the population may be higher than suspected (Hilton 
et a l, 2004; Ironside et al, 2006). This combined with growing understanding of the 
exceptionally long incubation periods through analysis o f Kuru (Collinge et al, 2006) has 
meant that there is still concern over the possible public health issues associated with 
vCJD.
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1.2 Decontamination of surgical instruments -  the issues
Due to the unique properties o f this infectious agent a number of questions need to be 
answered urgently to address public health concerns and therefore should be the focus of 
research (Ironside, 2006). These include the development of a screening assay which is 
specific, sensitive and flexible to enable detection in blood, the development of an 
effective treatment and the development of a validated decontamination method for 
processing of surgical instruments.
The remarkable resistance of the prion infectious agent to standard methods of 
decontamination and cleaning has been highlighted (Taylor, 1991; reviewed by Taylor, 
2000). A number of standard physical and chemical methods of decontamination were 
assessed in these studies, including dry heat; autoclaving; acids and bases; alkylating 
agents, detergent solvents and proteolytic enzymes. The results were startling as it was 
revealed that a number of the methods such as use of alcohols, aldehydes, and autoclaving 
did not eliminate infectivity, and far from inactivating the infectious agent, some made it 
more stable. It was also apparent that the most thermostable of all the strains tested was 
BSE 301. (Taylor, 1991; reviewed Taylor, 2000; Femie et a l, 2007). As a result of these 
studies, it was concluded that a combination of methods that aimed to disrupt the protein 
structure would be more effective and that BSE 301V would be the best model for testing 
any decontamination regimes to enable assessment of the worst case scenario.
The resistance of the infectious agent to standard methods of decontamination has been
further substantiated by reports of iatrogenic transmission resulting from inadequate
decontamination of neurosurgical instruments. One report details the results of a study
using an instrument which had been used on a known case of CJD, and treated with 70%
alcohol and formaldehyde vapour for sterilisation prior to storage for two years and
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thereafter implanted into a chimpanzee that later developed disease (Bernoulli et al., 1977). 
Although the methods by which the instruments were sterilised would not currently be 
considered adequate, the experiments raised concerns over the safety of neurosurgical 
instruments, especially given the long time span which had elapsed before transmission of 
infectivity. Cases have also been associated with neurosurgical / electroencephalography 
(EEG) electrode contamination (Will & Matthews, 1982) and a further five cases of 
possible iatrogenic transmission have been identified subsequently (reviewed by Brown et 
al, 2000).
A epidemiological case control study (Collins et al., 1999) was conducted comparing a 
group of patients with known or suspected CJD and a control group from the normal 
population which found that there was an increased association of at least 3 episodes of 
surgery with CJD and it has been postulated that this could be due to contamination present 
on surgical instruments. Furthermore, the authors found that the risk associated with 
surgical procedures increased over time and multiple operations.
In response to epidemiological studies and reports of iatrogenic transmission via
contaminated surgical instruments combined with increasing knowledge regarding the
resistance o f the infectious agent to standard methods of decontamination and sterilisation,
has resulted in risk assessments being undertaken by the Department of Health (DH). This
has lead to the introduction of measures designed to reduce this potential risk to public
health, including the incineration of all instruments used in surgery on known cases of CJD
and quarantining of ‘at risk’ cases. Reports of transmission of vCJD by blood and blood
products (Llewelyn et al., 2004; Peden et al., 2004; Wroe et al., 2006) has led to greater
numbers o f cases being considered within this ‘at risk’ category including haemophiliac
patients who were recipients of clotting factors and this has led to increasing numbers of
surgical instruments being quarantined, including high cost instruments such as
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endoscopes. There have been vastly different estimates of the prevalence of infection in the 
UK population. One retrospective study (Hilton et al., 2004) tried to estimate the 
prevalence of vCJD by the use of immunohistochemistry to examine an archive of 
appendix and tonsil pathology samples. The results were somewhat surprising as 3 
appendix samples showed an accumulation of the abnormal prion protein indicative of 
vCJD out of ~12,000 samples. This suggested that the prevalence of vCJD may be much 
higher than previously believed at around 237 persons per million of the population. This 
result highlights that the levels of risk are still unknown and may be higher than suspected 
and provides further support of the precautionary approach taken by the DH to reduce risk 
to the public.
There is clearly an urgent requirement for a reliable method of decontaminating surgical 
instruments. Treatments known to offer a significant log reduction in infectivity such as 
sodium hypochlorite (20,000 ppm active chlorine) would not be a practical method for 
routine use due to safety concerns for operators and potential damaging effect on surgical 
instruments. Alcohols have a well known bactericidal effect and they are often used in 
conjunction with formaldehyde for the cleaning and chemical sterilisation of certain 
surgical instruments including neurosurgical instruments such as electrodes. However, one 
study reports the potential for alcohols to fix prion proteins more tightly to the surface of 
surgical steel and recommends that alcohols should not be used for sterilisation of 
neurosurgical instruments (Prior etal., 2004).
As a result of concerns over the potential transmission of CJD via contaminated surgical 
instruments, questions arose regarding the efficacy generally of cleaning and 
decontamination processes currently taking place in sterile service departments (SSDs) 
across the NHS. In order to get an idea of the baseline standard, the DH commissioned an 
anonymised study o f actual used and reprocessed instruments from different hospitals,
covering different types o f surgical procedures and collected at the point of return to use. 
The results of these studies (Baxter et al., 2006; Lipscomb et al., 2006; Murdoch et al., 
2006) revealed that levels of residual protein on the surface of surgical instruments after 
processing typically ranged from 200 pg to over 2 mg. Indeed one instrument examined 
had a very high protein load of 45 mg. In common across the studies, the highest residual 
protein levels were associated with the surgical instrument sets used for tonsillectomies.
These findings raised concerns as they demonstrated that a proportion of instruments in 
normal circulation have significant levels of residual protein contamination. The studies 
although small, demonstrated variation in general standards of reprocessing of surgical 
instrument across the UK and that patients could potentially be exposed to significant 
levels of residual protein from surgical instruments, despite being deemed sterilised. Given 
the concerns about iatrogenic transmission of historical forms of CJD through 
contaminated surgical instruments, this could potentially pose a theoretical source for 
ongoing vCJD transmission. Furthermore the fact that the tonsillectomy instruments were 
shown to have the highest levels of residual protein was of concern as tonsil tissue has 
been identified as being a high risk tissue for vCJD with levels of infectivity at only 100 or 
1000 fold less than brain material (Bruce et al., 2001).
A question which has been posed is the effect of drying of proteinaceous material on the 
ultimate efficacy of cleaning methods with obvious implications for iatrogenic 
transmission of prion infectivity. Concerns over the drying on of biological material on 
route to Sterile Service Departments (SSDs), has prompted studies. One study (Lipscomb 
et al., 2007) examined the effects of pre-soaking versus drying on surface protein 
contamination and found that there was significantly less overall protein contamination 
levels when pre-soaking was used.
Dental instruments may pose a problem due to their contact with potentially contaminated 
peripheral nerve tissue. The level of gross contamination on the surface of endodontic files 
following use and standard reprocessing has been highlighted as a particular problem 
(Smith et al., 2002; Walker et al., 2007). An assessment o f this risk based on existing 
scientific knowledge and gaps in current understanding led the Spongiform 
Encephalophathy Advisory Committee (SEAC) to issue a statement that endodontic files 
and reamers should be single use. http://www.seac.gov.uk/statements/statement0506.htm
1.2.1 Novel decontamination methods
There has been a focus by researchers on the development of reliable, validated methods of 
surgical instrument decontamination. Indeed, there have been a wide range o f technologies 
developed to date and some commercially available products, Hamo 100 (Steris), 
Prionzyme -  M (Genencor) have been independently certified for use (CE marking). Hamo 
100 is an alkaline based detergent system, and Prionzyme M is based on proteases within 
an alkaline base and both have shown relatively good results for removal o f prion 
infectivity (Fichet et al, 2004; Fichet et al., 2007b; McLeod et al., 2004). The action of 
these products is certainly less harsh than treatment with 1 Normal (IN) solution o f  sodium 
hydroxide, however there are still limitations and Hamo 100 is not recommended for use 
with flexible endoscopes. It is clear that although that these commercially available 
methods offer reduction in prion infectivity that there is still a requirement for a method of 
accurately validating the process to show that the required reduction in infectivity is being 
achieved.
In addition, a number o f other decontamination methodologies currently being developed 
are showing promise (Table 1-1). One group o f researchers have reported significant
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reduction in RML scrapie infectivity on surgical steel wires as assessed by bioassay, when 
using a combination of ionic detergents and proteases combined with autoclaving (Jackson 
et al., 2005). This result is promising, however there are studies showing that there is a 
difference in the stabilities o f scrapie to vCJD and also mouse passaged BSE 301V 
(reviewed by Taylor, 2000) and it is therefore difficult to accurately gauge and compare 
methodologies (reviewed by Sutton et al., 2006).
Bioassay is currently the most reliable method o f accurately and sensitively assessing 
levels of infectivity and therefore is considered the “gold standard” and therefore all 
current decontamination methodologies are required to prove their efficacy in vivo using a 
suitable animal model. Bioassay methods vary markedly from the infectious agent utilised 
e.g. scrapie and mouse passaged BSE 301V, and the species of animals challenged e.g. 
mouse and hamster. In addition the various methods of delivery of the infectious agent are 
currently reported ranging from the use of stainless steel wires inoculated intra-cerebrally 
to stainless steel spheres, which aim to mimic exposure via surgical instmments (Femie et 
al, 2007). However, the most reliable and measurable way of assessing the reduction in 
infectivity by decontamination methodologies is by direct intra-cerebral inoculation of 
potentially infectious material and assessing the survival data of the animal model used 
(reviewed by Sutton et al, 2006).
The efficacy of gaseous hydrogen peroxide has also been assessed for reduction of
infectivity of the hamster 263K scrapie strain and the results showed some success both in
vitro and in vivo, demonstrating >4.5 log reduction (Fichet et al., 2007a). One main target
of the development of new technologies is the challenge to develop practical methods
easily transferable to current NHS sterile SSDs. Therefore this type of technology has the
benefit that it is an already ‘tried and tested’ method within industry and used successfully
on a wide range o f surfaces however this log reduction in infectivity is not sufficient to
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render surgical instruments safe in terms of decontamination. Another study reports on 
efficacy of a method normally used for the pasteurisation of food (Heindl et al., in press). 
This methodology has shown significant reduction in 263K scrapie in the region of 6-8 
logs, however again it is difficult to accurately compare methodologies.
The use of gas plasma has also been assessed for decontamination of prion protein on the 
surface of surgical instruments and again with the advantage that it is also a recognised 
methodology within industrial settings. This technology has the proven suitability for 
cleaning and sterilisation of a range of materials and surfaces, thereby showing potential 
for application across the wider range of surgical instruments for processing. One report 
has been published (Whittaker et a l, 2004) on the efficacy of gas plasma for cleaning 
dental endodontic files, and which was evaluated by visual assessment of the levels of 
surface contamination by scanning electron microscopy (SEM) before and after plasma 
cleaning. The results indicated that all organic matter had been fully removed by the 
cleaning process with no obvious damage to the instrument surface. A further study 
(Baxter et al., 2005) examined the application of this technology in comparison to stringent 
washing procedures, for the removal of 263K scrapie prion infectivity from the surface of 
stainless steel spheres and surgical instruments. The results of SEM analysis followed by 
bioassay showed complete removal of proteinaceous material and infectivity. The authors 
make the point that in the absence of a validated method o f removal of prion infectivity 
that the establishment of a method to ensure the complete removal of protein residue from 
the instmment surface is o f particular importance.
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Infectious
Agent
Animal Method Logio Reduction of 
infectivity
Reference
263K scrapie 
strain
hamster Hamo-100 >4.5 Fichet et al., 
2007a
263K scrapie 
strain
hamster Gaseous hydrogen 
peroxide
>5.5 Fichet et al., 
2007b
263K scrapie 
strain
hamster Pasteurisation 6-8 Heindl et al., in 
press
BSE 301V
(mouse
passaged)
mouse Prionzyme-M
(Genencor)
>4 McLeod et al., 
2004
263K scrapie 
strain
hamster Gas plasma Removal of 
infectivity beyond 
detection
Baxter et al., 
2005
RML scrapie hamster Combination of 
ionic detergents 
and proteases
Not reported Jackson et al., 
2005
Table 1-1 Comparison of reduction of infectivity by decontamination methodologies
A number o f initiatives to improve the standards of cleaning and sterilisation generally 
within the NHS has been started and there is clearly a great deal of research taking place 
focussed on the development of specific and practical methodologies to inactivate TSEs, 
and ultimately to provide reliable processes for use in SSDs to ensure the safety of 
processed surgical instruments with respect to CJD.
For any of these novel technologies summarised in Table 1-1, to be taken forward for use 
in SSDs for decontamination of high risk instruments as well as relatively low risk 
instruments there has to be a reliable method of assessing and validating methods before 
implementation.
One of the difficulties is the requirement of the use of bioassays as the only reliable way to 
measure whether prion infectivity has been reduced or removed. The development of a 
reliable and consistent method for conducting a bioassay has been a considerable 
challenge; however the importance of the establishment of a benchmark to enable 
comparison of new technologies cannot be underestimated. It has been raised however,
that assessment should utilise a relevant TSE strain, in order to ensure confidence in a 
methodology or product (Sutton et al., 2006). This is particularly important when a number 
of developed methodologies are showing considerable promise for transfer into practical 
use within the near future. In addition to validation o f the efficacy of a novel methodology 
at a developmental stage, there is an urgent requirement for the provision o f a process 
indicator to provide quality assurance of the reliability of the process once in place within 
SSDs and therefore this is also a requirement to enable integration of novel methods.
1.2.2 Blood and blood products
The possible public heath concerns associated with vCJD were further strengthened with 
the publication of a report of possible transmission through a blood transfusion. (Llewelyn 
et al., 2004) The recipient in this case had received blood from a donor who had developed 
vCJD 3 years after donating. The recipient subsequently developed vCJD > 6 years after 
receiving the transfusion. There is no epidemiological evidence to support transmission of 
other forms o f CJD, such as sporadic CJD, via blood transfusion (reviewed by Ludlam & 
Turner, 2006), but the publication of this article raised the possibility that this might not be 
the same for vCJD. The initial case was identified following establishment of a UK 
surveillance programme to assess the transmissibility of CJD by blood and blood products. 
A second probable case was identified in which the patient died of other causes but was 
known to be the recipient of blood from a donor who subsequently developed CJD. On 
post mortem, evidence of prion infectivity was found in the spleen and a lymph node and 
further analysis revealed that this patient was heterozygous at codon 129 (Peden et al., 
2004).
14
In response to growing concerns for the safety of the national blood stocks a number of 
measures were implemented nationally to lessen the risk. These include the use of 
surveillance and tracing of blood donations; sourcing o f plasma for production o f blood 
components from outside the UK; leucodepletion of all blood used for transfusion and 
exclusion from the donor pool o f individuals who have received a transfusion in the UK 
since 1980.
There are a small number of individuals within the UK, who have been known to have 
received blood transfusions from donors who subsequently developed vCJD. A third case 
within this group was reported (Wroe et al., 2006) and subsequently a fourth case was 
announced via a press statement by the Health Protection Agency (2007). 
(http://www.hpa.org.uk/webw/HPAweb&HPAwebStandard/HPAweb C /1 195733711457? 
p=l 171991026241) It has been reported that there are a further 23 people within this 
defined group, who have not as yet been diagnosed with vCJD. 
(http://www.hpa.org.uk/hpa/news/articles/press releases/2007/070118 vCJD.htm)
The measures and restrictions which have been put into place to reduce the risk from blood 
transfusion in the UK have impacted on the national supplies of blood and blood products. 
The development o f a suitable screening test has therefore become a goal for researchers 
within this field along with estimation o f sensitivity required to enable an assay to reliably 
detect infectivity in blood for the purposes o f ante mortem diagnosis and screening of 
blood stocks. To date there is still a lack o f an assay with sufficient sensitivity to meet this 
challenge (reviewed by Grassi et a l, 2008).
There is still some debate regarding the actual levels of infectivity present in blood and 
blood products. A review article (Brown, 2005) collected data from a large number of
infectivity studies in which surprisingly the in vivo models show a similar picture for sCJD 
as vCJD in blood, which raises questions about the assumed safety of blood from sCJD 
individuals. The infectivity in blood is mainly associated within the leucocyte fraction. The 
exact nature of the infectivity and circulating levels are currently unknown and rely largely 
on animal studies particularly rodents. This is the only animal model in which blood has 
been titrated in order to determine levels of infectivity and the results show that the levels 
are many logs lower than in the brains of the infected animals (reviewed Brown, 2005). 
The assumption is that the levels of PrPSc in human blood would also be very low, and 
therefore sufficient sensitivity would be required to detect several logs less than post 
mortem tests on brain in order for a blood assay to be useful. One study, Brown (2001), 
estimated that PrPSc could be expected to be present at levels of 100 infectious units per 
mL of buffy coat, which is equivalent to 1-10 pg.mL'1 and other estimates have been set 
10-fold lower at 10 infectious units per mL of peripheral blood (equivalent to 0.1-1 pg.mL' 
') (Cervenakova et al, 2003). In addition, there are other problems associated with 
detection o f TSEs in blood. Most of the assays currently being developed rely on spiking 
of either recombinant PrP or infectious brain material from animal studies within blood or 
sera as there is shortage of blood samples from CJD patients due to ethical reasons. 
However there is insufficient scientific evidence on whether the form of the infectious 
molecule is the same in circulating blood as within the brain and indeed it has been 
postulated that this is unlikely. This may mean that assays developed in this way may not 
be reliable (Brown, 2005). There is a significant gap in knowledge and understanding 
regarding prion infectivity within blood despite the obvious urgent requirement for 
development of a blood assay.
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1.2.3 Assays and detection
One of the biggest challenges in the development o f a sensitive and specific diagnostic test 
for CJD is the nature of the infectious agent itself. With no discovered nucleic acid, the use 
of traditional polymerase chain reaction (PCR) based assays are ruled out and this is 
combined with a lack o f host immune response enabling serology to be used. However 
there is undoubtedly an urgent requirement for reliable ante-mortem diagnostics, a blood 
test and method o f validating surgical instrument decontamination.
The problem of lack of sensitivity of assays has been a re-occurring theme and for ELISA 
type formats, this has been mainly due to a lack o f specific and sensitive antibodies. A 
number of different approaches have been used in an attempt to overcome sensitivity 
issues and indeed prompted the development o f the novel ultra-sensitive assay described in 
this thesis. A number o f currently published methods of detection, along with limits of 
detection achieved have been summarised in Table 1-2.
The use of luminescence has been previously reported as a method of increasing sensitivity 
and its use in a capture ELISA format for recombinant PrP and bovine brain homogenates 
from known positive BSE cases, has been described (Biffiger et al., 2002). This assay used 
6H4 (Prionics) as a capture system for proteinase K pre-treated brain homogenate and an 
in-house produced monoclonal antibody conjugate with a chemi-luminescent reporter for 
detection. The reported limit o f sensitivity for this assay was 30 pg.m L1 of recPrP and 
BSE positive bovine brain tissue was successfully detected in a blind trial,
Safar et al (2002) have developed a conformation dependant immunoassay, designed to
detect denatured and native forms of the prion protein utilising the difference in signal
between both forms to determine if the sample is positive for disease specific protein and
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results showed levels of detection in region of Ing.mL'1 o f PrP. Another publication by the 
same authors (Safar et al., 2005) reports sensitive detection of human prion disease in brain 
homogenates which exceeded the sensitivity achieved by immunohistochemistry in the 
same samples. The authors postulate that this is due to detection of sub clinical forms of 
the disease.
A novel format for detection o f PrPSc has been described which utilises a property of 
selective binding of PrPSc to a polymeric ligand. This enables the subsequent washing off 
of the normal cellular form PrP before detection using an ELISA format and this format is 
currently being developed for commercial use (Microsens) (Lane et al., 2003).
The lack o f known nucleic acid sequence in the infectious prion molecule has prevented 
the use of PCR methodology. However, one research group have developed a very 
inventive method of cyclic amplification of the protein misfolding of normal cellular 
protein PrPc into abnormal disease associated PrPSc (Saborio, Permanne & Soto, 2001). 
This process is based on the disruption of aggregates of PrPSc as it is formed which 
provides more template for the conversion of PrP and has been named protein misfolding 
cyclic amplification (PMCA). Recently a report o f the use of this assay for detection of 
reduction o f scrapie prion infectivity as a result of heating and autoclaving was published 
(Murayama et al., 2007). Results using this assay were reportedly as sensitive as the 
concurrent bioassay, thereby raising the possibility of the use of this technique for 
validation purposes. A version o f this approach has been used to detect PrPSc in blood (Pan 
et al., 2007). This assay format has also been used to detect prion infectivity in the plasma 
of GSS infected mice and the assay was shown to detect a sample which had 10 infectious 
units per mL (Soto et al., 2005), which is approaching the levels of sensitivity required for 
a human blood test. The use of a method of immunocapillary electrophoresis has also been
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evaluated for detection of abnormal prion protein in blood samples of CJD patients, 
(Lourenco et al., 2006) however the results demonstrated a low sensitivity of -50%.
Detection o f abnormal prion protein in other body fluids such as urine has been attempted. 
This would have obvious advantages diagnostically in elucidating the pathology of the 
human prion diseases and clinical risks associated (Head et al., 2005). This study, rather 
reassuringly, failed to detect the presence of PrPSc in any of the urine samples from cases of 
sporadic, variant or familial CJD.
Immunoassays have not been the only approach for detection o f CJD on the surface of 
surgical instruments. The use of microscopic techniques combined with fluorescent reagent 
have been carried out with detection within the picogram range achieved (Lipscomb et al., 
2006). Although it is perhaps unlikely that this methodology could be transferable for 
routine use in SSDs, it may provide a method for researchers to validate decontamination 
techniques without the use of bioassay.
The general target of antibody based detection system is the putative disease associated
isoform PrPSc; however this has not been conclusively proved as the TSE infectious agent.
One published study shows a strong correlation with 263K hamster scrapie and infectivity
(Beekes, Baldauf & Diringer, 1996). However, other studies have failed to find significant
accumulation of PrPSc in infected brain material (Barron et al., 2001; Manson et al., 1999).
In addition, there have been a number of reports from experimental studies which show a
lack of correlation of infectivity on bioassay with removal of immunoreactivity on Western
blots (Lourenco et al., 2006; McLeod et al., 2004). Furthermore, a recently published study
(Barron et al., 2007) shows convincing evidence that high titre infectivity can be
transmitted from the brains of animals that have shown little or no presence of
immunoreactivity for PrPSc. This therefore demonstrates that the presence of PrPSc may not
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be entirely reliable for the purpose o f diagnostics or validation of decontamination and 
reinforces the importance of bioassays until the nature of the infectious agent itself can be 
fully understood. However, in the absence o f an alternative, this surrogate marker is still 
commonly used as a marker for infectivity for development of detection assays.
There has evidently been much progress towards the development of sensitive detection 
assays for CJD for the purpose of validation of decontamination processes and for use in 
post mortem and blood assays (summarised in Table 1-2). However it is clear that there are 
still a number of unresolved issues, which have impeded progress of the development of 
suitable methodologies and thus there is still currently a requirement for validation by 
bioassay.
Antigen Method Detection limit Reference
Rec PrP Luminescent
ELISA
30 pg.mL'1 Biffiger et al, 2002
Disease specific 
prion
Conformation
dependant
immunoassay
1 ng.mL'1 Safar et al, 2002
Scrapie PMCA 10 infectious 
units per mL
Saborio, Permanne & Soto 
2001
Soto et al., 2005
Rec PrP Immunocapillary
electrophoresis
1 ng.mL'1 Lourenco et al., 2006
Rec PrP ELISA 20-60 pg. mL'1 Yamamoto et al (in press)
Rec PrP 
Scrapie
IPCR 1 fg .m L 1 
10 infectious 
units per mL
Barletta et al, 2005
Table 1-2 Comparison of limits of detection by published studies
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1.3 Ultra-sensitive detection and bioluminescence
The terminology o f chemiluminescence and bioluminescence cover the production of 
measurable light emission by either a chemical reaction or biological processes. 
Bioluminescence is a relatively rare process in nature, found in certain bacterial systems, 
several marine animals and in fireflies. In the latter case the enzyme responsible for light 
production is called luciferase and uses luciferin as a substrate which it converts to 
oxyluciferin + AMP + light, in the presence of ATP (reviewed by Kricka, 1995).
luciferin + ATP + O2 —* oxyluciferin + AMP + PP, + CO2 + light
There have been numerous uses identified for this reaction, particularly within 
biotechnology and products have been developed to enable this reaction to be utilised in a 
predictable and reliable way including luminometers, reagents and kits. The developed 
methodologies include the use of reporter gene based assays, biosensors, and also use of 
ATP released from bacteria upon lysis linked to production of measurable light. The use of 
ATP linked bioluminescence has been extensively used for hygiene monitoring within the 
food industry with light emission measured by hand held portable luminometers (Stanley, 
1989). However detection levels achieved tend to be quite low and typically in the realms 
of 104 cells with the other drawback that the methodology is non -specific and not able to 
differentiate between different bacteria particularly the presence of potentially pathogenic 
species. This technology has been further refined to enable specific detection of bacteria 
using phage mediated release of adenylate kinase (AK) (Blasco et al., 1998). This method 
applied the use of specific bacteriophages to lyse cells if present, which was followed by 
the release o f the cell contents which included AK which catalyses the equilibrium 
reaction:
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ATP + AMP <-> 2ADP (in the presence of Mg2+)
If an excess of ADP substrate is present then the reaction can be driven in the direction of 
production of ATP, which is the opposite of the cellular metabolism reaction, resulting in 
amplification of ATP which can be coupled to detection by bioluminescence and 
measurable light emission. In addition to the possibility of specific detection using AK as 
marker, an increase in sensitivity of a least 10-100 fold is demonstrable compared to 
detection of ATP alone. This use of this technology was further described (Squirrell, Price 
& Murphy, 2002) for specific detection of Escherichia coli (E. coli) 0157. Furthermore it 
is reported that 40 times as much ATP can be generated within one minute in the presence 
of an excess of ADP substrate than the initial starting amount (Chittock et al., 1998; 
Squirrell & Murphy, 1997). This amplification reaction is known to be linear and therefore 
high sensitivity can be achieved by increasing incubation time, results show detection of 1 
cell within an assay time of approximately 25 minutes.
1.4 Thermophilic adenylate kinases (AKs)
Adenylate kinases are ubiquitous enzymes which are found in most cell types and catalyse 
the equilibrium reaction:
Mg2+ ATP + AMP *  ► Mg2+ADP +ADP
Adenylate kinases have been discussed as potential enzymatic reporters for immunoassay
(Gadow et al, 1984; reviewed Kricka 1995). They potentially offer a number of
advantages over conventional alkaline phosphatase or horseradish peroxidase conjugates in
that they offer a significant amplification of signal via generation of ATP which can
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subsequently be coupled with sensitive bioluminescence detection. To date, however, their 
use has been limited by a failure to generate enzymatically active antibody conjugates. The 
use of thermostable adenylate kinases was considered as an alternative because enzymes 
isolated from thermophilic organisms tend to have the same characteristics as their 
derivative organism and are therefore potentially more robust than their mesophilic 
counterparts (Vieille & Zeikus, 2001).
Thermophiles are the name for organisms that can survive at temperatures above 45 °C and
many have been isolated from extreme environments such as hot springs or volcanoes.
Thermophiles are further classified by their optimal temperatures with further categories
termed extreme thermophiles or hyperthermophiles with optimum temperatures for growth
in excess of 80 °C. Thermophiles including hyperthermophiles are bacterial or archaeal in
origin. The archaea are a group of microorganisms which are distinct from bacteria and
single celled prokaryotes. It was originally thought that these organisms were relatively
rare and found mainly in extreme environments; however they have since been identified
in many common habitats. Naturally, enzymes contained within thermophiles have a
similar thermal profile in order for the organism to survive. Consequently enzymes isolated
from these organisms have found many uses, particularly in the biotechnology industry.
For example, thermostable DNA polymerases have been utilised as part of the polymerase
chain reaction (PCR) due to a requirement to survive throughout repeated heat steps to >90
°C. The most common DNA polymerase used for this purpose was isolated from a
thermostable bacterial species Thermus aquaticus, with one from Pyrococcus furiosus a
recent addition. In addition to extreme heat, some thermophiles and hyperthermophiles
require other unusual growth conditions such as the use of sulphur for respiration with the
production of sulphuric acid as a by-product. These organisms are therefore adapted to
growing in very low pH conditions as well as at high temperatures. Proteins and enzymes
isolated from these organisms tend to be robust and can survive extremes of temperature
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and pH compared to proteins isolated from mesophilic organisms which have optimal 
growth conditions at temperatures ranging from 25-40 °C (Brock, 1978). A great number 
of potential uses of robust enzymes have been identified by researchers and there has been 
a growing interest in thermophiles. However they tend to have complex growth 
requirements, particularly due to different requirements for temperature combined with 
extremes o f pH, pressure etc depending on the original source of the microorganism which 
can make them relatively hard to cultivate within laboratory conditions.
A number o f studies have examined the differences between proteins and enzymes isolated 
from mesophilic and thermophilic organisms in an attempt to identify the differences 
which confer thermostability. In the case of AKs, one theory is that the enzymes from 
thermophiles are more rigid than those from mesophiles (Vieille & Zeikus, 2001). 
However, many enzymes from hyperthermophiles are more active than the equivalent 
mesophilic enzymes, even at moderate temperatures of ~37 °C (Vieille et al., 2003), 
conflicting with the theory that the enzymes are more rigid, a characteristic which might be 
expected to reduce catalytic rate. Differences in amino acid composition have also been 
suggested (Argos et al., 1979). However despite numerous studies which have taken place 
particularly recently within this field, no single mechanism has been identified which 
explains the stability of enzymes isolated from thermophilic and hyperthermophilic 
organisms, however it is clear that this property has many potential uses especially within 
biotechnology.
A number o f AKs from thermophiles have specifically studied and a recombinant Bacillus
stearothermophilus AK was produced and compared to E coli AK to further elucidate the
structural and biochemical differences (Glaser et al., 1992). One of the key findings from
this study was that this AK included a tightly bound zinc atom as part of its structure,
which was not found in the mesophilic AK and it was hypothesised that complex with zinc
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confers a rigidity to the structure of this AK which may a contributory factor in the 
thermostability of this protein. Interestingly the Bacillus stearothermophilus AK was also 
shown to be more resistant to trypsin digestion than E coli AK. The role of zinc in the 
conferring stability of certain AKs has also been studied in the case of a different 
thermophile, Thermotoga maritima with some suggestion that its removal results in loss of 
thermostability (Vieille et al., 2003). This is interesting, however since not all thermophilic 
AKs have this structural zinc atom, it is clearly not the only explanation in terms of 
conferring thermostability.
Adenylate kinase isolated from the hyperthermophile Sulfolobus acidocaldarius has also 
been extensively studied and characterised (Kath, Schmid & Schafer, 1993). AKs from 
eukaryotes and eubacteria have been shown to have similar sequence and structure 
(Vonrhein et al., 1998). It was therefore assumed that Sulfolobus acidocaldarius AK 
therefore would also show a high degree of conserved sequences across different species. 
However, significant differences between the structure of the Sulfolobus acidocaldarius 
AK compared to mesophilic AK and also Bacillus stearothermophilus AK, were revealed 
and it was concluded that this was a novel class of AKs. In addition it was identified that 
this enzyme is trimeric whereas the majority of other AKs from hyperthermophiles are 
monomeric (Vonrhein et al., 1998). This trimer structure confers rigidity at the central 
hydrophobic interface and also features extended p sheet formation at this point, which is 
specific for Sulfolobus acidocaldarius AK. It has been demonstrated that weakening of the 
interaction o f the monomer subunits had a detrimental effect on the thermostability of the 
enzyme (Backmann et al., 1998; Bonisch et a l, 1996).
It has been found that several AKs derived from archaeal origin show similar sequence
homology, particularly methanococcal AKs and that these AKs are also trimeric in
structure and also contain the extensive p sheet formation at the central interface (Ferber et
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al., 1997). This has also been identified as the case for Sulfolobus solfataricus (Okajima et 
al, 2002). However a further study (Criswell et al., 2003) reports that the trimeric structure 
alone is not responsible for thermostability, but that hydrophobic interactions are the basis 
for thermostability. Studies on chimeric enzymes produced from the genus methanococcus 
(Criswell et al., 2003) designed with substitutions at the C or N terminal regions, found 
that it was possible to substantially alter the thermostability of the AKs by amino acid 
substitution and this may therefore be a useful strategy for the alteration o f enzymes to 
increase thermostability.
A monomeric AK derived from the hyperthermophile Thermatoga neapolitana has also 
been studied (Vieille et al., 2003). This AK has been shown to be stable up to temperatures 
in the region o f 100 °C but has also been shown to be highly active at mesophilic 
temperatures of -3 0  °C. Thermatoga maritima has also been shown to be not only active 
but highly active with the specific activity showing a 10 fold improvement on mesophilic 
AK such as E. coli AK.
There have been studies reviewed in (Vieille & Zeikus, 2001) which have suggested that 
protein engineering could accomplish an increase in thermostability of enzymes without a 
reduction in activity. This is based on the results of a number of studies which have shown 
that thermophilic enzymes tend not to be optimal for activity whereas mesophilic enzymes 
are less than optimal in terms of stability and it is postulated that this is probably due to 
lack of evolutionary pressure. This therefore leaves the potential that these enzymes could 
be further enhanced and optimised for specific uses, by the use of protein engineering.
There is therefore considerable potential for use of AKs from these sources for the
purposes of the development of an ultra-sensitive assay format using AK as a reporter
enzyme. This exploits the robust qualities of the enzyme to enable conjugation to take
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place without loss of enzyme activity and thermostable properties for removal of 
background signal resulting from AKs present from other sources. In addition, increasing 
knowledge within this area is opening up possibilities o f methods of protein engineering to 
further increase activity and thermostability thereby substantially increasing the potential 
of any developed assay (Criswell et al., 2003).
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2 Objectives of the Study
2.1 Development of a novel ultra-sensitive immunoassay for the detection 
of prion protein on surgical instruments
The aim o f this study was to develop an ultra-sensitive method for the detection of prion 
protein adhering to the surface of surgical instruments in order to detect residual 
contamination o f prions in situ for the purpose of validation o f decontamination 
methodologies. A novel antibody linked to thermostable AK coupled to ATP 
bioluminescent detection was therefore proposed to address these requirements (
Figure 2-1).
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Figure 2-1 Diagram  of the proposed ultra-sensitive Prion ELISA.
The assay  a llo w s u ltra -sensitive  detection  o f  m ateria l v ia co u p lin g  o f  A TP production  by aden y la te  k inase to 
b io lum inescence . T he assay  is designed to  a llow  sep ara tio n  o f  the  an tibody  from  enzym e fo llo w in g  b inding / 
w ash ing  phases and the  inactivation  o f  any  co n tam in a tin g  enzym e activ ity  by heat denatu ration . T he flexible 
fo rm at a llow s spec ific  issues concerned  w ith  d e tection  o f  prion  pro teins to be addressed .
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2.1.1 Variant Creutzfeldt-Jakob Disease
Creutzfeldt-Jakob Disease (CJD) is a relatively rare form of a human neurodegenerative 
disorder presenting as either a familial or sporadic disease at a frequency of approximately 
1 case per million population. The emergence of a new variant form (vCJD) as a novel 
form of the disease predominantly in a younger age group, thought to be due to 
consumption of bovine spongiform encephalopathy (BSE)-infected meat products (Bruce 
et al., 1997; Collinge et al., 1996), has raised the possibility of a large increase in the 
numbers o f cases. These factors have important public health consequences as there is 
potential for iatrogenic transmission through routes including surgery, transplants, 
transfusion and contaminated medical products (Brown 1998; Brown 2001, Llewelyn et 
al., 2004; Peden et al., 2004; Wroe et al., 2006). Detection of infective material and 
diagnosis o f infected individuals remain major problems in dealing with Transmissible 
Spongiform Encephalopathy (TSE) diseases both in humans and animals.
To address some o f the issues raised by vCJD and in relation to the established routes of 
iatrogenic spread, a sensitive assay is required for the detection of prion material. The 
development of the assay aimed to focus on making it applicable to detection of prion 
material in complex biological materials (e.g. tissue attached to surfaces, blood etc) and its 
use to validate cleaning and decontamination routines for surgical instruments.
2.1.2 Development of a model assay
In order to develop this assay it was decided that due to the fact that the suggested
approach was novel, with no published precedent that development of a model would be
advantageous. The aim was to establish the feasibility of the proposed immunoassay and
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specific parameters using inexpensive and readily available reagents. It would also avoid 
the requirement for biological containment at early stages of the assay development and 
allow optimisation of the assay without the use of infectious material.
2.1.3 Production of anti-PrP polyclonal antisera
It has been identified that prions are poorly immunogenic and there are difficulties 
associated with development o f disease specific antibodies due to the nature of the 
infectious agent (Prusiner, 1998). Therefore it was important to explore methods for 
improving the titre and specificity of antibodies produced. The plan was to evaluate the use 
of a combination of published methods (De Silva, Egodage & Wilson, 1999; Wopfner et 
al., 1999) to develop a range o f polyclonal antisera with different specificities using a 
range of prion mimetic peptides and a strategy designed to boost the immune response. It 
was hoped that exploration of a number of different approaches would enable production 
of stock of anti-PrP antibodies in order to convert the initially developed model assay to an 
immunoassay specific for detection of prions.
2.1.4 Thermostable adenylate kinases
It was proposed to use an available resource (CEPR Thermophile Culture Collection) as 
this would enable screening and selection of thermostable adenylate kinases for further 
characterisation and determination o f the presence of suitable qualities for use in the 
developed immunoassay. It was anticipated that once potentially suitable AKs were 
identified that work would focus on development of a method of producing a stock and 
therefore the use of recombinant DNA technology would be explored. Once a recombinant
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version of the selected AK was produced, the next phase was for methods of purification of 
AKs to be established based on the results of the characterisation studies.
2.1.5 Assessment of detection limits
The aim was that the assay would be fully optimised prior to work with prion infective 
material. Therefore detection limits for rec PrP would initially be assessed alone and 
followed by specific detection within various biologically relevant substrates such as 
neuronal tissue, blood and sera This would be followed by assessment for potential 
detection o f rec PrP on the surface of surgical instruments and the possibility of designing 
a format suitable for validation of decontamination processes within sterile service 
departments (SSDs). The aim was to utilise the results obtained in all the initial 
experiments to transfer to working with infectious prion material within suitable 
containment facilities and thereafter repeat the evaluation o f the AK-ELISA for sensitive 
detection o f prion infective material.
It is clear from the published literature that there still remain considerable gaps in the 
current scientific knowledge on the nature of the prion infectious agent. It was therefore 
hoped that an increased understanding would be gained during the course of the study on 
some of the scientific issues specific to this very unusual infectious agent.
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3 Development of a model thermostable AK immunoassay
3.1 Introduction
The aim was to demonstrate the feasibility of the proposed ultra-sensitive detection method 
for prion protein by the establishment of a model system. The assay required design of a 
number of unusual features to make it applicable to the specific problems associated with 
detection o f CJD on the surface of surgical instruments. The developed assay therefore 
required:
• To be ultra-sensitive to address the sensitivity problems associated with detection 
of prion infective material.
• To be able to detect prions within complex mixtures of biological material such as 
neuronal tissue or blood without compromise of the assay sensitivity.
• The flexibility to allow the potential separation of the antibody binding / washing 
and assay phases to enable specific detection of prion contamination on the surface 
of surgical instruments.
Additionally, in order for the assay to be routinely adopted within a clinical setting, the 
developed method had to be practical, relatively cost effective and applicable to standard 
hospital laboratories. There were a number of parameters proposed for the assay design, 
which had no precedent in published literature and therefore development of a model assay 
version allowed the various stages of the assay to be trialled using relatively inexpensive 
and readily available reagents. It also avoided the requirement for biological containment 
at early stages of the assay development by allowing establishment of the assay format 
without the use of infectious material.
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Figure 3-1 D iagram  o f the proposed ultra-sensitive Prion ELISA.
T he assay  a im s to provide u ltra-sensitive  d e tection  o f  prion  infective m aterial on surface o f  surgical 
instrum en ts b y  coup ling  o f  A TP production  b y  a th erm ostab le  adenylate  kinase to  b io lum inescence . The 
assay  is d e sig n ed  to allow  separation  o f  the an tib o d y  from  enzym e fo llow ing  b in d in g  / w ash ing  phases and 
the in ac tiv a tio n  o f  an y  contam inating  en zy m e activ ity  by heat denaturation . T he flex ib le  form at aim s to 
ad d ress spec ific  issues concerned w ith d e tectio n  o f  p rion  proteins.
Figure 3-1 shows a schematic o f the proposed assay format for detection o f prion proteins 
on the surface o f surgical instruments. The diagram demonstrates the use of thermostable 
adenylate kinase (AK) conjugated to an anti-PrP antibody via a cleavable linker which 
would enable separation o f the initial antibody binding step and allow the remaining steps 
o f the assay to be carried out using standard laboratory equipment. The inclusion of heat 
steps and incubation steps with ATPase are designed to remove all potentially 
contaminating AK and ATP prior to generation o f ATP by the thermostable AK and 
bioluminescent detection. For the purpose o f development of a model system the main 
focus was to firstly establish whether conjugation o f the thermostable AK to an antibody
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was possible without loss of activity of the enzyme. Secondly was that the AK could be 
subsequently cleaved and used to produce ATP which could be coupled to bioluminescent 
detection. AKs are ubiquitous enzymes which are found in most cell types and catalyse the 
equilibrium reaction:
Mg2+ ATP + AMP « » Mg2+ADP +ADP
The normal direction of the reaction for the purposes of cellular metabolism is in the 
direction o f formation o f ADP and AMP, however in the presence of an excess of ADP 
supplied as a substrate, the reaction can be driven in the opposite direction resulting in 
production o f ATP which can be detected using bioluminescence (Blasco et al., 1998).
The development of this model assay therefore aimed to establish ‘proof of principle’ of 
the AK assay and specifically of;
• Use of ADP as substrate for the production of ATP from bound thermostable 
adenylate kinase (AK) and subsequent bioluminescence detection.
• Successful conjugation of thermostable AK to an antibody molecule without loss of 
biological activity.
• Cleavage of the AK moiety without loss of biological activity to allow separation 
of antibody binding and detection if required and demonstration that detection of 
antigen using this methodology was possible.
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3.2 Materials and Methods
3.2.1 Comparison of different sources of ADP
A 1:10,000 dilution of Bacillus stearothermophilus AK (myokinase) (Sigma) was obtained 
and prepared as a stock solution in phosphate buffered saline (PBS) and 100 pi added to 
microtitre plate wells (Nunc-Immuno™ MaxiSorp™) with the exception of the controls. 
Two commercial samples of adenosine 5'-diphosphate (ADP) were obtained as follows: 
from a bacterial source (Roche) and equine muscle (Sigma) and prepared as 0.3 mM 
solutions in magnesium acetate buffer (15 mM magnesium acetate buffer + 1 mM 
ethylenediaminetetraacetic (EDTA), pH 6.7). Titrations of ADP were prepared by doubling 
dilutions in magnesium acetate buffer and 100 pi of each dilution was added to appropriate 
wells and incubated at room temperature for 30 minutes. 30 pi of Luciferin-luciferase 
(L/L) reagent (ATP Kit SL) (Biothema) was added to each well and read immediately in a 
plate luminometer (Berthold Orion) measuring relative light units (RLUs).
3.2.2 Comparison of the inherent A TP contamination
A further commercial source of ADP was obtained which was AK & Adenosine 5'- 
triphosphate (ATP)-free ADP (Celsis). 0.3 mM dilutions of all three ADP (Roche, Sigma, 
Celsis) were prepared in magnesium acetate buffer and 100 pi of each dilution was added 
to appropriate wells. 30 pi of Luciferin-luciferase reagent (ATP Kit SL, Biothema) was 
added to each well and read in a plate luminometer immediately.
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3.2.3 Purification of IgG
50 mL of polyclonal rabbit serum produced to Keyhole Limpet Haemocyanin (KLH) was 
obtained from the Biological Investigations Group (BIG), CAMR (no information was 
available on the method of production). 5 mL of sera was diluted to 20 mL with 20 mM 
potassium phosphate buffer, pH 7.0 and small particles removed by filtration using a 
Millipore filter (0.4 p). A Protein G Sepharose Fast Flow column (Pierce) was pre­
equilibrated with 20 mM potassium phosphate buffer, pH 7.0 using Fast Protein Liquid 
Chromatography (FPLC) (Pharmacia) and sample applied. The column was washed with 
the above buffer until the absorbance (280 nm) had returned to baseline. 2.5 mL fractions 
of purified IgG was eluted by addition of 100 mM Glycine, pH 2.5 and neutralised 
immediately in phosphate buffered saline (PBS). Peak fractions were identified using the 
chart recorder trace, collected, pooled and subsequently dialysed against phosphate 
buffered saline (PBS) (20 mM Phosphate buffer, 150 mM sodium chloride (NaCl), pH 
7.6).
3.2.4 Calculation of titre of purified IgG
The wells o f a 96 well Microtitre plate (Nunc-Immuno™ MaxiSorp™) were coated by 
addition of 100 pL per well of KLH (Sigma) diluted to 1 pg.mL'1 in coating buffer (0.05 M 
sodium carbonate buffer, pH 9.6) and incubated overnight at room temperature. Plates 
were washed three times in PBS containing 0.05 % Tween 20 (PBS-T) using a Multiskan 
AC Plate Washer and non-specific binding blocked by the addition of 300 pL per well o f a 
solution of 3 % dried milk (Marvel) diluted in PBS and incubated for 1 hour at 37 °C. The 
solution was removed by washing three times in PBS-T. The post purification antiserum
was diluted from 1:250 by doubling dilutions in PBS and incubated for 1 hour at 37 °C.
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The solution was removed by washing wells with PBS-T as previously described, followed 
by addition of 100 pi per well o f a 1:20,000 dilution of anti-rabbit IgG peroxidase 
conjugate (Sigma) and incubated for 1 hour at 37 °C. Following incubation the wells were 
washed as previously described and then 100 pL per well of tetramethlybenzidene (TMB) 
liquid substrate (Sigma) was added and incubated for 15 minutes at room temperature. 
Colour development was stopped by the addition of 100 pL per well of 1M sulphuric acid, 
absorbance (450 nm) read on a Multiskan plate reader (Labsystems).
3.2.5 Estimation of protein concentration
Coomassie Plus Protein Assay reagent (Pierce) was used by adding 50 pi of each sample / 
standard to a tube and adding 1.5 mL o f Coomassie Plus Reagent, mixing and incubating at 
37°C for 30 minutes before reading the absorbance (595nm) in a spectrophotometer 
(Labsystems). A standard curve was created by using a range o f bovine serum albumin 
(BSA) standards supplied with the kit to calculate known values at 0.4, 0.6, 0.8, 1.0, 1.2, 
1.4, 1.6 mg.mL'1. The protein concentration of the sample was calculated with reference to 
the standard curve.
3.2.6 Concentration of the IgG sample
Concentration of the purified IgG samples was achieved by ultra-filtration using Ultrafree- 
15 (Millipore) 10 kDa filter. Each filter was loaded with 10 mL of the protein solution and 
samples spun at 3000 rpm in a microcentrifuge for 20 minutes and the process repeated 
twice (3 x 20minutes). When concentration to approximately 1.5 mL was achieved a 
further 5 mL of sample was added to each filter and the procedure repeated until required.
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3.2.7 Comparison of thermal stability of AKs
Two samples of AK (myokinase) were obtained, one isolated from a thermophilic 
microorganism Bacillus stearothermophilus (Sigma) and the second isolated from rabbit 
muscle (Sigma) and diluted to an initial starting concentration of enzyme activity of 1 
unit.mL'1 (one unit of specific activity is defined as that producing 1 pmol of ATP.min-1 at 
70 °C) and then diluted. 100 pi of each preparation was added to wells in a microtitre plate. 
The plate was heated to 40, 50, 60 or 70 °C for 10 minutes followed by readjustment to 37 
°C in a thermocycler (Techne), 100 pi of 0.13 mM of ADP (Celsis) in magnesium acetate 
buffer was added diluted as before and incubated for 30 minutes at 37 °C. Production of 
ATP was measured as RLU in the plate luminometer by the addition of 30 pL of luciferin- 
luciferase reagent (Biothema).
3.2.8 Conjugation of AK to purified IgG
Adenylate kinase (Myokinase) isolated from the thermophilic bacteria Bacillus
stearothermophilus (Sigma) was diluted to a concentration of 10 mg.mL"1 in PBS (20 mM
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phosphate buffer, 150 mM sodium chloride (NaCl), 1 mM EDTA pH 7.5). The 
heterobifunctional reagent, N-Succinimidyl 3-(2-pyridyldithio) propionate (SPDP) (Pierce) 
was used for the conjugation reaction at 10-fold molar concentration of SPDP to protein. A 
4.1 mM concentration of SPDP was required to derivatise AK prior to conjugation to IgG. 
This was achieved by dissolving 2.6 mg of SPDP in 20 pi of anhydrous 
dimethlysulphoxide (DMSO) followed by the addition of 10 pi of this solution drop wise 
to the dissolved AiC and mixed for 1 hour at room temperature using a magnetic stirrer.
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The derivatised solution was transferred to pre-prepared dialysis tubing (VWR) and 
dialysed extensively against PBS overnight at 4 °C to remove unreacted SPDP. 12 mg of 
dithiothreitol (DTT) was dissolved in 500 pi of PBS and 250 pL added to the SPDP 
derivatised AK and incubated at room temperature for 30 minutes while mixing 
continuously using a magnetic stirrer. The resultant solution was dialysed against PBS to 
remove DTT overnight at 4 °C. 500 pL of the stock solution of purified anti-KLH IgG (20 
mg.mL'1) was diluted with 500 pL of PBS to a final concentration of 10 mg.mL'1 and 
derivatised with SPDP as described above. Unreacted SPDP was removed by passing the 
solution through a PD10 column (Pierce) pre-equilibrated with PBS. 1 mL fractions were 
collected and the presence of IgG determined by measurement of the absorbance (280 nm) 
using a UV spectrophotometer and quartz cuvette. The fractions containing the protein 
were pooled and concentrated by ultra-filtration as described in section 3.2.6. Two ratios of 
IgG to AK which were 2:1 and 1:2 respectively were calculated and conjugated by addition 
of the required amount of modified IgG to derivatised and reduced AK followed by 
incubation overnight while mixing at room temperature. The conjugation reaction was 
stopped by the addition of 10 pL of a 5 mg.mL'1 solution of N-ethyl maleimide (Sigma) 
that was freshly prepared in anhydrous DMSO followed by incubation for 30 minutes at 
room temperature. The unreacted N-ethyl maleimide removed by dialysis against PBS.
3.2.9 Assessment of conjugation by HPLC gel filtration
A TSK2000 HPLC gel filtration column was pre-equilibrated with PBS and calibrated by 
the addition of the following standard preparations; cytochrome C (bovine heart), bovine 
serum albumin (BSA) and alcohol dehydrogenase (ADH) obtained from Sigma UK. A 
standard curve was prepared based on the retention time in minutes of the known 
molecular weight (kDa) and this was used to determine the molecular weights of unknown
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samples. After the last stage of the conjugation procedure (modified AK and IgG were 
combined as described in section 3.2.8), the reaction was followed by loading 20 pL 
samples of the conjugation preparation onto the pre-equilibrated and calibrated TSK 2000 
column at different time intervals throughout the conjugation process to monitor the 
reaction and a trace obtained.
3.2.10 DTT cleavage of the conjugate preparation
0.5 mL of the prepared conjugate solution was loaded onto the TSK2000 HPLC gel 
filtration column and peak fractions were collected manually as described in 3.2.9. 20 pL 
of the conjugate was re-loaded onto the column to check the purity of the conjugate 
fraction prior to DTT (Sigma) cleavage. DTT cleavage was achieved by incubating the 
conjugate preparation with 25 mM DTT for 30 minutes at room temperature. Cleavage of 
the conjugate preparation to derivative fractions of IgG and AK was monitored by loading 
20 pL samples onto the column and peak fractions collected manually as before and a trace 
of the reaction obtained.
3.2.11 Detection of KLH by anti-KLH-AK conjugate
A microtitre plate was coated with KLH and blocked as described in section 3.2.4. 100 pL 
per well of anti-KLH-AK conjugate was added from a starting dilution of 1:250 in PBS 
and diluted using doubling dilutions. Following incubation for 1 hour at 37 °C and then 
wells washed as previously described. 100 pL of 0.3 mM ADP was prepared in magnesium 
acetate buffer and added to the appropriate wells and incubated for 30 minutes at 37 °C. 30 
pL o f luciferin-luciferase reagent (Biothema) was added and the results read immediately
by plate luminometer (Orion Berthold). Controls wells which omitted antigen; antibody- 
AK conjugate and ADP respectively were included within the assay.
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3.3 Results
3.3.1 Bioluminescent Detection
In order to produce a model bioluminescent assay, it was crucial that a method of 
generating ATP from the bound marker enzyme, thermostable adenylate kinase, was 
developed. ADP was purchased from a number of commercial sources for assessment and 
comparison. However initial results using ADP generated ATP, followed by 
bioluminescent detection routinely showed very high background results, which made the 
assay unreadable (results not shown). Therefore it looked likely that the non-specific light 
emission could be due to reagent contamination, for example, contaminating AK present in 
the luciferin-luciferase reagent and / or ATP contamination of the purchased ADP 
substrate.
The two initially purchased samples o f ADP (Roche and Sigma) were tested directly by 
ATP bioluminescent assay and the results showed that there was an appreciable quantity of 
contaminating ATP. Contact was made with a small research company who were 
developing ATP bioluminescent detection as a direct measure of bacterial contamination 
on environmental surfaces and who had developed a set of ATP and AK free reagents 
which they were keen to have assessed for a different use (Celsis, Cambridge, UK) This 
low-ATP ADP has a contamination level of ATP at 0.1 ppm (compared to ~ 0.2% quoted 
in the other reagents) which, made it ideal for this purpose and also had been further 
purified to remove any contaminating adenylate kinase.
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C o m p a r is o n  o f  ATP c o n ta m in a t io n  w ithin c o m m e rc ia l ly  a v a i la b le  A D Ps
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Figure 3-2 Com parison o f three different samples o f ADP
0.3 m M  d ilu tions o f  A D P (R oche, S igm a, C elsis) w ere  p repared  in m agnesium  acetate bu ffer and 100 p i o f  
each dilu tion  added to  ap p ro p ria te  w ells. 30 p L  o f  L u ciferin -luciferase  reag en t (A T P Kit SL) (B io them a) w as 
added  d irec tly  to each w ell and  the resu lts read  in a plate  lu m in o m ete r (B erth o ld  O rion) im m edia tely  (R L U s).
Figure 3-2 shows the results o f the ATP bioluminescent assay which was carried out 
directly on the three samples of ADP reagent to determine the actual degree o f ATP 
contamination present within the reagents (3.2.2). The results demonstrated that two o f the 
purchased samples o f ADP substrate (Roche and Sigma) both contained significant levels 
o f ATP contamination, whereas the ADP substrate from Celsis was of sufficient purity to 
solve the problem of high background signal generated from presence of inherent ATP. It 
was clear therefore that a sample of ATP-free ADP was critical for the development o f a 
model assay using thermostable AK. as a marker enzyme.
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3.3.2 Calculation of titre o f purified anti-KLH IgG
IgG was purified using the methodology described in Section 3.2.3 and the titre of the anti- 
KLH assessed by ELISA to determine if the antibody had sufficiently high titre to be 
useful for conjugation to thermostable AK for use in the model assay (3.2.4).
Estimation of titre of purified IgG samples
2.500
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1.000
0.500
0.000
Dilution of purified IgG
Figure 3-3 Calculation of the titre o f  anti-KLH IgG purified from polyclonal antisera.
A m icro titre  plate w as coated , b lo ck ed  and sam ples added as d escribed  in sec tion  3.2.4. Post purification  
an tise ra  were dilu ted  from  1:250 d ilu tio n  and incubated  for 1 hour at 37 °C. T he p resence  o f  bound an tibody  
w as detected  using a secondary  p e ro x id ase  labelled an tibody  fo llow ed  by  co lou rim etric  detection  using  
te tram eth lybenzidene  (T M B ) substra te  and  m easu rem en t o f  absorbance (450  nm ).
The results demonstrated that the purified fraction o f anti-KLH IgG had a titre of 
approximately 1:16,000 - 1:32,000, and therefore was suitable for use in the model assay 
and conjugation to thermostable AK.
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3.3.3 Estimation of protein concentration of purified anti-KLH IgG
The protein concentration was estimated to be in excess of 1 mg.mL'1 as described in 
section 3.2.5. However, in order to improve the success of the conjugation chemistry, it 
was desirable that the protein concentration should be in the region of 10 mg.mL'1 and 
therefore the purified IgG was further concentrated by ultrafiltration (3.2.6). Two samples 
of concentrated purified IgG were obtained which contained approximately 20 mg.mL"1 
and stored frozen at -20 °C until used.
AK (myokinase) isolated from the thermophile Bacillus stearothermophilus (Sigma) was 
purchased for assessment for suitability as the thermostable marker enzyme for 
conjugation to antibody to establish ‘proof o f principle’ for the methodology. In order to 
determine if  this purchased stock of adenylate kinase had the correct properties for use in 
the model assay, a comparison of the thermostability of this enzyme was carried out with 
AK isolated from a different source of AK relevant to potentially contaminating tissue and 
therefore rabbit muscle AK was selected for this purpose (Sigma). The two sources of AK 
were compared for thermostability (3.2.7) by heat treating at temperatures ranging from 
37-70 °C for 10 minutes before incubating with ADP substrate followed by a standard 
bioluminescent assay and the results are shown in Figure 3-4.
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3.3.4 Comparison of thermostability of AKs
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Figure 3-4 C om parison of therm ostability of two sam ples of AKs
Tw o sources o f  A K  (Bacillus stearothermophilus and  rabb it m uscle) w ere  d ilu ted  from  sam e starting  
concen tra tion . In pan e ls  B and C the sam e d ilu tions o f  enzym e w ere  used  but w ere  in cu b a ted  for 10 m inutes 
in the m icro titre  p late  a t 60 °C  (panel B) and 70 °C (panel C) w hile panel A  had no hea t trea tm en t, p rio r to 
incubation  w ith  A D P and  detection  o f  A T P by b io lum inescence  assay.
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The results showed a significant difference in thermostability of the two sources of AK. B. 
stearothermophilus adenylate kinase was shown to be stable and active at temperatures 
significantly higher than required to inactivate conventional adenylate kinases (e.g. rabbit 
muscle adenylate kinase). Figure 3-4 shows comparison of the activities of AKs isolated 
from rabbit muscle AK and B. stearothermophilus with or without incubation at 60 or 70 
°C. The results of this assay demonstrated that B. stearothermophilus AK was 
thermostable and therefore suitable for use in the model assay. However it was noted that 
at 70 °C, there was considerable reduction (~10-fold) in the activity of B. 
stearothermophilus AK and therefore a more thermostable AK would be essential for the 
final assay format as it was anticipated that heat steps of at least 70 °C would be required, 
especially if  detection of prion infectivity was to be achieved within a biological material 
such as neuronal tissue, blood or sera where a significant contamination of thermolabile 
AK would be expected.
3.3.5 HPLC analysis of conjugation reaction
A number of antibody-enzyme conjugates were prepared using the heterobifunctional 
reagent SPDP (3.2.8). The method was evaluated and optimised to a ratio of antibody to 
enzyme of 1:3 respectively. The conjugates showed a peak at approximately 200 kDa by 
fractionation by HPLC gel filtration which was consistent with the expected molecular 
mass of the antibody-AK conjugate (Figure 3-5).
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Figure 3-5 C haracterisation o f  anti-KLH AK conjugates by HPLC.
Purified  an ti-K L H  IgG  w as co n ju g a ted  to B. stearo therm oph ilus A K  usin g  SPD P. The process resu lted  in the 
form ation o f  stab le  Ig G -A K  co n ju g a tes as dem onstra ted  by size frac tio n a tio n  on an H PLC  colum n (panel A). 
C onjugates w ere  p u rified  (p an el B). Panel C show s the c leav ag e  o f  the  con jugates into constituen t IgG  and 
A K  fractions as labe lled , by  red u ctio n  w ith D T T  d em onstra ting  that the m olecu les can be c leaved  to a llow  
the release o f  the en zy m atic  activ ity . X -axis show s re ten tion  tim e (m in u tes) and  Y axis show s abso rb an ce  
280nm . Note th e  re ten tio n  tim es for the HPLC colum n d iffer b e tw een  panel A  and panels B and C.
48
The purified conjugate was demonstrated to be cleavable by incubation with 25 mM 
dithiothreitol (DTT) for 30 minutes to yield active enzyme and the subsequent 
bioluminescence reaction to be unaffected by this concentration o f DTT (3.2.10). These 
results demonstrated that the B. stearothermophilus AK could be used to generate antibody 
enzyme conjugates without loss o f biological activity unlike previously reported results 
with mesophilic AK, (Gadow et al., 1984).
3.3.6 Detection of KLH with anti-KLH IgG-AK conjugate
Detection of KLH antigen by anti-KLH-AK conjugate
1000000
anti-KLH conjugate
100000
10000
1:1600 1:3200 1 :6400 1:12800 control1:8001:100 1:200 1:400
Dilution of conjugate
Figure 3-6 Model AK ELISA -detection of KLH antigen by anti-K LH -AK  conjugate.
M icro titre  p late  w ells w ere coated  w ith  K LH  at a concen tra tion  o f  l p g .m L ' . T he K LH antigen w as detected  
by the  addition  o f  serially  d ilu ted  a n ti-K L H -A K  conjugate  w hich  w as fo llow ed  by incubation  w ith A D P after 
w ash in g  o f  the wells w ith PB S-T . T he A T P produced  w as m easured  as R L U  in a plate lum inom eter by  the 
ad d ition  o f  30 pL  o f  L/L  reagent.
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The anti-KLH IgG-AK conjugate preparation was assessed by AK-ELISA to determine if 
successful detection of the KLH antigen by the use of the model assay format could be 
achieved (3.2.11). Several parameters of the assay were optimised prior to this assay and 
included increasing the length and temperature of the incubation with ADP and this 
resulted in a positive result. This was demonstrated by a titration curve in response to 
dilution of the antibody-enzyme conjugate thereby demonstrating detection of KLH at a 
coating concentration of 1 pg.mL'1 (Figure 3-6).
3.4 Discussion
The aim was to develop a model to demonstrate ‘proof of principle’ of the proposed assay 
in order to demonstrate that various parameters of the assay were feasible such as 
successful conjugation of the antibody to AK without the loss of the biological activity of 
the enzyme and to prove that AK could be coupled with bioluminescent detection 
technology.
This was particularly important as the ultimate aim of the assay was detection of BSE 
301V infectious mouse brain, or CJD which would necessarily involve biological 
containment. Hence the assay could be trialled and optimised without the requirement for 
containment at the early stages of development.
ATP bioluminescence has been shown to offer a sensitive detection methodology and has 
been extensively used for bacterial detection within hygiene monitoring (reviewed Kricka, 
1995). The potential use of AK labelled antibody coupled with bioluminescent detection 
by generation of ATP has been recognised previously, however conjugation of a 
mesophilic AK to an antibody had resulted in the loss of biological activity of the enzyme
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(Gadow et al., 1984). The plan was to use an AK isolated from a thermophilic 
microorganism as they tend to be more robust with inherent thermostable properties due to 
the growth conditions of the originating microorganism (Vieille & Zeikus, 2001). It was 
therefore hoped that the use of a thermostable AK for this purpose would avoid problems 
associated with loss of enzyme activity with the additional advantage that the heat stability 
properties could be utilised within the final assay format and enable inclusion of heat steps 
to effectively remove signal resulting from contaminating AKs. This was important as it 
was proposed that the assay would enable sensitive detection of prions within biological 
materials such as tissue or blood. It was therefore critical to establish that conjugation of a 
thermostable AK to an antibody was possible using a potentially more robust enzyme 
isolated from a thermophilic microorganism, without a resulting loss o f enzyme activity or 
thermostable properties.
It was ultimately hoped that the final assay format would enable detection of prion 
contamination on the surface of surgical instruments and therefore the assay had to be 
flexible to allow the potential separation of the antibody binding / washing and assay 
phases and allow the remaining steps of the assay to be carried out using standard 
laboratory equipment. Therefore once it was established that conjugation of the antibody to 
AK could be successfully achieved it then remained to show that cleavage of the AK 
moiety, without loss of activity, was possible using readily available reagents.
AKs catalyse the equilibrium reaction:
Mg2+ ATP + AMP < » Mg2+ADP +ADP
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As discussed previously, the normal direction of the reaction for the purposes of cellular 
metabolism is in the direction of formation o f ADP and AMP, however in the presence of 
an excess of ADP supplied as a substrate, the reaction can be driven in the opposite 
direction resulting in production of ATP which can be detected using bioluminescence 
(Blasco et al., 1998).
Researchers have previously described this methodology for the purpose of specific 
detection o f bacteria by lysis using bacterial phages to release intracellular AK followed by 
incubation with ADP and bioluminescent detection of ATP generated (Blasco et al., 1998; 
Squirrell, Price & Murphy, 2002). The use o f an excess of ADP substrate was therefore 
chosen as a method of producing ATP from the bound AK arid which would hopefully 
result in amplification of the signal with benefits in sensitivity of detection. The other 
important assay parameters proposed in the original plan was the combination treatment 
with ATPase or apyrase followed by inclusion of heat steps to inactivate any 
contaminating ATP or thermolabile AK present before incubation with ADP. The inclusion 
of this combination of steps would ensure that the entire bioluminescent signal was a result 
of generation of ATP by the thermostable AK antibody label and not due to the presence of 
contaminants, from e.g. biological tissue present. The use of apyrase as a method of 
reducing contaminating ATP present in biological samples when detecting bacteria for the 
purpose of hygiene monitoring has been described previously (Sakakibara et al., 1997).
Evaluation o f initially sourced commercial ADP showed that there was a high degree of
ATP contamination present which rendered them unfit for this purpose as it caused an
extremely high background signal which effectively obliterated any results obtained
utilising this method. It was obvious then that this was a critical step and good quality
reagents were necessary to ensure that no AK or ATP was introduced at this stage, which
would be after the heat inactivation and apyrase steps in the proposed model assay. This
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was particularly important as one of the requirements of the assay would be a capability of 
detection o f very small amounts of ATP generated from the AK antibody level in order 
that the assay could be truly ultra-sensitive. It was therefore established as crucial that 
reagents were free of contamination from either ATP or AK.
Contact was made with a small research company who were developing ATP 
bioluminescent detection as a direct measure of bacterial contamination on environmental 
surfaces and who had developed a set of ATP and AK free reagents which, they were keen 
to have assessed for a different use (Celsis, Cambridge, UK) (Squirrell, Price & Murphy, 
2002). The Celsis ADP stated that the contamination level of ATP was 0.1 ppm which 
made it potentially ideal. A quick comparison of inherent ATP contamination of the three 
sources of ADP by direct ATP bioluminescence immediately indicated that the use o f this 
ADP reagent would effectively remove the high background signal which was obscuring 
the results when using all the other commercially available ADP. This therefore enabled 
the AK ELISA to be further developed and optimised.
In order for the proposed assay methodology to be successful, the properties of
thermostability of the AK label would be required to be utilised in order for suitable heat
steps to be included in the assay to remove any AK from alternative sources such as
contaminating biological tissue. This was particularly important due to the ubiquitous
nature of AKs, which are present in most cell types and which therefore could result in
high non-specific background generation of ATP. Therefore it vital that the AK used was
sufficiently thermostable to withstand significantly higher temperatures that a normal
source of AK. B. stearothermophilus AK has been previously described as thermostable
(Glaser et a l, 1992) and the results of this study (3.3.4) demonstrated stability and activity
at temperatures of 60 and 70 °C which was significantly higher than temperatures capable
of inactivating conventional adenylate kinases (e.g. rabbit muscle adenylate kinase). This
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showed that this enzyme was suitable for use to establish the feasibility of proposed assay 
however it was apparent that although the B. stearothermophilus AK enzyme showed 
reasonable heat stability at 60 °C there was a considerable loss of activity, approximately 
10-fold, apparent at higher temperatures such as 70 °C. For development of the final assay 
therefore, it was identified as desirable that a more thermostable AK should be sourced, to 
enable inclusion of heat inactivation steps of temperatures of 70 °C and above, in order to 
effectively remove AK present in potentially substantial amounts of contaminating tissue 
on the surface of surgical instruments.
The use of a standard antigen-antibody combination was selected for development of the 
initial model with keyhole limpet haemocyanin (KLH) chosen as antigen. This enabled 
extensive evaluation of the conjugation methods using relatively inexpensive and readily 
available reagents. KLH is commonly used as a carrier protein for haptens for the 
production of antisera, therefore sera produced to alternative haptens using this carrier 
protein will have high immunoreactivity for KLH This combined with the readily 
commercial availability of purified KLH at relatively low prices meant that this was a 
practical combination for use for this purpose (Harlow & Lane, 1988). The conjugation 
method was optimised and the reaction followed using HPLC gel filtration and the results 
demonstrated successful conjugation and the purified conjugate fraction found to have 
active AK by subsequent bioluminescent detection. These results demonstrated that the B. 
stearothermophilus AK unlike mesophilic AKs, could be used to generate conjugates, 
which retain biological activity and therefore suitable for this purpose.
Another key stage of development of the assay was to demonstrate that it was possible to
cleave the AK moiety from the bound antibody without loss of the biological activity of
the enzyme. This is potentially a critical step for applications of the assay where the
binding and washing phases need to be carried out in situ, e.g. for the validation of surgical
54
instrument decontamination, to enable completion of the assay using standard laboratory 
equipment. The conjugate was demonstrated to be cleavable by incubation with 
dithiothreitol (DTT) to yield active enzyme and the subsequent bioluminescence reaction 
to be unaffected by the concentration of DTT (25 mM) required to cause linker cleavage. 
This thereby indicated that it would be possible to include this step in the final assay 
format without detriment to detection o f antigen.
It therefore remained to demonstrate use of the model assay for detection of the antigen 
selected for the purpose using the thermostable AK immunoassay. A number of assay 
conditions were further optimised prior to this, including length and temperature of 
incubation steps and concentration of ADP substrate. The results of the optimised AK- 
ELISA demonstrated a titration curve in response to dilution of the antibody-enzyme 
conjugate demonstrating successful detection of KLH at a coating concentration of 
1 pg.mL'1 using the novel methodology and thereby establishing “proof of principle”.
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4 Selection of improved thermostable adenylate kinases
4.1 Introduction
A thermostable adenylate kinase isolated from Bacillus stearothermophilus was used 
within development of the model assay to demonstrate the feasibility of the proposed 
methodology. It was shown that this AK still retained activity at temperatures of up to 70 
°C; however it was noticeable that there was substantial loss of activity (~10-fold) at this 
temperature, which would make its use unsuitable for the final assay format. The ultimate 
aim of the methodology being designed was to enable sensitive detection of prions within 
an excess of biological material such as blood and neurological tissue. This would 
therefore, necessitate inclusion of sufficient heat steps to reduce background signal from 
contaminating AKs contained endogenously within tissue. This combined with economic 
reasons due to the commercial cost of the Bacillus stearothermophilus AK, made it 
necessary to an alternative AK with superior thermostable properties which would be able 
to be produced in-house in sufficient quantities to allow development of the assay.
Enzymes isolated from thermophiles tend to more robust than their mesophilic 
counterparts (Vieille & Zeikus, 2001). Furthermore, thermophiles are classified by their 
optimal temperatures with an additional category termed extreme thermophiles or 
hyperthermophiles which have optimum temperatures for growth in excess of 80 °C. 
Proteins and enzymes isolated from these organisms can survive extremes of temperature 
and pH compared to proteins isolated from mesophilic organisms which have optimal 
growth conditions at temperatures ranging from 25-40 °C (Brock, 1978). Studies on the 
thermostability of several AKs from hyperthermophiles have been published and show that 
these enzymes can survive temperatures of above 80 °C (Ferber et al., 1997; Kath, Schmid
& Schafer 1993; Okajima et al., 2002; Vieille et al, 2003). Thermophiles, including 
hyperthermophiles can be bacterial or archaeal in origin and therefore the aim was to 
screen AKs isolated from all these categories to increase the potential range of different 
AKs for evaluation, in order to identify suitable alternatives for use in the final assay 
format. In addition, it was important that any AKs identified as a result o f this screen, were 
assessed specifically for potential production of recombinant versions to enable large 
quantities to be produced.
4.2 Materials and Methods
4.2.1 Isolation of affinity purified AKs
A number of different thermophilic microorganisms of bacterial and archaeal origin were 
available from an in-house thermophile culture collection (CEPR Thermophile Culture 
Collection) which included samples of biomass for each of the microorganisms, which had 
been previously grown using defined growth condition, by Mrs Jean Carr (Sharp & Raven, 
1997). This enabled isolation of AKs from the microorganisms listed (Table 4-1).
1 g of biomass from each sample was suspended in 9 volumes of 50 mM Tris-HCl, 200 
mM NaCl, pH 7.5 and vortexed for 2-3 seconds to disperse the cell paste. Each aliquot was 
sonicated on ice for 5 minutes (10 cycles, 30 seconds on/ 30 seconds off) using an MSE 
Soniprep 150 adjusted to an amplitude of approximately 18 microns. The aliquots were 
centrifuged at 6000 rpm using a centrifuge (Biofuge Primo) fitted with 6 x 50 mL conical 
tube rotor for 10 minutes and the supernatants recovered. The supernatants were passed 
through 0.45 p Minisart filters (sterile) and collected in separate sterile plastic 50 mL 
conical tubes and stored at 4 °C.
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Organism Domain Growth T 0pt pH 0pt
1 Aeropvrum pernix Archaeon Aerobe 95 °C 7.0
2 Alicvclobacillus acidocaldarius Bacterium Aerobe 65 °C 3.5
3 Aquifex pyrophilus Bacterium Microaerophile
oooo 6.5
4 Bacillus caldotenax B T 1 Bacterium Aerobe 65 °C 7.0
5 Bacillus sp ecies PS3 Bacterium Aerobe 65 °C 7.0
6 Bacillus stearothermophilus 11057 Bacterium Aerobe 65 °C 7.0
7 Bacillus stearothermophilus 12001 Bacterium Aerobe 65 °C 7.0
8 Bacillus thermocatenulatus Bacterium Aerobe 65 °C 7.0
9 Clostridium stercocorarium Bacterium Anaerobe 55 °C 7.0
10 Meiothermus ruber Bacterium Aerobe
UoO\o 6.5
11 Pvrococcus furiosus Archaeon Anaerobe 95 °C 7.5
12 Pvrococcus horikoshii Archaeon Anaerobe 95 °C 7.0
13 Pvrococcus woesei Archaeon Anaerobe 95 °C 7.0
14 Rhodothermus marinus Bacterium Aerobe 70 °C 6.5
15 Sulfolobus acidocaldarius 98-3 Archaeon Aerobe 75 °C 2.5
16 Sulfolobus shibatae B 21 Archaeon Aerobe 75 °C 2.5
17 Sulfolobus solfataricus P2 Archaeon Aerobe 75 °C 2.5
18 Thermoanaerobacter ethanolicus Bacterium Anaerobe 65 °C 6.0
19 Thermoanaerobacter thermosulfurogenes Bacterium Anaerobe 65 °C 6.5
2 0 Thermobrachium celere Bacterium Anaerobe 60 °C 7.0
21 Thermococcus litoralis Archaeon Anaerobe 85 °C 6.5
22 Thermus aquaticus Y T 1 Bacterium Aerobe -j o o O 8.0
23 Thermus caldophilus G K 24 Bacterium Aerobe 70 °C 8.0
Table 4-lThermophilic microorganisms
Thermostable AKs with inclusion o f  whether o f bacterial or archaeal domain and details o f  optimal growth 
temperature and pH o f the microorganisms screened for thermostable AKs.
Clarified cell extracts were passed through 1 mL Hitrap Blue affinity columns (Amersham 
Pharmacia Biotech). The columns were prepared for use by removing the stoppers and 
connecting 10 mL syringes via the adaptors provided. Care was taken to avoid introducing 
air to the column at all times. The column preservative buffer was displaced by passing 10 
column volumes of binding buffer (50 mM Tris-HCl, 200 mM NaCl, pH 7.5) through each 
column. Following equilibration with binding buffer, supernatants were loaded manually at 
~ 0.5-1 mL.min'1. The columns were then washed with 10 further column volumes of 
binding buffer to elute all non-bound material. Adenylate kinases were affinity eluted 
using a buffer comprising 10 mM ATP, 10 mM AMP, 10 mM MgCh, 50 mM Tris-HCl, 
200 mM NaCl, pH 7.5 and collected as 1 mL aliquots and stored at 4 °C until required. The
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columns were regenerated by passage of 10 column volumes of 2 M NaCl, followed by a 
further 10 column volumes of binding buffer.
4.2.2 AK activity assay
All fractions were diluted 1:500 in 50 mM Tris-HCl, pH 7.5 and 100 pi of each dilution 
was added to a well of a thermostable white microtitre plate (Nunc®) in duplicate. 5 pi of 
apyrase (Celsis) was added to each well, including controls which comprised; sample (pre­
affinity purification); flow through sample; wash stage sample and elution buffer alone. 
The apyrase was incubated with the samples for 30 minutes at 37 °C and subsequently 
inactivated by incubation at 65 °C for 10 minutes. The plate was cooled to room 
temperature and 100 pi o f 0.13 mM ADP was added in 15 mM MgAC, 1 mM EDTA, pH 
6.7 buffer and incubated for 20 minutes at 70 °C (or 80 or 90 °C for characterisation of 
thermostability profile) and subsequently cooled to room temperature before the addition 
of 10 pi of luciferin-luciferase reagent. The relative light units (RLUs) values were read by 
luminometer (Berthold Orion). For purification, all fractions identified as containing AK 
activity were pooled and dialysed extensively against PBS or 50 mM Tris-HCl, pH 7.5.
4.2.3 Protein estimation
An estimate of the protein content of the purified AK was performed using 3 methods
• The use of BCA kit (Pierce), according to manufacturer’s instmction by 
comparison to a prepared standard curve
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• Absorbance (280nm) using a quartz cuvette and UV spectrophotometer. The 
concentration o f AK was determined by absorption at 280 nm and extinction 
coefficient for AK defined as A \ m g/m L 0.52.
• The use o f Biorad DC (detergent compatible) protein assay, according to 
manufacturer’s instructions by comparison to a prepared standard curve
4.2.4 Isolation o f genomic DNA
Seven thennophilic organisms were grown using individually defined growth conditions. 
The procedures for the growth o f these organisms are complex and vary according to the 
origin of the organisms. The fermentation conditions for all the organisms have been 
described. The organisms were freshly grown using defined growth conditions (Sharp, 
Raven 1997) by Mrs Jean Carr and Mr Clive Buswell.
Thermophile Accession number Database
Ae ropy rum per nix NC 000854 Genbank
Archaeoglobus fulgidus NC 000917 Genbank
Pyrococcus abyssi NC 000868 Genbank
Pyrococcus horikoshii NC 000961 Genbank
Pyrococcus horikoshii NC 000961 Genbank
Thermotoga maritima NC 000853 Genbank
Sulfo/obus acidocaldarius NC 007181 Genbank
Sulfo/obus solfataricus NC 002754 Genbank
Table 4-2 List of therm ophiles cultured for isolation of genom ic DNA
T he therm oph ilic  o rg an ism s w ere  cu ltu red  using  defined  g row th  cond itions and genom ic D N A  w as iso lated  
to  enable po ten tia l p ro d u c tio n  o f  recom binan t versions. N .B . P y ro co ccu s horikoshii had tw o A K  g enes w ith in
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the sequence for cloning. Genomic D N A  was isolated from the microorganisms using the Wizard® Genomic 
D N A  Purification Kit (Promega) for Gram positive and Gram negative organisms according to 
manufacturer’s instructions.
4.2.5 PCR amplification of AK using designed primers
The primers were specifically designed based on the genomic sequence of each organism 
and included restriction enzyme sites for BamHl or Sail for forward and reverse primers 
respectively + “GC”.
1. Aeropyrum pernix
AEROPERNBAM.FOR (25 mer) G CGG ATCCG TGA AGG TGA GAC ACC C 
AEROPERNSAL.REV (26 mer) GCG TCG ACT TAG AGG TTC TTT ATG AG
2. Archaeoglobusfulgidus
ARCHAEFULBAM.FOR (27 mer) GCG GAT CCA TGA ACC TGA TTT TTC TCG 
ARCHAEFULSAL.REV (27 mer) GCG TCG ACT CAG GAT TTG ATC TTT TCC
3. Pyrococcus abyssi
PYROABYSBAM.FOR (29 mer) GCG GAT CCA TGA ACA TAC TTA TTT TTG GG 
PYROABYSSAL.REV (27 mer) GCG TCG ACT CAT CGC CTA TTT TCC TGG
4. Pyrococcus horikoshii (AK1)
PYROHORIAK 1 BAM.FOR (27 mer) GCG GAT CCA TGA ATA TCC TAA TCT TTG 
PYROHORIAK1SAL.REV (25 mer) GCG TCG ACT CAT CGC CTA CTC CTA G
5. Pyrococcus horikoshii (AK2)
PYROHORIAK2BAM.FOR (32 mer) GCG GAT CCA TGC CCT TTG TAG TCA TTA TTA CG 
PYROHORIAK2SAL.REV (28 mer) GCG TCG ACT CAA GCA TAT TCC TTC ACC G
6. Thermotoga maritima
THERMMARIBAM.FOR (30 mer) GCG GAT CCA TGA TGG CGT ACC TTG TCT TTC 
THERMMARISAL.REV (33 mer) GCG TCG ACT CAT TTA TCA CTC CAC CCT ATT ATC
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7. Sulfolobus acidocaldarius
SULFACIDOBAM.FOR (30 mer) GCG GAT CCA TGA AGA TTG GTA TTG TAA CTG 
SULFACIDOSAL.REV (30 mer) GCG TCG ACT TAC TTC ATA GAC CTT ATT ATC
8. Sulfolobus solfataricus
SULFSOLBAM.FOR (30 mer) GCG GAT CCA TGA AAA TAG GTA TAG TAA CTG 
SULFSOLSAL.REV (32 mer) GCG TCG ACT CAC ATT AAG GAA TTT ATT ATT TC
10 pL of Thermopol buffer (20mM Tris-HCl, lOmM NH4 S 04, lOmM KC1, 2mM MgS04, 
0.1% Triton X-100, pH 8.8) (New England Biolabs) 2.5 pL (2mM) MgCl2, 1 pL dNTPs 
(200 pM), 1 pL of each primer (forward and reverse) diluted to 100 pmoles, 1 pL of 
genomic DNA template, 1 pL o f Vent polymerase (New England Biolabs) plus 82.5 pL of 
distilled H20  were added to 0.2 mL PCR tubes. The negative control consisted of the DNA 
template replaced by distilled H20 . A standard PCR programme was run overnight. The 
PCR products were analysed by running on a 1.2 % pre-cast agarose gel (E-Gel®, 
Invitrogen) with a 100 bp and 1 kb DNA ladders (Invitrogen). The relevant bands were 
excised from the gel and purified using Qiaquick Gel Extraction kit (Qiagen), according to 
the manufacturer’s instructions.
4.2.6 TOPO Cloning and Transformation
An A-overhang was created on the gel extracted PCR products to allow cloning into TOPO
TA vector (Invitrogen). This was achieved by the addition of 8 pL of PCR products with 1
pL o f Taq polymerase and 1 pL of 10 mM dATP and incubation at 72 °C for 10 minutes.
Following this, the TOPO cloning and transformation reaction was carried out according to
manufacturer’s instructions. Once the procedure was complete, 10 pL or 100 pL of each
transformation reaction was spread on art L-agar plate containing 100 pg.mL'1 ampicillin.
The plates were incubated overnight at 37 °C and analysed for colony growth the next day.
62
4.2.7 Sub-cloning of AK gene into pET28a
DNA was isolated from sub-clones using Wizard® SV 96 Plasmid DNA Purification 
(Promega) following manufacturer’s instructions. The correct insert was confirmed by 
performing a BamHI / Sail restriction enzyme digest prior to sequencing by the addition of 
8 pL o f plasmid preparation, 1 pL of BamHI, 1 pL of Sail, (Restriction enzymes, New 
England Biolabs) 2 pL of Sal buffer and 8 pL of distilled H2O to a microcentrifuge tube 
followed by incubation for 3°hours at 37 °C. The results were analysed by running on a 1.2 
% agarose E-gel (E-Gel®, Invitrogen) and visualising with UV light using the Bio-Rad Gel 
Documentation system. The BamHI / Sail digest fragment were excised from the gel and 
purified using Qiaquick Gel Extraction kit (Qiagen), according to the manufacturer’s 
instructions. The pET 28a vector (Novogen) was BamHI and Sail digested and 
dephosphorylated using 1 unit of alkaline phosphatase for 30 minutes at room temperature. 
Ligation of the Bam / Sal fragment was carried out by the addition of 3 pi of the vector, 7 
pL of the insert, 3 pL of 5 x ligase buffer, 1 pL of 10 mM ATP and 1 pL (0.2-0.4U / pL ) 
of the DNA ligase and incubating overnight at 16 °C. After overnight incubation, a further 
0.5 pL o f T4 DNA ligase was added to each reaction to ensure full ligation and incubated 
for 20-30 minutes at room temperature. 2 pL of the ligation mix was added to an aliquot of 
Escherichia coli (E. coli) JM109 cells (Stratagene) and incubated on ice for 5 minutes. 
Cells were heat shocked at 42 °C for 1 minute and returned to ice. 250 pL of SOC medium 
was added and further incubated for 1 hour at 37 °C, while shaking horizontally. 10 and 
100 pL aliquots were inoculated onto L-agar plates containing kanamycin (35 pg.mL'1). 
The agar plates were incubated at 37 °C overnight and subsequently analysed for colony 
growth. Colonies (3) were picked and inoculated into 5mL of L-Broth containing 
kanamycin (35 pg.mL'1) and incubated overnight at 37 °C.
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4.2.8 Transformation of Sulfolobus AK into E. coli
Sulfolobus acidocaldarius adenylate kinase in the vector pET3a (AmpR) was supplied by 
Professor G Schafer (Vonrhein et al., 1998) and Sulfolobus acidocaldarius adenylate 
kinase in the vector pET28a were transformed into BL21 (DE3) (Novagen) or JM109 
(DE3) E. coli competent cells (Promega). In addition codon enhanced strains of E. coli 
BL21 (DE3) pACYC ILE ARG 10 cells, expressing rare tRNAs suitable for enhancing 
expression levels of AT-rich genes were used. (Novogen) (Zdanovsky & Zdanovskaia, 
2000). 20 pL aliquot of the appropriate cells were transformed by the addition o f 2-4 pi of 
plasmid DNA, the cells were left on ice for 30 minutes and then heat shocked for 50 
seconds at 42 °C. The cells were returned to ice for a further 2 minutes followed by the 
addition of 1 mL o f L-Broth and incubated at 37 °C for 1 hour in a shaking incubator. The 
cells were subsequently plated on L-agar plates containing antibiotics ampicillin, (100 
pg.mL1); or kanamycin (25pg.mL1) plus chloramiphenicol (35 pg.mL'1) 250 pi per plate, 
as appropriate, and incubated overnight at 37 °C. The cells transformed with the AK genes 
were grown in 8 L fermenters and cell paste harvested (CEPR Fermentation Plant).
4.2.9 Mini-expression study
Three colonies were picked from each plate and inoculated into 3 mL of L-broth
containing kanamycin (25 pg.mL'1) and chloramphenicol (35 pg.mL'1). The cultures were
incubated at 37 °C for 3.5 hours, while shaking at 200 rpm. The cultures were induced by
the addition of isopropyl-p-D-thiogalactoside (IPTG) (500 pM) and grown for a further 2
hours at 37 °C. The cells were pelleted by centrifugation at 13,500 rpm (19150 x g) in
microcentrifuge for 10 minutes. The supernatant was discarded and the pellet resuspended
in 300 pi of PBS and sonicated by 3 cycles of 30 seconds on / 30 seconds off at
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approximately 18 p at full power on ice. The resulting solution was centrifuged at 13,500 
rpm for a further 5 minutes and the supernatant retained for analysis.
4.2.10 Calculation of specific activity
Specific activity is defined as pmol of ATP mg'1, min'1.
1 unit of AK » 1 pmol o f product formed per minute at a given temperature i.e. 1 pmol of 
ATP generated from ADP per minute (BioThema AB, ATP kit SL 144-041). Purified AK 
sample was diluted 1:200,000 and 1:400,000 in 15 mM magnesium acetate buffer + 1 mM 
EDTA, pH 6.7. ADP was prepared as a 135 pM solution in the above buffer and 160 pL 
was added to appropriate wells. Dilutions of AK were added to the wells (1:100, 2 pL / 
well). The assay was controlled by the inclusion of wells excluding ADP and AK 
respectively. The microtitre plate was incubated at 70 °C for 30 minutes then cooled to 20 
°C using the Thermocycler (Techne). 30 pL of the ATP reagent (Luciferin-luciferase) 
(BioThema) was added to each well and the RLU measured in a plate luminometer 
(Berthold Orion). ATP standard (supplied) was added to the wells (10 pL) and ATP 
produced was calculated using the equation:-ATPsmp = 10'7 x Ismp/ (Ismp+std -  Ismp)-
4.2.11 Heat treatment purification step
Approximately 10 g of frozen cell paste was weighed and re-suspended in 3 volumes of 20 
mM Tris-HCl, 1 mM EDTA containing 900 mM NaCl at pH 7.5. The cells were sonicated 
(MSE Soniprep 150) on ice (~20 microns) using 25 cycles of 30 seconds on/ 30 seconds 
off and the supernatant collected by centrifugation at 6000 x g for 30 min at 4 °C. Heat
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labile proteins were removed by heat treatment at 80 °C in a water bath for 20 min and the 
resulting precipitate removed by centrifugation at 6000 rpm for 30 min.
4.2.12 Affinity purification
HiTrap Blue columns 3 x 5  mL (Amersham Pharmacia) were joined in sequence and 
equilibrated with 5 column volumes o f 20 mM Tris-HCl, 1 mM EDTA, 900 mM NaCl, pH 
7.5 using FPLC chromatography ( Pharmacia) 150 mL of the heat-treated supernatant was 
applied to the column using a Superloop (GE Life Sciences) and the flow through 
collected. After loading of the sample, the column was washed with 20 mM Tris HC1, 1 
mM EDTA, 200 mM NaCl, pH 7.5 at a rate of 0.2 mL.min overnight and a sample of wash 
solution collected. The column was re-equilibrated with a further 5 column volumes of 200 
mM Tris-HCl, 1 mM EDTA, 900 mM NaCl, pH 7.5 and the AK eluted using buffer 
containing 10 mM ATP, 10 mM AMP, 10 mM MgCh in 200 mM Tris-HCl, 1 mM EDTA, 
200 mM NaCl, pH 7.5 at a rate of 1 mL.min and 2.5 mL fractions collected. Regeneration 
of the column was achieved by washing with further 5 column volumes of elution buffer 
followed by 5 column volumes of 200 mM Tris-HCl, 1 mM EDTA, 900 mM NaCl, pH 7.5 
and then rinsed with 20 % ethanol.
4.2.13 Gel filtration
A Superdex 75 Hiload 16/60 preparative column was pre-equilibrated with 50 mM Tris- 
HCl, pH 7.5 with approximately 250 mL of buffer using FPLC chromatography 
(Pharmacia). A 2 mL sample o f affinity purified, heat treated supernatant was loaded via a 
sample loop and the buffer re-applied to the column. The peak was identified by measuring
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absorbance (280nm). Fractions were collected in 2.5mL aliquots and the AK activity 
assessed by AK activity assay.
4.2.14 SDS-PAGE assessment of purification of AK
Proteins were analysed by SDS-PAGE on 4-12 % Bis Tris gels (Invitrogen NuPAGE® 
Novex Gels). Samples were prepared by adding each sample (25 pL) to 75 pL of distilled 
H2O Nupage LDS (x 4) sample buffer (25 pL) was added to each and the samples heated to 
99 °C for 2 minutes. Novex Mark 12 Standards were used as markers and the gel apparatus 
was set up per manufacturer’s instructions. 5 pL of markers or 25 pL of samples were 
added to relevant wells and the gel run for 50 minutes in MOPS running buffer 
(Invitrogen) and proteins visualised using the Colloidal Blue staining kit (Invitrogen) 
according to the manufacturer’s instructions. The gel was photographed using the Biorad 
gel documentation system.
4.2.15 Characterisation of dynamic range of AK
Sulfolobus acidocaldarius AK was diluted over a log range in 50 mM Tris-HCl, pH 7.5 
and 100 pL of each dilution was added to a well of a thermostable white microtitre plate 
(Thermofast, Abgene) in duplicate. 100 pL of 0.13 mM ADP was added in 15 mM MgAC, 
1 mM EDTA, pH 6.7 buffer and heated to 30, 50 and 70 °C for 20 minutes then cooled to 
room temperature before the addition of 30 pL of luciferin-luciferase reagent (Biothema) 
to each well. The RLU values were read by luminometer.
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4.3 Results
4.3.1 Screening for alternative thermostable adenylate kinases
The aim of this work was to identify potential candidate AKs with improved thermostable 
properties, for comparison to the AK isolated from Bacillus stearothermophilus used 
previously in the model assay. This was achieved through access to a thermophile culture 
collection (CEPR Thermophile Culture Collection), which enabled isolation of AKs from a 
range of thermophilic organisms, to determine if any could be identified which were 
optimal for the purpose of further development of the ultra-sensitive assay. In order to set 
up a screen of the thermophiles, biomass was prepared from each of the organisms on the 
list (Table 4-1) and a method of isolating AKs from this biomass established (4.2.1). This 
enabled a large number of AKs to be compared from a range of bacterial and archaeal 
thermophiles with different inherent properties. The initial screening of twenty-four 
thermophilic microorganisms yielded a number of organisms with highly active and 
thermostable AKs and the results are shown in Figure 4-1. An assessment was carried out 
at increasing temperatures of 70, 80 and 90 °C to fully evaluate the thermostability of the 
different AKs isolated from a range of microorganisms.
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Thermostability of AKs - heat treatm en t at 70°C
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Aquifex pyrophilus
Bacillus caldotenax BT1
Bacillus species PS3
Bacillus stearothermophilus 11057
Bacillus stearothermophilus 12001
Bacillus thermocatenulatus
Clostridium stercocorarium
Meiothermus ruber
Pyrococcus furiosus
Pyrococcus horikoshii
Pyrococcus woesei
Rhodothermus marinus
Sulfolobus acidocaldarius 98-3
Sulfolobus shibatae B12
Sulfolobus solfataricus
Thermoanaerobacter ethanolicus
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Figure 4-1 Assessment of the therm ostability at 70, 80 and 90 °C of AKs
The A K s w ere  iso lated  from  the b io m ass by  affin ity  chrom atography  u sin g  se lec tive  absorption  and 
deso rp tion  from  C ibacron B lue 3A  (B lu e  S epharose). The supernatan t w as trea ted  w ith  apyrase to destroy  
A TP p resen t from  e lu tion  b u ffer and ap y rase  su b sequen tly  inactivated  by heat trea tm en t at 65 °C prior to  A K
assay.
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In Figure 4-1, many AKs showed little or no loss of activity at 80 °C compared to a base 
line of 70 °C. In addition, some of the identified AKs retained up to 30% of their activity 
at 90 °C. This result demonstrated that potentially more suitable candidate AKs than 
Bacillus stearothermophilus AK were available for inclusion in an assay format utilising 
heat treatments of up to 80 °C to remove background signal.
The AKs identified from this round o f screening with suitable thermostable properties for 
use in the assay were Pyrococcus furiosus, Sulfolobus acidocaldarius, Sulfolobus 
solfataricus, Sulfolobus shibatae B21, Rhodothermus marinus and Thermococcus litoralis, 
which all demonstrated considerable residual activity of ~ 30 % following incubation at 90 
°C and high activity at 80 °C. This identified them as potentially useful for the developed 
assay to enable inclusion of heat steps o f temperatures of 70-80 °C, to remove any residual 
contaminating thermolabile AK present in a large excess of biological material.
4.3.2 Production of recombinant thermostable AKs
The results of the screening showed that there were several AKs with the required 
properties for use as an enzyme label in the proposed assay. In order for sufficient 
quantities of AK to be obtained, which would enable purification and subsequent 
conjugation to antibody, it was important that a method was developed to enable 
production of a stock of enzyme of consistent quality. It was therefore decided that 
recombinant DNA technology would provide the best approach. A difficulty was 
encountered however, as it was discovered that there were few known genomic sequences 
to enable design of specific primers for PCR amplification of AKs. On further 
investigation, it was found that seven o f the thermophiles included in the initial screening
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had known genomic DNA sequences with identified AK genes. These were Aeropyrum 
pernix, Archaeoglobus fulgidus, Pyrococcus abyssi, Pyrococcus horikoshii, Thermotoga 
maritima, Sulfolobus acidocaldarius and Sulfolobus solfataricus and the latter two were 
identified as highly thermostable from the screening process. It was therefore decided that 
recombinant AKs would be produced o f these 6 thermophiles. This would enable 
assessment and comparison of the AKs from two identified as being highly stable at 
temperatures of 80 °C and above with AKs from alternative sources. It was decided that it 
was worth assessing AKs with perhaps less thermostability but with other potentially 
suitable qualities such as successful over-expression in E. coli for reasons of practicality.
In order to carry out PCR amplification of the AK genes, genomic DNA had to be isolated 
from biomass obtained by growth of the thermophiles using the individually defined 
growth conditions (4.2.4). A method of isolating genomic DNA from Gram positive 
microorganisms was originally attempted for all the cell pastes. However it was found that 
this method was only successful for Thermatoga maritima, which was the only bacterial 
culture and also known to be a Gram positive organism. Therefore an alternative method of 
genomic DNA extraction had to be identified for the archaeons. A method suitable for 
extraction o f genomic DNA from Gram negative microorganisms was then trialled and 
found to be successful (Wizard® Genomic DNA Purification Kit). The genomic DNA 
extracted from all the thermophiles was used as templates for PCR amplification of the 
adenylate kinase genes from each organism (4.2.5) and analysis of the PCR product carried 
out using a 1% agarose gel (E-gel) to identify whether any of the PCR products were of the 
expected size of ~600 bp.
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Sample number
1. Aeropyrum pernix
2. Negative control
3. Archaeoglobus fulgidus
4. Negative control
5. Pyrococcus abyssi
6. Negative control
7. Pyrococcus horikoshii (AK1)
8. Negative control
Figure 4-2 Analysis o f PCR products
G enom ic D N A  w as ex trac ted  from  biom ass for all the m ic ro o rg an ism s in the above list. T he D N A  w as used  
as tem plate  for the  P C R  am plification  o f  the A K  genes usin g  sp ec ia lly  designed  prim ers based  on the  know n 
D N A  sequence  o f  the  m icroorgan ism s. N egative  con tro ls  w e re  included  betw een each  sam ple  lane, w ith  
w ater rep lacing  g en o m ic  D N A  tem plate
Sample number
1. Pyrococcus horikoshii (AK2)
2. N eg ativ e  con tro l
3. Thermatoga maritima
4. Negative Control
5. Sulfolobus acidocaldarius
6. N eg ativ e  con tro l
7. Sulfolobus solfataricus
8. N eg ativ e  con tro l
D N A  1 2  3 4  5 6 7 8
l a d d e r  s a m p l e  no
Figure 4-3 Analysis o f PCR products
The expected size of the PCR products was ~ 600 base pairs and the results in Figure 4-2 
and Figure 4-3 indicate that AK genes had been successfully PCR amplified from four of 
the samples. The samples were Pyrococcus abyssi, Thermatoga maritima, Sulfolobus 
acidocaldarius and Sulfolobus solfataricus. Production of recombinant AKs was continued
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by cloning of the PCR products into a TOPO TA vector (4.2.6) before subsequent sub­
cloning into a pET28a expression vector (4.2.7). In addition, a sample of recombinant 
Sulfolobus acidocaldarius AK contained within the vector pET3a was kindly donated by 
Professor G Schaeffer (Vonrhein et al., 1998) and enabled a stock of AK to be prepared 
initially while work was carried out to produce a more suitable recombinant AK.
4.3.3 Over-expression of recombinant AKs
In order to determine the success of the production of recombinant AKs within the vector 
pET28a expression studies were performed as described in section 4.2.9.
In addition, over-expression o f Sulfolobus acidocaldarius AK which had been supplied 
within pET3a vector (Vonrhein et al., 1998) was carried out by transformation into E. coli 
BL21 (DE3) cells and this stock of recombinant AK was purified as described previously 
(4.2.11). The yield obtained on over-expression was rather low (0.5-1 mg.L'1), however it 
enabled work to begin on various stages of assay development while production of an in- 
house recombinant AK was developed with a higher yield.
I
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Key
1. Molecular weight markers
2. Pyrococcus abyssi (pre induced 
sample)
3. Pyrococcus abyssi (post induced 
sample)
4. Thermotoga maritima (pre induced)
5. Thermotoga maritima (post induced)
6. Sulfolobus acidocaldarius (pre -  
induced)
7. Sulfolobus acidocaldarius (post 
induced)
8. Sulfolobus solfataricus (pre)
9. Sulfolobus solfataricus (post­
induced)
10. Molecular weight markers
Figure 4-4 SDS-PAG E analysis of over-expressed recom binant AKs
O v er-ex p re ssed  A K s from  Pyrococcus abyssi, Thermatoga maritima, Sulfolobus acidocaldarius and  
Sulfolobus solfataricus pre and  post indu ctio n  (see  key). S upernatan t co n ta in in g  the  ov er-ex p ressed  pro tein  
w as an a ly sed  by SD S-P A G E  on 4-12 %  B is T ris gels w ith  M O Ps runn ing  bu ffer. T h e  p ro te ins on the gel 
w ere  v isu a lised  using  C ollo idal B lue S ta in in g  k it (Inv itrogen) and  im aged  by  B io rad  gel docum entation  
system .
Key
i . Molecular weight markers
2. Pyrococcus abyssi (pre induced
sample)
3. Pyrococcus abyssi (post induced
sample)
4. Thermotoga maritima (pre induced)
5. Thermotoga maritima (post induced)
6. Sulfolobus acidocaldarius (pre -
induced)
7. Sulfolobus acidocaldarius (post­
induced)
8. Sulfolobus solfataricus (pre)
9. Sulfolobus solfataricus (post­
induced)
10. Molecular weight markers
Figure 4-5 SDS-PAG E analysis o f over-expressed recom binant AKs (heat treated)
Pyrococcus abyssi, Thermatoga maritima, Sulfolobus acidocaldarius and Sulfolobus solfataricus pre and 
p o st in d u ctio n  (see  key).
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The supernatant containing the over-expressed protein was heat treated by incubation at 80 
°C for 20 minutes before centrifugation to remove the heat labile proteins from the E. coli 
host, prior to being re-analysed by SDS-PAGE 4-12 % Bis Tris gels with MOPs running 
buffer. The proteins were visualised using Colloidal Blue Staining kit (Invitrogen) and the 
gels by Biorad gel documentation system.
SDS-PAGE analysis demonstrated that only recombinant AK from Sulfolobus 
acidocaldarius and Sulfolobus solfataricus had been successfully over-expressed and also 
retained thermostability as shown by the presence of protein bands of approximately 24 
kDa in both the pre and post heat treated samples (Figure 4-4 & Figure 4-5).
The results of the SDS-PAGE analysis showed that the recombinant AK derived from 
Sulfolobus acidocaldarius had been over-expressed in a somewhat greater quantity within 
the same volume of sample, denoted by the presence of a larger band of the expected 
molecular mass (-24 kDa). It was therefore decided that work would focus on the 
production of this recombinant AK as this would enable production of sufficient quantities 
to enable preparation of a large batch of AK for use in conjugations to anti-PrP antibodies. 
The yield of this recombinant AK was substantially greater than found with Sulfolobus 
acidocaldarius recombinant AK within pET 3a vector and was shown to be in the region 
of 5-10 mg.mL'1
4.3.4 Purification of recombinant A K
The purification of the Sulfolobus acidocaldarius recombinant AK was achieved in a two 
stage process (4.2.11). The initial stage of work on over-expression of recombinant AKs 
analysed by SDS-PAGE showed the effect o f heat treatment at 80° C. This demonstrated
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1the efficacy of this as a first stage of purification which inactivated and precipitated 
proteins derived from the host E. coli. Figure 4-4 & Figure 4-5 (Lanes 7), show Sulfolobus 
acidocaldarius recombinant AK with and without the inclusion of a heat step of 80 °C for 
20 minutes which precipitates heat labile proteins within the supernatant. SDS-PAGE 
analysis demonstrates the effectiveness of this first stage purification with removal of 
approximately 80% of the heat labile, E. coli derived protein.
Additional work took place to develop a method of further purification and this was 
achieved by an affinity purification step involving adsorption of the enzyme to a Blue 
Sepharose column, followed by specific elution with a low concentration of adenylate 
kinase co-factors (AMP+ATP in the presence of magnesium ions) (4.2.11). This was 
followed by evaluation of the additional benefit o f inclusion of a gel filtration step using a 
preparation grade Superdex column. (4.2.13). The results of a comparison of the addition 
of sequential purification steps of heat treatment; affinity purification and gel filtration are 
shown in Figure 4-6. The results of the SDS-PAGE analysis show that there was no 
additional benefit from the inclusion of this step and in fact the protein band is purified to 
near homogeneity after the first two steps and the inclusion of gel filtration results in a loss 
of sample. It was therefore decided that this step would be omitted and purification of bulk 
quantities o f Sulfolobus acidocaldarius AK would be achieved by the use of heat step 
followed by affinity purification alone.
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31 kDa
Key
1. M olecular weight markers
2. heat treated supernatant
3. A ffinity purified (5pl)
4. A ffinity purified (25pl)
5. Gel filtration peak 1(5pi)
6. Gel filtration peak l(25pl)
7. Gel filtration peak 2 (5pl)
8. Gel filtration peak 2 (25pl)
9. M olecular weight markers
Figure 4-6 SDS-PAG E analysis of com parison of Sulfolobus acidocaldarius AK
A nalysis o f  Sulfolobus acidocaldarius A K  purified  by three d ifferent m ethods; lane 2; heat treatm ent alone, 
lanes 3-4; a ffin ity  p u rification  fo llo w in g  h ea t treatm ent; lanes 5-8; heat trea tm en t / affin ity  purification  
fo llow ed  by ge l filtration . P rote ins w ere  analysed  by  SD S-P A G E  on 4-12%  Bis T ris ge ls w ith  M O Ps running 
buffer. The pro te ins w ere  v isua lised  using  C o llo ida l B lue Stain ing  kit (Inv itrogen) and  the gel using  B iorad 
gel d o cum en tation  system .
4.3.5 Calculation o f Specific Activity
The specific activity of the purified batch o f Sulfolobus acidocaldarius AK was calculated 
as 2000 units.mg"1. One unit o f specific activity is defined as that producing 1 pmol of 
AT P. m in 1 at 70 °C (4.2.10).
4.3.6 Characterisation o f dynamic range o f AK
In order to further characterise Sulfolobus acidocaldarius AK and its thermostable 
properties, it was decided to investigate the results of incubation with ADP at varying 
temperatures, to assess the effect on the production of ATP by this AK (Figure 4-7).
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Dynamic range of Sulfolobus acidocaldarius  AK with varying 
temperature
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Figure 4-7 C haracterisation of the dynamic range o f AK  over varying tem peratures
A standard  A K  assay  was carried  out by titra tin g  A K  in ten -fo ld  d ilutions over a long log range and 
incubation  w ith  A D P  w as carried  out at vary ing  tem p era tu res  o f  30, 50 and 70 °C, be fo re  co o lin g  to  room 
tem peratu re  an d  ad d itio n  o f  L /L  reagent. RLU values read  on plate lum inom eter.
The result showed that the enzyme had an exceptionally long dynamic range o f greater 
than 8 logs, which was unaffected by temperatures. This result also showed that there was 
a theoretical limit o f detection of AK o f less than 100 attograms.
4.3 . 7  Long-term storage of purified thermostable AKs
Freeze-drying was evaluated as a method for the long-term preservation and storage of 
purified thermostable adenylate kinase. This was assessed using a short time course trial 
which was achieved by freeze-drying samples o f two different batches o f purified enzyme.
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These samples were then reconstituted with water and the adenylate kinase activity of pre 
and post freeze-drying samples was calculated by a standard bioluminescent assay. There 
was an approximate 15 % loss of activity in both cases (results not shown), which was 
considered acceptable and therefore this method was considered suitable for use in the 
preparation of stocks of purified enzyme. Long term storage of adenylate kinase by this 
method however, has still to be evaluated.
4.4 Discussion
The results discussed in Chapter 3, established that successful preparation of Bacillus 
stearothermophilus AK antibody conjugates was achievable and that utilisation of the 
inherent properties of thermostability was possible to reduce background signal from other 
s of AK. It was identified however, that although the Bacillus stearothermophilus AK was 
suitable for heat steps of temperatures up to 60 °C, there was a noticeable loss of activity at 
70 °C. As the ultimate objective of the developed assay was to enable detection of 
potentially very low amounts of infectious prion material within a possible vast over­
excess of biological material such as neuronal tissue, it was imperative that the enzyme 
label was able to retain activity at temperatures sufficiently high to inactivate heat labile 
AKs and to enable sensitive detection in this format. In addition, the cost of purchasing a 
commercial AK was financially prohibitive especially to allow all the stages of the assay to 
be fully developed and optimised. Therefore an alternative AK was necessary, which 
would exhibit the robust thermostable qualities required and which could be economically 
produced in a recombinant form to enable production and purification of sufficient 
quantities to develop this assay format fully.
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During this time, a sample of plasmid DNA containing recombinant Sulfolobus 
acidocaldarius AK in the vector pET3a was kindly donated by Professor G Schaeffer 
(Vonrhein et al, 1998). This was transformed into E. coli (BL21) cells and subsequently 
over-expressed and purified to provide an initial stock of AK for use in initial 
development. However, the use of this vector was not ideal as induction of over-expression 
o f recombinant protein is not well controlled and the overall quantity of recombinant 
protein produced using this system, tends to be low. The results of initial work on over­
expression showed that this was the case with this recombinant thermostable Sulfolobus 
acidocaldarius AK and the yield was approximately 0.5 mg per Litre of culture. Therefore 
work continued to identify potentially alternative AKs with perhaps more suitable qualities 
for use and subsequent development of a more successful recombinant version.
The screening of biomass from twenty four thermophilic microorganisms resulted in the 
identification of a number of highly active and thermostable AKs, showing no appreciable 
loss of activity at temperatures of up to 80 °C and indeed, a small number retained enzyme 
activity at temperatures of 90 °C. Hence it was clear that there were several potential 
alternative AKs with superior qualities for use in the development of this assay format. 
Once candidate AKs had been identified the work then focussed on production of 
recombinant versions; however the available information on the genomic sequence of the 
identified thermophiles and AK genes was sparse. However, several thermophiles had 
published sequences of AK genes two of which were candidate AKs identified during the 
screening for thermostability. This enabled specific primers to be designed for these plus a 
number of other .thermophilic AKs for comparison (Bae, Phillips 2004; Glaser et al, 1992; 
Kath, Schmid & Schafer 1993; Okajima et a l, 2002). The thermophiles with known 
sequences were Pyrococcus abyssi, Thermatoga maritima, Sulfolobus acidocaldarius and 
Sulfolobus solfataricus.
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Work therefore concentrated on attempts to produce these four AKs recombinantly. It had 
been previously published that there was difficulties associated with efficient over­
expression of recombinant proteins from e.g. microorganisms such as archeaons or 
Clostridial neurotoxins in traditional host strains such as E. coli (Kim et al., 1998; 
Zdanovsky & Zdanovskaia, 2000). This was thought to be due to the AT rich content o f the 
Sulfolobus acidocaldarius and Clostridial neurotoxin genomes being problematic for over­
expression in the GC rich E. coli. In addition there is codon usage for arginine and 
isoleucine which are rare in E. coli. It had been hypothesised that introduction and 
amplification of these specific tRNA genes for rarely used codons can vastly improve 
levels of over-expression of the recombinant proteins in the E. coli host strain. Therefore a 
host strain was procured which expressed the rare tRNAs for use in expression o f the 
recombinant AKs (Zdanovsky & Zdanovskaia, 2000). Work therefore concentrated on 
transformation into a codon enhanced E. coli strain expressing rare tRNAs. This method 
was shown to be successful with an approximate 10-fold increase in yield to 5-10 mg per 
Litre of culture.
Attempts to produce recombinant versions of these identified AK were analysed by mini­
expression studies followed by analysis by SDS-PAGE and included heat treatment of the 
supernatants at 80 °C. The results showed that the only recombinant AKs produced from 
Sulfolobus acidocaldarius and Sulfolobus solfataricus had been successful. Further 
analysis of results of expression studies showed that Sulfolobus acidocaldarius was more 
efficiently over-expressed, therefore it was decided that this AK would become the focus 
for further development.
A purification process was developed for the recombinant Sulfolobus acidocaldarius AK
and the initial plan was to develop a three stage purification process in order to achieve
maximum purification. Analysis of the first stage of purification however, showed that the
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initial heat treatment of 80 °C for 30 minutes was an extremely efficient purification step 
which effectively removed a large proportion of the contaminating thermolabile proteins 
from the E. coli host strain and achieved approximately 80 % purity. The addition of the 
affinity purification step using adsorption to a Blue Sepharose column, followed by 
specific elution with a low concentration of adenylate kinase co-factors (4.3.4) 
demonstrated purification to near homogeneity on SDS-PAGE analysis, whereas the 
addition of a gel filtration step merely resulted in loss of sample. It was therefore decided 
that the addition of a gel filtration step during production of a batch of AK, would provide 
no additional benefit. It was clear from these results that the inherent thermostable 
properties o f the AK provided a very effective first stage purification method. The fact that 
only two purification steps were required meant that problems associated with loss of 
material during the purification process were largely avoided and enabled a preparation of 
a stock of approximately 100 mg of purified AK for use in development of the assay.
In order to carry out conjugation reactions, it was a requirement for a reliable method of 
protein estimation to be identified and a number of methods were evaluated. It was found 
however that the values given by analysis of the same sample by BCA, Biorad DC assay 
and measurement of absorbance (280 nm) were vastly different. In fact the differences 
were in the order of 100 fold between the different methods. The reasons for this were 
never resolved within the period of the project and eventually Biorad DC was used along 
with SDS-PAGE and a known standard. It was hypothesised that it may have been due to 
the structure of this AK which has been shown to be trimeric with a highly condensed 
hydrophobic structure (Vonrhein etal., 1998).
Some further investigation was carried out in order to further characterise the recombinant
Sulfolobus acidocaldarius AK and the range of activity at different temperatures. The
results were surprising as there was an expectation that the AK from a thermophile would
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have an optimum activity at temperatures required for growth of the source organism and 
for Sulfolobus acidocaldarius the optimum temperature for growth is 75 °C. The results of 
the characterisation of the AK activity showed that the enzyme was unaffected at a range 
of temperatures o f 37-70 °C. A linear range o f activity was shown over greater than 8 logs 
and demonstrated that the potential limit o f detection of this enzyme was less than 100 
attomoles. This demonstrated further the suitability of Sulfolobus acidocaldarius AK for 
use in the development of an ultra-sensitive assay format as the enzyme is clearly robust 
and likely to be unaffected by all the various assay conditions encountered but with a clear 
potential to reach very sensitive detection limits.
A method o f long term storage of the purified AK had to be established to allow the next 
stages of assay development to progress and freeze drying was shown to be suitable as it 
resulted in a fairly minimal loss of approximately 15 % of activity which was considered to 
be acceptable. The long term storage of the purified freeze dried stock of AKs was not 
formally evaluated, however it was noted that the stocks of AK stored in this way during 
the course o f this project showed no appreciable loss of activity over a time period of one 
to two years.
In summary, the results demonstrated that an alternative thermostable AK had been 
identified and recombinant version successfully produced: a purification method 
established and a substantial stock of AK of consistent quality prepared. In addition, a 
method of successful long term storage was identified. The results also demonstrated that 
this thermostable AK showed surprising versatility and the potential to attain sensitivity of 
less than 100 attomoles if used in a suitable format.
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5 Production of anti-prion polyclonal antisera
5.1 Introduction
It was considered beneficial for the project that antibodies of the desired specificities to 
PrP were developed. Antibodies produced to recombinant PrP e.g. 6H4 (Prionics) were 
available commercially but the cost was financially prohibitive, and therefore the aim was 
the production of an in-house batch of antisera suitable for use in the development of an 
ultra-sensitive prion ELISA.
One of the biggest challenges in the development of a sensitive and specific detection 
method for CJD is the nature of the infectious agent itself, which is believed to be an 
altered form of normal cellular protein, with no discovered nucleic acid, which rules out 
the use of traditional polymerase chain reaction (PCR) based assays, and this is combined 
with a lack of host immune response and therefore the use of serology (Prusiner, 1998). It 
has also been acknowledged that PrP is poorly immunogenic (Prusiner et al.,, 1993). 
Considerable difficulties have been encountered in the development of antibodies to the 
putative disease associated form PrPSc, because of the misfolded protein conformation 
therefore resulting in few disease specific epitopes for targeting. Only a few antibodies 
have been described to date that claim to detect PrPSc and distinguish it from PrPc (Korth et 
al, 1997; Moroncini et al., 2004; Paramithiotis et al., 2003).
A strategy was therefore designed to boost antibody responses to the antigen in order to 
generate polyclonal sera which would hopefully fulfil this purpose. This involved the 
design of peptides based on highly conserved regions of mouse, bovine and human PrP 
(Wopfner et al, 1999). This was combined with a novel method of antigen presentation
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and the use of an unusual prime / boost strategy to produce polyclonal sera (De Silva, 
Egodage & Wilson 1999; van der Werf et al„ 1994). The aim was to characterise the 
produced antisera for reactivity with recombinant PrP, non-infectious mouse brain and 
infectious mouse brain to determine suitability for use in the development of this assay.
5.2 Materials and Methods
5 .2 .1 Design of prion derived peptides
Six regions of high homology between mouse, human and bovine prion protein amino acid 
sequences were selected for peptide synthesis and antibody production (Wopfner et a l, 
1999). These peptides were synthesised commercially with an N- terminal cysteine 
residues and with and / or without a C-terminal cysteine and conjugated to mycobacterial 
purified protein derivative (PPD) carrier protein to effect a more immunogenic antigen 
presentation. These mixed inocula, including structurally constrained peptides (with 
cysteine residues at both ends) and linear peptide antigens were used to immunise rabbits 
following an initial priming stage with Bacille Calmette-Guerin (BCG) (vaccine for 
intradermal use (Statens Serum Institut, Denmark). Tuberculin Purified Protein Derivative 
(PPD) (Statens Serum Institut, Denmark) is used to measure the immune response to 
persons either exposed to tuberculosis (TB) or vaccinated with BCG. The use of PPD 
combined with BCG has been postulated as an effective method for production of anti­
hapten antibodies (De Silva, Egodage & Wilson, 1999).
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Peptide la: CGGSRYPGQGSPGGC 
Peptide lb: CGGNRYPPQGGC 
Peptide lc: CKKRPKPGGGWNTGGC 
Peptide 2: CGGWGQPHGGC 
Peptide 3: CGGY ML GSAMSRPIIHFGNDYEC 
Peptide 4: CDYEDRYYRENMHRYPNQVYYRPVDC 
Peptide 5: CVNITIKQHTVTTTTKGENFTETDC 
Peptide 6: CITQYQRESQAYYQRGASC
Figure 5-1 Synthetic peptide sequences for polyclonal antisera production
These three peptides were prepared 
separately and combined for 
subsequent immunisation o f  the rabbits 
to produce sera 1
5.2.2 Polyclonal antibody production protocol
All peptides were commercially prepared (Severn Biotech) as above and also without the
C-terminal cysteine residue (designated 1 cys and 2 cys) and both forms conjugated to PPD
and keyhole limpet haemocyanin (KLH) (Sigma). The immunisation protocol was carried
out by the Biological Investigations Group (BIG) at HPA-Porton Down. This protocol
consisted of pre-immunisation of Dutch rabbits (approximately 2.5 kg) with 0.1 mL of
reconstituted freeze dried BCG in two sites, following collection of sample of 1 mL of
pre-immune sera. After a period of 4-6 weeks, the rabbits were inoculated with each
peptide-PPD conjugate composed of 0.1 mg of each of peptide 1 (a,b,c in both 1 cys and
2 cys forms) or 0.3 mg each of the 1 cys and 2 cys forms for all the other peptides,
dissolved in 1 mL 0.9 % sterile saline in an equal volume o f Freund’s incomplete adjuvant
(Sigma). This was administered as 2 aliquots of 0.75 mL and 2 aliquots of 0.25 mL. The
immune response was boosted by three further cycles of peptide-PPD conjugate injection
of four 0.25 mL aliquots prepared as described and administered at 4-6 week intervals.
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Three samples (~ 0.5-1 mL) of immune sera were taken 7-14 days after each boost cycle. 
The rabbits were immunised with 0.6 mg total of each peptide-PPD conjugate. After the 
final boost of antibody response which was confirmed by serum analysis by ELISA, 
terminal exsanguination was carried out and sera collected.
5.2.3 Monitoring of antibody titre
Antibody titres were monitored throughout by ELISA. Microtitre plates were coated with 
the appropriate synthetic peptide conjugated to an alternative carrier protein, bovine serum 
albumin (BSA) to exclude antisera produced to the carrier protein alone. KLH conjugated 
to appropriate peptides was coated at a concentration of 0.1 mg mL 1 in coating buffer 
(0.05M Sodium Carbonate buffer (BDH, UK), pH 9.6), (100 pL per well), overnight at 
room temperature, followed by a washing step and subsequent blocking with 3 % casein in 
PBS for 1 hour (200 pL per well). Anti-rabbit IgG peroxidase conjugate (Sigma) was 
added diluted in PBS+0.05% Tween-20 (PBS-T) and incubated for 1 hour at 37 °C. After 
washing, 100 pL of 3,3’,5,5’-Tetramethlybenzidene (TMB) substrate (Sigma) was added to 
the wells and incubated at room temperature for 15 minutes. The reaction was stopped by 
the addition of 100 pL of 1M sulphuric acid and absorbance (450 nm) read on a 
colourimetric plate reader (Multiskan Ascent, Thermo Life Sciences).
5.2.4 Purification of polyclonal antisera
The six antisera (denoted PAb 1-6) produced following terminal exsanguination were
initially purified by ammonium sulphate precipitation, which was achieved by the addition
of a volume of saturated ammonium sulphate solution (BDH, UK) to a concentration of
50% at 4 °C , followed by centrifugation at 13,500 rpm. The pellet was retained and re-
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dissolved in PBS and then dialysed to remove ammonium sulphate. Following this step, 
each corresponding peptide was immobilised individually on a cross-linked agarose 
support matrix using a SulfoLink Kit (Pierce), according to manufacturer’s instructions. 
The amount of peptide coupled was estimated and the efficiency of the reaction 
determined, enabling calculation of the molar equivalent of antibody to peptide. The 
peptide-affinity columns were then used for affinity purification of the polyclonal 
antibodies to their constituent peptides.
5.2.5 Characterisation of polyclonal antisera by ELISA
All the polyclonal sera (PAbl-6) were characterised by ELISA to determine specificity to 
purified recombinant PrP (rec PrP) (AbCam recombinant murine PrP). This was achieved 
by coating rec PrP onto a microtitre plate at a concentration of 0.1 pg. mL 1 and the plates 
subsequently blocked with 3% casein (skimmed milk powder), in PBS. Sera PAbl-6 and 
affinity purified sera PAbl-6 were diluted to an initial protein concentration of 25 pg.m L_1 
and then diluted (doubling dilutions) to compare detection of rec PrP. A 1:20,000 dilution 
of anti-rabbit IgG peroxidase conjugate in (PBS-T) was added to the wells and incubated 
for 1 hour at 37 °C. After washing, 100 pL o f TMB substrate (Sigma) was added to the 
wells and incubated at room temperature (RT) for 15 minutes. The reaction was stopped by 
the addition o f 100 pL of 1M sulphuric acid (Sigma) to each well and absorbance (450 nm) 
read on a colourimetric plate reader (Multiskan Ascent, Thermo Life Sciences).
5.2.6 Characterisation of polyclonal antisera by Western blot
A single infectious stock of mouse passaged BSE (301V) infectious mouse brain 
homogenate (iMBH) had been previously established by Dr Neil Raven and Mr Clive
Buswell, and kept stored at -80 °C. The method has been previously described (McLeod et
a l, 2004, Taylor et al., 2002). The stock was prepared by homogenisation of 48 infected
mouse brains in 4 volumes o f PBS and this sample was passed sequentially through
increasingly fine gauge needles (Becton Dickinson) until free flowing. Normal mouse
brain homogenate was prepared by the same method (MBH). Analysis of the detection
specificities of PAbl-6 compared to 6H4 (Prionics) was achieved by SDS-PAGE followed
by Western blotting. This was carried out using 4-12 % Bis-Tris NuPage gels in Mops
electrophoresis buffer under reducing conditions (Invitrogen). Protein bands were
visualised using Colloidal Blue Staining Kit (Invitrogen) and compared to Multi Mark
molecular weight markers (Invitrogen). Samples o f iMBH and protease digested iMBH
were prepared by the addition of 10 % (v/v) o f 20 mg mL -1 protease solution, Purafect Ox
(Genenecor) and incubation at pH 12 for 30 minutes with rec PrP included as a control.
Western blotting was used to confirm the presence of immunoreactive bands. Protein
bands resulting from SDS-PAGE electrophoresis were transferred to nitrocellulose using
400 mL of pre-prepared NuPage containing methanol (80 mL). Nitrocellulose membrane
was pre soaked for 30 seconds in methanol before rinsing briefly in water and then soaked
in ~50 ml transfer buffer for 5-10 minutes. Blotting pads and two pieces of filter paper in
transfer buffer (no air bubbles) were pre-soaked prior to opening the gel cassette and
removing the wells with a knife. The pre soaked filter paper was placed on the gel without
trapped air bubbles. The surface of the gel was moistened with transfer buffer before
positioning the presoaked nitrocellulose membrane on the gel. The sandwich was
assembled in the transfer apparatus as shown in the NOVEX instructions. Fill the chamber
with ~200 ml transfer buffer until the gel/membrane is just covered and the unit run at 20
V constant voltage for 40 min. Once transfer had been completed, the nitrocellulose
membrane was removed and then blocked overnight in PBS-T + 3% casein. The membrane
was incubated with either purified PAB1-6 described in section 5.2.4 (diluted 1:500) or the
monoclonal antibody, 6H4 (Prionics) diluted 1:10,000 in PBS-T. After washing three times
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with PBS-T, either a 1:1000 dilution of anti-rabbit IgG peroxidase (Sigma) or anti-mouse 
IgG peroxidase conjugate (Sigma) was added as appropriate and the membrane incubated 
for 1 hour at room temperature. Washing was repeated and the membrane visualised by the 
addition of TMB (Sigma).
5.3 Results
5.3.1 Characterisation of polyclonal antisera by ELISA
Antibodies were characterised by ELISA for their interaction with rec PrP (Figure 5-2, 
Figure 5-3 and Figure 5-4). Prior to affinity purification, three of the antibodies were 
shown to detect a concentration of 0.2 jig. mL of rec PrP by ELISA. After affinity 
purification, all six polyclonal antibodies showed increased titres to rec PrP. In addition, 
PAb2, 3 and 5 showed a response to recombinant PrP after affinity purification, although 
they had not previously given a result above that of the negative control (Table 5-1).
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3.500
3.000
2.500
PAb1
Affinity purified PAb1E
I  2.000
0)oc3n
o 1.50010A
<
1.000
0.500
0.000
25 12.500 6.250 3.125 1.563 0.781 0.391 0.195 0.098 0.049 0.024
Dilution of sera (protein concentration pg.ml’1)
Effect o f affinity purification on detection of recPrP by peptide 2 polyclonal sera
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Figure 5-2 Detection o f  rec PrP by affinity purified P A bl & 2
Rec P rP  was c o a ted  a t a co n cen tra tio n  o f  0.1 pg. m L 1 Sera  P A b l & 2 d ilu ted  to  25 jag. m L ' '  and  then  
dilu ted  to co m p are  de tec tio n  o f  rec PrP. A n ti-rabb it IgG  p ero x idase  conjugate (S igm a) w as added  a fte r 
w ash ing  steps and  b o u n d  an tib o d y  conjugate de tected  w ith  T M B  substrate.
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Effect of affinity purfication on detection of recPrP by peptide 3 polyclonal sera
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Effect of affinity purification on detection of recPrP by peptide 4 polyclonal sera
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Figure 5-3 Detection o f rec PrP by affinity purified PAb 3 & 4
Rec P rP  w as coated  at a con cen tra tio n  o f  0.1 jag. m L  S era  PA b3 & 4 d ilu ted  to 25 gg. m L ' '  and  then  
d ilu ted  to com p are  detection  o f  rec PrP. A nti-rabb it IgG  pero x id ase  con jugate  (S igm a) w as added  afte r 
w ash in g  steps and  bound  an tibody  conjugate  detected  w ith  T M B  substra te.
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Effect o f affinity purfication on detection of recPrP by peptide 5 po lyclonal sera
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Effect of affinity purfication on detection of recPrP by peptide 6 polyclonal sera
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Figure 5-4 Detection o f rec PrP by affinity purified PAb5 & 6
Rec PrP  was coated  a t a co n cen tra tio n  o f  0 .1 pg. m L '1 Sera PA b5 & 6 d ilu ted  to 25 jig. mL _l and then d ilu ted  
to com pare de tec tio n  o f  rec P rP . A nti-rabb it IgG  peroxidase con jugate  (S ig m a) w as added after w ash ing  steps 
and bound an tib o d y  co n ju g a te  de tec ted  w ith T M B  substrate.
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VPolyclonal Sera Number Sera (pg. mL ‘!) Affinity purified (pg. mL_1)
PAbl 25 0.1
PAb2 - 3.1
PAb3 - 3.1
PAb4 12.5 0.8
PAb5 - 0.8
PAb6 25 0.2
Table 5-1 Comparison of detection of rec PrP by PAbs.
Note: the lower figure denoting increase in sensitivity o f  detection.
5.3.2 Characterisation of polyclonal antisera by Western blot
It was clear that the anti-prion antibodies derived from the in-house polyclonal antisera, 
PAbl-6, demonstrated specificity in respect to rec PrP in both ELISA, although an affinity 
purification step was required in order for a number of the antisera. Only one antibody 
(PAb3) recognised the putative PrPSc monomer bands in corresponding Western blots 
employing BSE (301V) infectious mouse brain homogenate (Figure 5-5). Four of the 
antibodies (PAb2, PAb3, PAb5 and PAb6) identified protease-digestion resistant bands of 
higher molecular weight (up to 9 bands having an apparent molecular weight range of 
approximately 40-70 kDa). PAbl and PAb4 by contrast failed to identify any bands in 
protease-digested BSE infectious samples.
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Figure 5-5 W estern blot detection o f rec PrP and BSE (301V) iiVIBH
In fec tious M B H  w as p ro tease  d igested  w ith  P u ra fec t O x (G enencor) at 60 °C , pH  12 for 30 m inutes and 
co m p ared  to  rec PrP  control. T he blo ts w ere in cu b a ted  w ith  e ither a 1:250 d ilu tion  o f  P A b l-6  or a 1:10000 
d ilu tio n  o f  6 H 4 , fo llow ed  by incubation seco n d ary  antibody , an ti-rabb it IgG -H R P (S igm a) or a 1:1000 
d ilu tio n  o f  a n ti-m o u se  IgG -H R P (Sigm a). T he p ro te in s w ere  v isualised  using  TM B .
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These results, which are summarised in Table 5-2 were initially promising as detection of 
rec PrP had been achieved to some extent by all of the antibodies by ELISA and Western 
blot and levels of detection on ELISA had been substantially improved by affinity 
purification of the antisera. However, the results o f the Western blots were disappointing 
because although four of the antibodies (PAb2, PAb3, PAb5 and PAb6) identified protease 
resistant bands o f higher molecular weight, (up to 9 bands having an apparent molecular 
weight range of approximately 40-70kDa) only PAb3 identified the highest o f the 
characteristic PrPSc bands within the infectious MBH sample.
Polyclonal sera rec PrP iMBH
PAbl V
PAb2
PAb3 V
PAb4 V
PAb5
PAb6 V
6H4 V V
Table 5-2 Summary of detection of recPrP and iMBH by polyclonal antisera and 6H4
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5.4 Discussion
The availability of anti-prion antibodies that are capable of preferentially recognising the 
protease resistant form of PrP (PrPSc) remains a significant issue for the development of 
immunoassays (Gilch et al, 2003). The cost of commercially available antibodies is 
generally prohibitive and therefore for the progress of this project it was considered 
important to attempt to generate a source of in-house antibodies for use in the development 
of the assay. It is generally recognised that PrP is poorly immunogenic and it has been 
hypothesised to be due to the ubiquitous presence o f cellular prion proteins and the failure 
of the immune system to generate auto-antibodies (Prusiner et al, 1993). Therefore the aim 
was to employ a strategy designed to boost antibody responses to the prion mimetic 
peptides, to attempt to overcome the problems associated with generation of anti-prion 
antibodies.
An approach which has been previously been taken was the use of cyclic presentation of 
peptides to potentially enhance the immune response by providing some conformational 
similarity to native protein structure (De Silva, Egodage & Wilson, 1999; van der Werf et 
al, 1994). The peptides were therefore synthesised with N and / or C-terminal cysteine 
residue in order that both cyclic and linear peptides would be presented on conjugation to a 
carrier protein.
In addition, an alternative method was employed that utilised an alternative carrier protein, 
protein purified protein derivative (PPD), in conjunction with pre-immunisation with BCG. 
This had previously been described by researchers as a technique to improve the serum 
antigen response and production of hapten specific polyclonal and monoclonal antibodies. 
PPD is used as a measure of T-cell response to either tuberculosis or BCG and had
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therefore been suggested for use as an alternative carrier protein (De Silva, Egodage & 
Wilson, 1999). The use o f this approach was therefore adopted within this study.
Characterisation of the anti-PrP polyclonal sera produced using these strategies showed 
moderate to high titres against the immunogen itself. Further analysis by ELISA 
demonstrated that after affinity purification that all the polyclonal sera (PAbl-6) detected 
rec PrP to some extent and therefore it was anticipated that these antisera would be useful 
in the development of ultra-sensitive assay for detection o f rec PrP and infectious prion 
material. It was clear, however on further characterisation by Western blot that whilst 
PAbl, 3, 4, 5 and 6 were able to recognise rec PrP, only PAb 3 was able to recognise the 
putative PrPSc monomer in Western blots employing BSE (301V) infectious mouse brain 
homogenate (iMBH).
PAb3 and three further antibodies (PAb2, PAb5 and PAb6) also recognised a series of up 
to nine higher molecular weight bands (approximately 40-60 kDa) in protease-digested 
MBH, and with no comparable high molecular weight bands observed in non-infectious 
MBH, whereas the antibodies PAbl and PAb4 failed to identify any bands in protease- 
digested BSE infectious samples. It was hypothesised that these higher molecular weight 
bands were potentially significant and additional research was carried out which did not 
form part of this study, however it was eventually identified that these bands were 
probably caused by the presence of a bacterial contaminant in the original infectious MBH 
sample.
In both ELISA and Western blots, the commercial antibody 6H4 showed significantly
better detection of rec PrP than the in-house polyclonal antisera and additionally showed
detection of the characteristic PrPSc bands within the protease digested infectious MBH. It
was therefore apparent that despite the use of strategies to attempt to increase the success
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of the production of specific anti-prion polyclonal antibodies that the antisera produced 
were of limited use for further development of the assay.
It was therefore decided that further development of the ultra-sensitive prion ELISA would 
focus on the use of the commercially available monoclonal antibody 6H4, with the 
advantage that it would enable comparison of the detection limits achieved with other 
published material (Barletta et al., 2005; Biffiger et al., 2002; Lourenco et al., 2006).
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6 Development of ultra-sensitive prion AK-ELISA
6.1 Introduction
The potential for iatrogenic transmission o f CJD through a number of routes such as 
surgery and blood transfusion continues to be identified as an issue ( reviewed in Grassi et 
al., 2008 and Ironside, 2006). Consequently there remains an urgent requirement for 
development of reliable and suitable processes for inactivation of prions for inclusion 
within sterile service departments (SSDs) within the NHS. Alongside development of 
novel processes for removing prion infectivity on surgical instruments, there is a 
requirement for methods of validating this process. In addition there is evidence of 
transmission of vCJD through blood transfusion which has highlighted the requirement for 
a sensitive detection assay suitable for screening of blood (Llewelyn et al., 2004; Peden et 
al., 2004; Wroe et al., 2006).
Attempts by researchers to develop assays with suitable levels of sensitivity required have 
been hampered by lack of specific antibodies for the disease associated form of the prion 
protein. It was therefore decided that the priority was to focus on development of the 
detection end of the assay to enhance the overall sensitivity as far as possible. Therefore 
the potential use of a novel AK reporter enzyme was explored the possibility of increased 
detection o f prion proteins within large excesses of biological material such as neuronal 
tissue. There are a number of decontamination methodologies currently being developed 
(Baxter et al., 2005; Fichet et al., 2007; Heindl et al, (in press); Jackson et al., 2005; 
McLeod et al., 2004; Whittaker et al., 2004) and therefore there is clearly a requirement 
for a method of validation of these processes which would be suitable for use in settings 
such as SSDs.
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The focus o f this phase of the study was to use the previous findings to enable further 
development of a flexible assay format to deal with the specific requirements of TSE 
detection. One of the main aims was optimisation of all aspects of the novel assay format 
to enhance sensitivity of detection as far as possible.
In order to optimise the prion AK-ELISA all assay conditions were identified for full 
evaluation and these included:
1. Identification of optimal dilutions of antibody-AK conjugate and incubation 
conditions.
2. Optimisation of reduction of non-specific binding of antibody-AK conjugates by:
a. Comparison of blocking methods including casein, bovine serum albumin, 
(BSA) and various commercial blocking reagents (Sea Block, SuperBlock 
(Pierce)).
b. Analysis of presence of detergent e.g. Tween-20, in the conjugate diluent
3. Identification of optimal conditions for thiol- cleavage of the AK moiety from 
bound conjugate including assessment of:
a. Various cleavage methods using increasing concentrations of Dithiothreitol 
(DTT), Tris(2-carboxyethyl) phosphine hydrochloride (TCEP.HC1) and 2- 
Mercaptoethanesulfonic acid (MESNA). Efficacy of transfer was monitored 
by assessing residual AK activity in comparison to the transferred AK 
activity.
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b. Use o f different buffers and pH conditions e.g. carbonate, borate, phosphate 
and tris buffers in addition to PBS. The pH conditions assessed were 
relevant to the buffering capacity of the various solutions assessed.
c. The efficacy of cleavage was assessed at varying temperatures (20-70 °C).
4. Assessment of conditions to optimise maximise ATP generation by AK;
a. Optimisation of the concentration of the ADP substrate required by 
assessing a full range of concentrations (lpM  -  ImM).
b. Assessment of effect of temperature (37-80 °C) on generation of ATP
5. Optimisation of reduction of the non-specific background signal produced by 
contaminating AK and ATP present in tissue.
a. Determination of the optimal temperature and duration of heat inactivation 
step to effectively reduce background signal without affecting the activity of 
the thermostable AK. A range of temperatures from 50-90 °C were 
examined over a time course of 5- 30 minutes.
b. Assessment of the conditions required for effective ATP hydrolysis by 
ATPase (apyrase) followed by method of inactivation of apyrase prior to 
completing the assay. A range of conditions such as the concentration of 
apyrase required; the length of incubation followed by assessment of a 
range of temperatures to inactivate the apyrase (37-70 °C) were examined.
Further optimisation was carried out prior to performing the assay described (6.3.7) 
including:
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6. Optimisation of practical aspects of assay:
a. Comparison of methods used for heat step including evaluation of heat 
block versus PCR thermocycler.
b. Evaluation of the use of plate luminometer injectors for delivery of 
luciferin-luciferase reagent and impact on results.
7. Establishment of internal controls for use in all AK-ELISA assays
Evaluation of assays performed in order to establish a method of calculating a reliable 
assay cut-off point for identification of detection limits. The optimised AK-ELISA would 
then be used to assess limits o f detection of rec PrP and infectious prion material on the 
surface of surgical steel and within the presence of biologically relevant material and 
compared to the use of 6H4 in other published studies and also with a traditional HRP 
assay format.
6.2 Materials and Methods
6.2.1 Conjugation of 6H4 to thermostable adenylate kinase
As discussed in Chapter 5, it was decided to concentrate on the use of a commercially 
available antibody, 6H4 (Prionics) for the purposes of optimisation and evaluation of the 
novel assay format for detection of prion protein.
A 10 mg stock of freeze dried thermostable Sulfolobus acidocaldarius adenylate kinase
was reconstituted in 1 mL of distilled H2O and then dialysed against PBS (2 x 4 L)
overnight at 4 °C. 0.3 mg of the water soluble and long chain form of the
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heterobifunctional reagent, N-Succinimidyl 3-(2-pyridyldithio) propionate (sulfo-LC- 
SPDP) (Pierce) was added directly to the sample and stirred for 1 hour at room 
temperature. The derivatised AK in solution was transferred to pre-prepared dialysis tubing 
and dialysed extensively against PBS overnight at 4 °C to remove unreacted SPDP. 6H4 
was supplied as 1 mg of purified antibody within 0.5 mL of buffer and subsequently 
derivatised by the direct addition of 0.3 mg of the sulfo-LC-SPDP to this solution and 
stirring for 1 hour at room temperature. Unreacted SPDP was removed by dialysis against 
PBS. Concentration of protein was estimated using by Biorad Protein Assay and 
absorbance (595nm). The derivatised AK was reduced by the addition of dithiothreitol 
(DTT) followed by incubation for 30 min at room temperature. The DTT was removed by 
passing the sample down a PD10 column (Pierce) pre-equilibrated with PBS and 1 mL 
fractions collected. A 5:1 ratio o f AK to IgG was calculated using molar ratios and the two 
derivatised solutions combined. The reaction was stirred overnight at room temperature. 
The conjugation reaction was stopped by the addition of 10 pL of 5 mg.mL'1 solution of N- 
ethyl maleimide (Sigma) freshly prepared in anhydrous DMSO followed by incubation for 
30 minutes at room temperature and the unreacted N-ethyl maleimide removed by dialysis 
against PBS. The conjugate preparation was stored frozen at -20 °C.
6.2.2 Detection of rec PrP by optimised prion ELISA
Rec PrP (murine PrP, AbCam) was diluted to a starting concentration of 500 ng.mL'1 and 
diluted in carbonate coating buffer, pH 9.6 across the wells of a microtitre plate 
(Nunc©MaxiSorp) 100 pL / well (in duplicate) and incubated overnight at room 
temperature. The assay was controlled by inclusion of wells omitting rec PrP, 6H4-AK and 
ADP substrate respectively. The plate was sealed using a clear plate sealer (Greiner) for all 
incubation steps to protect from contamination or loss of volume.
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All washing steps were carried out on a Wellwash AC 96 well plate washer and wells 
washed (x4 ) with 300 pL PBS-Tween 0.05% (PBS-T). After initial coating of the antigen, 
unbound antigen was removed prior to blocking o f non-specific binding by the addition o f 
300 pL per well o f 5% casein diluted in PBS-T and incubated for 30 minutes at 37 °C. 
Following an additional wash step a 1:2,000 dilution o f 6H4-AK conjugate diluted in 5% 
casein / PBS-T was added followed by incubation for 1 hour at room temperature while 
shaking gently at -150  rpm in a microtitre plate incubator / shaker (Heidolph Titramax 
1000). Following incubation with conjugate, the plate was washed prior to addition o f a 25 
mM solution of 2-mercaptoethane sulfonate (MESNA) (Sigma) diluted in 50 mM Tris- 
HC1, pH 7.2 which was further incubated at 45 °C for 30 minutes. The contents o f the 
plate were transferred to a white luminometer plate using a multi-channel pipette. The plate 
was placed in a thermocycler or heat block (Eppendorf) for the heat inactivation step at 80 
°C for 20 minutes to inactivate contaminating thermolabile AK, followed by addition o f 5 
pL / well o f apyrase (Luminase, Celsis, reconstituted in PBS) for inactivation o f 
contaminating ATP present prior to ATP generation. 100 pL of 135 pM ADP (Celsis) 
prepared in 15 mM MgAc, 1 mM EDTA, pH 6.8.and added to appropriate wells followed 
by incubation for 20 min at 70 °C using a PCR thennocycler or heat block (Eppendorf). 
ATP reagent (Biothema L / L reagent) was added to each well (30pl) either using a m ulti­
channel pipette or Luminometer injection system (Berthold Orion) before reading o f the 
relative light units (RLUs) generated by ATP.
6.2.3 Detection o f PrP in situ on the surface o f surgical instruments
Surgical grade stainless steel disks of (5 mm diameter) (Goodfellow; Cambridge Ltd) were 
placed and glued in the bottom of a microtitre well. These were coated by carefully placing
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solution of rec PrP and / or non-infectious mouse brain homogenate (MBH) in coating 
buffer (100 pL) on the surface of the disk and incubating overnight at room temperature. 
The unbound antigen was removed by washing with PBS-T before addition of 100 pL of a 
1:2,000 dilution of 6H4-AK conjugate within PBS-T + 5% casein and incubated for 1 hour 
at room temperature. After another wash step, the AK was cleaved from the bound 
conjugate by treatment with lOOpl of 25 mM MESNA in 50 mM Tris -HC1 pH 7.2 at 45 
°C for 30 minutes. The contents of the microtitre well were transferred to a white 
thermocycler compatible microtitre plate. Thermal inactivation of contaminating AK was 
achieved by heating to 80 °C for 10 minutes. Apyrase (Celsis) (5 pL) of was added to each 
well and incubated at 37 °C for 30 minutes followed by inactivation of the apyrase by 
incubation at 65 °C for 10 minutes. 100 pL of 135 pM ADP (Celsis) prepared in 15 mM 
MgAc, 1 mM EDTA, pH 6.8.was added to appropriate wells and incubated for 20 min at 
70 °C using a heat block (Eppendorf). The luminometer injection system was primed with 
ATP reagent (Biothema L / L reagent). The microtitre plate was cooled to room 
temperature before addition of 30 pi per well.
6.2.4 Detection of rec PrP present in neuronal tissue
This assay was carried out as the method described above (6.2.2), with the exception that 
rec PrP was diluted into a two different concentrations of non-infectious mouse brain 
homogenate (MBH) at 5,000 and 50,000 fold excess. The assay was then completed as 
described (6.2.2).
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6.2.5 Detection of rec PrP present in whole blood
This assay was carried out as the method described above (6.2.2), with the exception that 
rec PrP was diluted into sheep’s blood (TCS Biosciences). The assay was then completed 
as described (6.2.2).
6.2.6 Detection of rec PrP present in sera
This assay was carried out as the method described (6.2.2); with the exception that rec PrP 
was diluted into undiluted sheep’s sera (Sigma). The assay was then completed as 
described (6.2.2).
6. 2.7 Detection of infectious MBH (non-proteinase K digested)
A single infectious stock of mouse-passaged BSE (301V) infectious mouse brain 
homogenate was established as described (McLeod et al., 2004; Taylor et al., 2002) by Dr 
Neil Raven and Mr Clive Buswell. Titration of this material by dilution and re-inoculation 
into indicator mice identified a titre of approximately 108 9 infectious units per gram mouse 
brain. A batch non-infectious mouse brain homogenate was prepared and stored. The 
iMBH was diluted from a starting concentration of 1 mg.mL'1 in coating buffer (100 pL) 
and incubated overnight at room temperature. The assay was then completed as described 
in section 6.2.2.
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6.2.8 Detection of iMBH in situ on surface of surgical steel disks
The infectious mouse brain homogenate (iMBH) was prepared as described previously 
(6.2.7). Surgical grade stainless steel disks of (5 mm diameter) (Goodfellow; Cambridge 
Ltd) were placed in the bottom of a microtitre well. Infectious mouse brain homogenate 
was prepared as described (6.2.7). The iMBH was diluted from a starting concentration of 
1 ng.mL'1 and diluted in coating buffer (100 pL) and incubated overnight at room 
temperature. The assay was then completed as described in section 6;2.2.
6.2.9 Comparison of assay formats
Detection o f rec PrP using 6H4 within an HRP assay format was carried out by the 
following method. Rec PrP (recombinant murine PrP, AbCam) was diluted to a starting 
concentration of 500 ng.mL'1 and diluted in carbonate coating buffer, pH 9.6 across the 
wells of a microtitre plate (Nunc©MaxiSorp) (100 pL ) followed by overnight incubation 
at room temperature. The assay was controlled by the addition of three controls which 
omitted antigen; primary antibody; and secondary antibody respectively. The plate was 
sealed with a clear plate sealer (Greiner) to protect from contamination or loss of volume 
during incubation and heat steps.
All washing steps were carried out on a Wellwash AC 96 well plate washer and wells 
washed (x4) PBS-T. The plate was washed prior to blocking of non-specific binding by the 
addition o f (300 pL) of 5% casein diluted in PBS-T to the wells and incubation for 30 
minutes at 37 °C. A 1:5000 dilution of 6H4 (Prionics) was added to the wells (100 pL) 
diluted in PBS-T + 5% casein and incubated at 37 °C for 1 hour. The solution was 
removed by washing wells, before addition of 1:20, 000 dilution o f anti-mouse IgG
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peroxidase conjugate (Sigma) which was incubated for 1 hour at 37 °C. Following 
incubation the wells were washed as previously described and then tetramethlybenzidene 
(TMB) substrate (Sigma) was added (100 pL) and incubated for 15 minutes at room 
temperature. Colour development was stopped by the addition of 1M sulphuric acid (100 
pL). Absorbances (450nm) were read using Multiskan plate reader (Labsystems).
6.3 Results
6.3.1 Optimisation of AK- ELISA detection of rec PrP
As discussed in section 6.2.2 it was decided that further development of the assay would 
focus on the use of rec PrP in combination with 6H4-AK conjugate as previous results 
obtained had shown that this conjugate achieved the most sensitive detection of rec PrP. 
This gave an additional benefit in that it allowed the optimisation stages to be carried out 
without the requirement for the use of infectious material and containment facilities. The 
parameters evaluated to optimise the assay are fully described in section 6.2.2 and the 
results are as follows:
1. Optimal dilutions of conjugate and incubation conditions.
The optimal dilution of 6H4-AK conjugate was determined as a dilution of 1:2,000 
dilution with PBS-T containing 5% casein followed by incubation for 1 hour at room 
temperature.
2. Optimisation of blocking of non-specific binding of the antibody-AK conjugates. 
Optimal blocking of non-specific binding was obtained using a solution of 5% casein 
in PBS-T and incubation for 30 minutes at 37 °C.
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3. Identification of optimal conditions for cleavage of AK from bound conjugate.
The results were assessed by examination of the residual AK activity versus transferred 
AK following transfer and washing of plate, which enabled comparison of the efficacy 
of the various methods assessed. All of the methods assessed resulted in approximately 
80-85% cleavage of the AK. The use of MESNA was chosen ultimately because it is 
relatively inexpensive and non-toxic at a concentration of 25 mM and incubation at 45 
°C for 30 minutes.
4. Optimal ATP generation by AK
The optimal quantity of ADP was determined to be as 100 pL of a 135 pM solution of 
ADP (Celsis) diluted in magnesium acetate buffer containing 1 mM EDTA with 
optimal incubation defined as 70 °C for 20 minutes.
5. Optimisation of reduction of non-specific background signal by contaminating AK 
and ATP present in tissue.
A heat treatment step o f 80 °C for 10 minutes was sufficient to inactivate 
contaminating thermolabile AK activity even from vast excess of biological material, 
without affecting the activity of the recombinant Sulfolobus acidocaldarius AK. 5 pL 
of apyrase per well followed by, incubation at 37 °C for 30 minutes was sufficient to 
inactivate even high quantities of ATP present in the solution and use of heat treatment 
at 60 °C for 10 minutes to subsequently inactivate the apyrase prior to ATP generation.
Controls were established to be included in every assay by exclusion of antigen, 6H4-AK 
conjugate and ADP substrate sequentially. In addition, a control of ATP standard 
(Biothema) was also included to ensure that the luciferin luciferase reagent was within an
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optimal range of RLUs and to allow reliable comparison between assays performed at 
different times.
6.3.2 Detection of rec PrP by fully optimised AK- ELISA
All the various conditions of the assay were fully optimised as described in sections 6.2.2 
and 6.3.1 using detection of a constant concentration of rec PrP with 6H4-AK. This 
established format was then used to determine detection limits of the assay specifically for 
rec PrP alone, before comparison within different biologically relevant substrates such as 
neuronal tissue, blood and sera and on the surface of stainless steel.
The first objective was therefore to establish sensitivity for detection of rec PrP coated 
directly on a microtitre plate and the assay was completed as described (6.2.2). The results 
shown in Figure 6-1 demonstrate that detection of 15.6 pg.mL’1 of rec PrP was achieved, 
which equates to 0.67 pM (670 fM) of rec PrP. Statistical analysis was performed using the 
Minitab programme and a paired T-test gave a probability (P) value of 0.012 (deemed 
significant if  less than 0.05) therefore demonstrating that this detection value in respect to 
the control was statistically significant. The use of statistics in repeated assays was used to 
establish a method of determining a cut-off value and this was deemed as the value of the 
control plus 3 times the standard deviation.
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Detection of recombinant PrP by AK-ELISA
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Figure 6-1 Detection o f rec PrP by PrP AK- ELISA.
R ec PrP w as coated  onto  w ell o f  a m icro titre  p late from  a starting  co n cen tra tio n  o f  125 pg.m L  1 and d ilu ted  
by doub ling  d ilu tions and  the p ro te in  de tected  using  6 H 4-A K  con jugate  as described . The assay d e tected  15.6 
p g .m L '1 and the  con tro l show n  to be s ta tistica lly  significant. (P a ired  T -T est g iv ing  a P value o f  0 .012). T he 
figu res w ere ad ju s ted  to the con tro l, (con tro l =  0).
Paired T-Test for 15.625 - control
StDev SE Mean 
831 480
0 0
831 480
15.625 
control 
Di f ference
N Mean
3 4388
3 0
3 4388
95% Cl for mean difference: (2324, 6453)
T-Test of mean difference = 0 (vs not = 0): T-Value = 9.15 P-Value = 0.012
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6.3.3 Detection of rec PrP on surfaces.
The next main objective was to determine if the use of this novel AK format would enable 
detection o f rec PrP in situ on the surface of surgical grade stainless steel in order to 
explore the potential of the developed method for use for validation of cleaning and 
sterilisation processes specifically for prion infective material. This assay which utilised 
surgical grade stainless steel disks was therefore designed as a model for this use and the 
assay carried out as described (6.2.3). The rec PrP was allowed to fully dry prior to 
completing the assay in order to mimic potential conditions encountered following surgery. 
In Figure 6-2, the results show that ~ 40 ng.mL"1 rec PrP (~1.6 nM) can be detected on 
surfaces relevant to surgical instrument decontamination in situ.
However, compared to the results demonstrated for direct detection of rec PrP (Figure 6-1) 
the results were less sensitive with detection of nanogram levels compared to picograms. In 
addition the graph produced shows that the results on dose response were not linear. It was 
hypothesised that this may be due to the binding characteristics of rec PrP to stainless steel, 
which has not been optimised for binding of proteins unlike that of commercially available 
microtitre plates. It was hoped that use of infectious material may be an improvement due 
to the nature of the infectious agent which is known to adhere efficiently to surfaces such 
as stainless steel. It was decided therefore, to concentrate on the potential use of the assay 
format for detection within blood and tissue until the in situ detection could be repeated 
using BSE (301V) infectious MBH. This delay was due to the lack of availability of 
suitable containment facilities until a relatively late stage of this study.
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D e t e c t i o n  o f  r e c  P r P  o n  s u r f a c e  o f  s u r g i c a l  s t a i n l e s s  s t e e l  d i s k s
1 0 0 0 0 0 0
1 0 0 0 0 0
Figure 6-2 D etection o f rec PrP on the surface of surgical stainless steel disks.
Rec PrP  w as coa ted  onto  surgical-steel grade d isks an d  the presence o f  bound  an tigen  de tected  by 6H4-AK. 
con jugate  fo llo w ed  by  the standard  A K -E L ISA . The fig u res w ere  adjusted  to contro l, (co n tro l =  0).
6.3.4 Detection o f rec PrP in a background of neuronal tissue
The previous results demonstrated that the developed assay format was capable o f very
sensitive detection o f recombinant prion material using the AK-ELISA for direct detection
within a microplate format, and to some degree o f detection on the surface o f surgical
steel. It was therefore decided to evaluate the potential of this methodology for detection of
recombinant prion material within complex biological samples. Mouse brain homogenate
(MBH) was used to simulate these conditions, as this provided a good example of the type
of tissue expected to be found on surgical instruments potentially contaminated with CJD.
In order to fully evaluate the sensitivity o f detection o f an antigen within this type of
substrate, two dilutions o f non-infectious mouse brain homogenate (MBH) were used, to
simulate worse case scenario o f detection within a vast excess of biological tissue and this
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was used to assess the limits of the assay. Figure 6-3 demonstrates the results of this assay 
with detection limits of rec PrP within both samples containing MBH at 5,000 and 50,000 
fold excess calculated as 3.91 ng.mL'1 (cut-off value calculated to be 7360 RLUs). This 
result demonstrated that utilisation of the thermostable properties of the AK reporter had 
effectively removed all contaminating AK prior to ATP generation and detection even 
from samples containing a vast excess of material. The detection of -400 pg of rec PrP was 
less than previously seen, furthermore on additional analysis of the results showed that the 
RLU value for this concentration of rec PrP was -  20,000 therefore there is clearly the 
potential for more sensitive detection of rec PrP within this existing format.
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Detection of recPrP in the presence of two concentrations of MBH
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Figure 6-3 Detection o f rec PrP in the presence of two concentrations o f MBH.
Rec PrP  w as dilu ted  in the p resence o f  tw o co n cen tra tions o f  m ouse  b ra in  hom ogenate  and bound  to an 
E LISA  plate. The rec PrP  w as de tected  using  6H 4-A K , fo llo w ed  by A T P generation  and b io lu m in escen t 
detection . T he assay  show s a lim it o f  detection  o f  3.91 ng. m L '] w ith  the assay  unaffected  by the p resen ce  o f  
d ifferen t excesses o f  M BH . T he de tection  lim it is ca lcu la ted  as negative  con tro l +  3 x standard  d ev ia tion ; the 
c u t-o ff  w as estab lished  as 7360)
6.3.5 Detection o f rec PrP within whole blood
It has been identified within recent publications that there remains an urgent requirement 
for the development o f a blood test, both as a diagnostic and for screening for blood 
donations (reviewed in Grassi et al., 2008 and Ironside, 2006). It was therefore decided 
that one focus o f the research study would be to evaluate the potential o f the developed 
AK-ELISA for this purpose. Sheep’s blood was used as it is readily available
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commercially and it was important to determine if  the sensitivity of detection would be 
affected by the presence o f whole blood components within the assay format.
Detection of recPrP spiked into whole blood
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Figure 6-4 Detection o f rec PrP spiked into whole blood.
Rec PrP  (l 000  ng) w as d ilu ted  (5 -fo ld  d ilu tions) in the p resence  o f  sh e e p ’s blood and bound to a m icro titre  
p late  The rec PrP w as de tec ted  using  6H 4-A K , fo llow ed by A T P g en era tion  and b io lum inescen t d e tection  
T he assay  sh o w s a lim it o f  d e tectio n  o f  1.6 n g .m L '1 (T he detection  lim it is calcu la ted  as negative con tro l +  3 
x standard  d ev ia tion  and c u t-o ff  calcu la ted  as 10495)
This assay was carried out by spiking a dilution o f rec PrP within blood (6.2.5) and 
thereafter the assay was completed as standard and the results are shown in Figure 6-4. The 
results show sensitive detection of 1.6 ng.mL"1 rec PrP using this assay format within a 
substrate o f whole blood. The cut-off value was calculated as -  10,000 RLU and as the 
RLU value for the lowest concentration assessed was -40,000 RLU this again showed
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potential for more sensitive detection by further titration of rec PrP, even without further 
optimisation of the assay.
6.3.6 Detection of rec PrP within serum
In order to further explore the potential of the assay to detect prion material within blood 
and blood products, it was decided that blood sera would be used as a diluent for rec PrP to 
assess the sensitivity of the assay within this substrate. Sheep’s serum was used for the 
assay due to the commercial availability. The assay was carried out as described in 6.2.6 
and the results are shown in Figure 6-5. The limits of detection were assessed using the 
calculated cut-off value as 1.6 ng.mL'1. The results of the assays described demonstrate 
that the use of the thermostable AK within the novel format is sufficient to effectively 
remove contaminating AK and ATP present in blood and sera without compromise of the 
assay sensitivity.
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Detection of recPrP spiked into serum
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Figure 6-5 D etection of rec PrP spiked into serum .
Rec P rP  w as d ilu ted  in the p resence o f  sh e e p ’s sera and  detected  using  the A K -E L IS A  form at. The rec PrP 
w as de tected  using  6H 4-A K , follow ed by  A T P  genera tion  and b io lum inescen t d irection . T he assay  show s a 
lim it o f  d e tec tio n  o f  1.6 ng.m L"1 (T he d e tec tio n  lim it is calcu la ted  as negative  con tro l +  3 x standard  
d ev ia tio n  and  ca lcu la ted  as 10495)
6.3.7 Detection of iMBH (non-proteinase K digested)
It had been shown that sensitive detection o f recombinant prion protein was possible alone 
or within biological substrates such as neuronal tissue, blood and serum. It therefore 
remained to explore the potential of the assay for detection o f infectious prion material. 
This part o f  the project was hampered by the late availability o f suitable containment 
facilities, which impacted on the number o f assays possible using infectious material, 
therefore full evaluation o f the use o f the developed methodology for this purpose was not 
possible. An ELISA was set up using infectious MBH (iMBH) 6.2.7 and the results are
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shown as a graph in Figure 6-6. The results show detection o f 0.32 p g .m L 'o f  non­
proteinase K digested iMBH within this format.
AK ELISA- detection of iMBH (non-proteinase K digested)
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Figure 6-6 Detection o f non-proteinase K digested iM BH by AK-ELISA
The iM B H  w a s d ilu ted  d irec tly  on the p late and  d e tected  using  a standard  A K  E LISA . T he de tection  lim it is 
calcu lated  as n eg a tiv e  con tro l +  3 x standard  dev iation ; cu t - o f f  ca lcu la ted  as 544)
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6.3.8 Detection of iMBH on the surface of surgical steel disks
Detection of titration of iMBH on the surface of surgical steel disks
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Figure 6-7 Detection o f iM BH on surface of surgical steel disks
iM B H  was d ilu ted  from  a starting  concen tra tion  o f  10 00  p g .m L '1 in 5 -fo ld  d ilu tions across a m ic ro titre  plate 
con ta in ing  5 m m  surg ical g rade sta in less steel disks and  a llo w ed  to dry. A fte r w ash ing  the A K -E L IS A  w as 
carried  out as standard . The results ind icate  that there  is so m e  detection  o f  iM B H  on the su rface  as show n by 
dose response curve and  de tection  lim it o f  ~  40pg . m L '1 ach ieved .
The studies were extended to look at direct detection o f prion material on stainless steel 
disks. Figure 6-7 shows the results obtained in standard ELISA format with iMBH diluted 
and coated directly onto stainless steel disks mounted within a microtitre plate. Significant 
issues were observed with non-specific binding o f the 6H4-AK conjugate to the control 
(“unblocked” stainless steel), which made the results difficult to interpret. It was not 
possible to identify specific binding to iMBH components below the 40 pg.mL"1 (4 pg) 
shown.
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A number o f methods were investigated in order to overcome the problems of non-specific 
binding of the AK to the wells in the stainless steel disk assay e.g. methods of pre-coating 
the microtitre wells with non-binding material before the disks were glued on however this 
was not resolvable. On further investigation it was apparent that the observed background 
binding to surgical steel was due to the thermostable AK component of the conjugate 
which appears to binds very tightly to steel. The potential to use this property to model 
protein adsorption and desorption, relevant to prion-directed cleaning and decontamination 
processes, is being now being explored on separate projects taking place at HPA-Porton 
Down.
6.3.9 Comparison of AK-ELISA with HRP format
In order to asses the potential benefits of the developed AK ELISA particularly in terms of 
sensitivity and ability to detect antigen within an excess of biological material, a 
comparison was made with detection of rec PrP using a traditional HRP format. The results 
of detection of rec PrP alone by both the.AK-ELISA and with HRP assay is displayed 
alongside the results of detection of rec PrP within a complex biological background. The 
HRP assay was performed as described (6.2.9) and these results compared direct detection 
of rec PrP within a microtitre plate with detection of rec PrP within neuronal tissue and 
sera. Sensitive detection of PrP by the AK-ELISA is demonstrated with limits of 15 
pg.mL'1 (equivalent of detection of 15 pg) directly and in the presence of neuronal tissue 
and blood. The results of this comparison'demonstrate that the AK-ELISA format using 
6H4 is approximately 100-1000-fold more sensitive than the HRP assay format.
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Comparison of assay formats for detection of rec PrP
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Figure 6-8 Comparison of assay form ats
D etection  o f  rec PrP using 6H 4 and an  H R P assay  w as com pared  to d e tec tio n  usin g  the 6H 4 alone and w ith in  
a 50, 000 fo ld  excess o f  M B H  and d em o n s tra ted  that detection  using  the novel A K  -E L IS A  is 100-1000 fold 
m ore  sensitive  that trad itional H R P -E L ISA .
The limits of detection achieved by the AK-ELISA for rec PrP alone, on surgical grade 
stainless steel and within biologically relevant substrates such as neuronal tissue, blood and 
sera, are summarised in Table 6-1.
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Figure Sample Detection limit (ng.m L1)
Figure 6-1 Rec PrP (in buffer) 0.015
Figure 6-2 Rec PrP on stainless steel 40
Figure 6-3 Rec PrP within MBH 3.91
Figure 6-4 Rec PrP in whole blood 1.6
Figure 6-5 Rec PrP in serum 1.6
Figure 6-6 iMBH in buffer 320
Figure 6-7 iMBH on stainless steel 4000
Table 6-1 Summary of detection limits achieved by AK ELISA
6.4 Discussion
The ultimate goal was to develop an assay that could be routinely adopted within a hospital 
setting. Therefore, the developed ultra-sensitive assay format required the design of a 
number of unusual features to make it applicable to the specific problems associated with 
detection of prion proteins and specifically for the use for validation of cleaning and 
decontamination protocols. Thus the assay was required to be ultra sensitive and able to 
detect PrP in complex mixtures and finally to allow practical separation of the binding / 
washing and assay phases to enable use for detection on the surface of surgical 
instruments. A further aim was to assess the practicality of the design and consider 
implications for use in clinical settings and possible conversion to a high throughput 
format.
In experiments reported in Chapter 4, AK-conjugates prepared with the commercial 
antibody 6H4 showed significantly better detection of rec PrP than those produced using 
in-house polyclonal antisera. Therefore, to allow comparison of the assay results with other 
published material given the relatively poor recognition of rec PrP by the polyclonal 
antibodies and poor availability and performance of other anti-prion monoclonal 
antibodies, the 6H4 conjugate was used for further development. Therefore the focus of 
this phase of the research was to use the results reported and discussed in the previous 
chapters to enable development of a flexible ultra-sensitive assay format described, for 
evaluation for detection of prion protein alone, on the surface of surgical steel and in the 
presence of biological complex material such as tissue, blood or sera.
125
A working stock of 6H4-AK conjugate was prepared to enable development and 
optimisation of all stages of the AK-ELISA for .detection of prion protein. A number of 
parameters of the assay methodology were optimised at this stage using detection of a 
defined concentration of rec PrP with 6H4-AK. Details of all the parameters examined and 
ideal conditions identified are described in sections 6.2.2 and 6.3.1 and included 
identification of the following conditions; conjugate dilution and incubation conditions; 
blocking of non-specific binding; optimal cleavage of AK moiety from bound conjugate; 
incubation of ADP substrate for maximum ATP production; temperature and duration of 
heat inactivation steps; in addition to a number of technical features of this assay regarding 
the type of microtitre plate, heat inactivation method etc.
After the initial optimisation the bioluminescent prion AK ELISA was evaluated to 
determine the limits of detection of rec PrP alone. The results showed that the use of this 
assay had enabled detection of 15.6 pg.mL"1 o f rec PrP, thereby demonstrating the potential 
of this format to achieve high levels of sensitivity. The results were shown to be 
statistically significant and the repeated assays carried out during the optimisation phases 
were used to determine a reliable cut-off value defined as: negative control + 3 x standard 
deviation, for use in subsequent assay development.
It was clear that the assay was suitable for direct detection of antigen on the surface of a
microtitre well; therefore the next stage was to evaluate the use of the prion AK-ELISA for
detection of rec PrP on an alternative surface of surgical grade stainless steel. The use of
surgical grade stainless steel coupons was used as a model for the surface of surgical
instruments. This assay was technically difficult and quite problematic due to difficulties in
affixing the stainless steel disks to the base o f a 96 well microtitre plate and subsequent
problems associated with the disks being dislodged from this surface during the washing
procedure. In order to set up ELISA type assays there is a range of commercially available
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microtitre plates for use with a range of well defined protein binding characteristics which 
can be suited to the purpose. It was difficult however to establish the binding conditions for 
proteins to surgical steel and it was obvious during the course of establishing a limit of 
detection for this assay, that there was a problem with consistently high background counts 
even within the control wells, which was not solved by using any available blocking 
methods. Evaluation with AK alone, established that there was some suggestion that the 
AK was binding to the stainless steel and thereby causing a high background signal. 
However, despite this high background, a dose response of rec PrP was detectable using 
this assay even on the surface o f surgical steel and showed detection of approximately 40 
ng.mL'1. These results demonstrated that although there were clearly problems with some 
non-specific binding that there was a potential for further development for detection of 
prion material on surgical instruments for the validation of cleaning and decontamination 
protocols. The assay also demonstrated the use of the flexible format allowing the binding 
of the antibody-AK conjugate to be separated from the detection to enable direct detection 
on the surface of surgical instruments using this method It was also hypothesised that the 
properties of the infectious agent itself would aid binding to stainless steel mimicking the 
situation seen with surgical instruments and it was therefore anticipated that when the 
assay was repeated using infectious brain material that the results would be improved.
A further requirement of the assay was the ability to detect PrP in the presence of complex 
biological samples. One o f the samples examined as being relevant to likely end use for the 
assay was the detection of rec PrP in the presence of non-infectious mouse brain 
homogenate (MBH) and the results demonstrated sensitive detection of rec PrP within a 
vast excess of brain tissue. The use of the thermostability of the AK reporter label enabled 
detection to take place without additional steps and without compromise to sensitivity. The 
limits of detection achieved by the assay was well above the control value and suggested
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that there was the potential for increased sensitivity of detection even within this type of 
biological background and present format without additional optimisation.
Other examples of biological relevant substrates for detection which would be relevant to 
the end use are blood and sera particularly as it has been identified that there is still an 
urgent requirement for the development of blood for screening assay and also as a 
diagnostic test (Grassi et al., 2008; Ironside, 2006). In our study, experiments were carried 
out using whole blood and sera as diluents for dilutions of rec PrP and again it was 
demonstrated that very sensitive detection was achievable of 160 pg, showing that 
sensitive detection was not adversely affected by the presence of blood. At the lowest 
concentration level detected the results were still significantly above that of the control 
demonstrating that potential increases in sensitivity were possible within the existing 
format. In addition the results o f detection of rec PrP in the presence of sheep’s sera also 
demonstrated the same detection limits. The levels of infectivity present in blood has 
currently been estimated as in the range of 0.1-10 pg.mL'1 (Brown, 2001; Cervenakova et 
al., 2003). These results therefore opened up the possibility with some further optimisation 
that this assay may be suitable for detection of prion material in blood products particularly 
with detection limits achieved using rec PrP alone shown to be 15.6 pg.m L1. It is therefore 
approaching the levels of sensitivity desired for this use with perhaps some additional 
optimisation to increase the levels of sensitivity of detection. However a certain amount of 
caution is required before extrapolating results obtained using recombinant version of the 
normal prion protein PrP and indeed spiked infectious brain material to detection of prion 
infectivity in blood. The actual form of the infective prions in blood is presently unknown 
however, the suggestion that its conformation may be different in circulating blood and in 
brain tissue suggests that the problems may not only be in terms of sensitivity (Brown 
2001).
128
The assay was evaluated to detect rec PrP on surgical steel surfaces and in complex 
biological samples as analogues to the samples that would be examined in a clinical 
setting. The use of the assay to specifically detect infectious material was hampered by 
lack of suitable containment facilities to enable this work to be completed until very late 
within the duration of the project.
Using the standard mouse passaged BSE-30IV infectious mouse brain homogenate 
(iMBH) detection of PrP without proteinase K digestion was assessed and the results 
shown in Figure 6-6 showed detection limits for iMBH as 320 ng.mL'1. Due to the lack of 
a proteinase K step prior to detection, it was difficult to equate the detection limit achieved 
with levels of actual infectivity. However it had been previously noted that the relative 
proportion of disease-associated prion based on relative signal of MBH and iMBH at the 
same protein concentration demonstrated that iMBH consistently showed a 10-fold higher 
signal to MBH (results not shown) which suggested that around 90% of the signal was due 
to the disease associated form, (using the assumption that MBH contains only PrPc 
whereas iMBH contains PrPSc and PrPc). Extrapolating from the original protein 
concentration of iMBH used which was 200 mg.mL'1 (10% homogenate ~ 108 infectious 
units) the detection limit achieved was estimated as ~ 16 infectious units per well. This 
therefore demonstrates the potential sensitivity of the detection of prion infectivity using 
the AK-ELISA within this microtitre plate format.
A further attempt was made to detect iMBH on the surface of surgical Steel disks and it 
was anticipated that the use of infectious material would bind to this type of surface more 
effectively than non-infectious recombinant prion protein due to the binding characteristics 
of the altered form of the infectious protein. However detection was hampered by non­
specific binding of the AK label to the surgical steel disks. This was rather unexpected and
it has been postulated that it is due to the condensed hydrophobic nature of the AK enzyme
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(Vieille & Zeikus, 2001; Vonrhein et al., 1998). This specific property of S. acidocaldarius 
AK, although not useful for the identified purpose of this assay, is now being explored for 
use as a potential indicator method relevant to decontamination and sterilisation processes 
relevant to infective prion material.
Another measure of the increase in sensitivity of detection of rec PrP was in straight 
forward comparison to the use of 6H4 antibody using a traditional HRP format. Further 
optimisation of the AK-ELISA had taken place and which included the use of injectors to 
deliver the luciferin-luciferase reagent to improve the speed and maximise the RLU values 
obtained, combined with the use of a heat block instead of a thermocycler for the heating 
steps and microtitre plates with increased binding capacity. This fully optimised assay was 
used for comparison with detection of rec PrP using 6H4 and HRP ELISA. The results 
showed that detection using the novel assay was approximately 100-1000 fold more 
sensitive than traditional HRP-based ELISA. In addition, further optimisation of the ultra­
sensitive assay had increased detection of rec PrP to 400 fM rec PrP both directly and 
even in complex biological samples such as neuronal tissue and blood
The results therefore showed the considerable potential of this novel ultra-sensitive 
detection assay system and signified that the AK-ELISA format was suitable particularly to 
be applied for the detection of prion material in blood or other clinical samples. In order 
for the AK-ELISA format to useful for validation of surgical instrument decontamination, 
however there would need to be a substitution of the AK used as the reporter enzyme to an 
alternative AK that showed less adherent properties to stainless steel.
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7 Discussion
7.1 vCJD - a public health issue?
The possibility o f surface contamination of surgical instruments with CJD infectious 
material remains a significant public health issue raising the possibility of onward 
transmission. The total number of deaths from definite or probable vCJD is 163 to date 
(March, 2008) with a further 3 cases incubating disease (The National Creutzfeldt-Jakob 
Disease Surveillance Unit (NCJDSU) 2008) which in terms of numbers affected is 
relatively low. This has given rise to speculation that the vCJD “epidemic” is coming to an 
end and therefore no longer poses a risk to public health. However, given the widespread 
exposure o f the UK population to BSE in the 1980s and early 1990s, it is possible that 
there are significant numbers of people incubating the disease. This possibility has been 
strengthened by the publication of a prevalence study, (Hilton et al, 2004a) which 
retrospectively examined appendix and tonsil pathology samples. The results indicated that 
numbers may be significantly higher than the current known clinical cases. Furthermore, 
whilst all the clinical cases of vCJD have been homozygous for methionine at codon 129, 
there is now evidence that both valine homozygous (Hilton et al., 2004a; reviewed by 
Ironside et al., 2006), and heterozygous genotypes (Peden et al., 2004) may also be 
capable of acquiring the disease. These cases are currently sub clinical in presentation, 
however the clinical outcome is unknown and there is a great deal of uncertainty 
surrounding the actual levels of risk. Studies on the human prion disease Kuru (Collinge et 
al., 2006) and also from transgenic animal studies (Bishop et al., 2006) have raised the 
possibility that very long incubation periods perhaps even extending beyond a normal 
average life span may be possible. These studies, taken in context with the results of the 
prevalence study could raise the possibility of the presence of sub clinical infections within
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the UK population. This is particularly true for persons not genetically pre-disposed to 
develop disease by being either valine homozygous or heterozygous at codon 129. 
Whether these people represent a further risk to the more susceptible individuals via 
surgery, transplant or blood transfusion remains unknown. Cases of iatrogenic 
transmission of inherited and sporadic CJD by surgery have been reported in the scientific 
literature (Brown et al., 2000; Will & Matthews, 1982). Although there are no known cases 
of iatrogenic transmission of vCJD by surgery there is convincing evidence of vCJD 
transmission by blood transfusion (Llewelyn et al., 2004; Peden et al., 2004; Wroe et al., 
2006; HPA 2007). In addition, the tissue distribution of vCJD has been shown to be 
markedly different to that of other human forms of CJD with identification of infectivity 
associated with the lymphoreticular system, including tonsil, spleen and lymph nodes 
which may mean that that iatrogenic transmission of vCJD may be a greater threat (Hilton 
et al., 2004b). In addition, a number of recently published studies have highlighted that 
current decontamination practices within sterile service departments (SSDs) may require 
general improvement as significant levels of protein surface contamination was identified 
on surgical instruments post processing and at point of use (Baxter et al., 2006; Lipscomb 
et al., 2006a; Lipscomb et al., 2006b; Murdoch et al., 2006). It is clear therefore that there 
is potential for transmission of CJD through a number of routes such as surgery and blood 
transfusion and as such there remains a risk to public health until improved cleaning and 
sterilisation techniques are in place suitable for inactivation of prion infectivity with 
practical methods of validating the process and development of a sensitive detection assay 
suitable for screening of blood (Ironside, 2006).
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7.2 Aim of research
This research project aimed to address the problems associated with sensitive detection of 
prion proteins by the development of a novel ultra-sensitive detection method based on a 
thermostable adenylate kinase (AK) reporter antibody label. To achieve these goals the 
assay needed to take into consideration the current understanding of the nature of prions in 
blood and the very clear gaps in our knowledge (particularly related to the form of prions 
in blood and the observed adherence of prions to steel surfaces), whilst maintaining a clear 
view of how such an assay would be applied by different end-users. This study describes 
the development of this methodology including investigation of potential for ATP 
generation by the enzyme to be coupled to bioluminescent detection. The developed 
methodology has the flexibility to enable direct detection on surgical instruments and 
within biological substrates such as blood and tissue with utilisation of the thermostability 
of the AK. It would also be very easy to alter the method to incorporate new reagents as 
the understanding of the nature of prions develops in the future.
7.3 Development of a model assay
Significant problems have been encountered in attempts by researchers to develop assays 
for sensitive detection of CJD and it has been hampered by lack of specific antibodies for 
the disease associated form of the prion protein. It has been acknowledged that the prion 
protein is poorly immunogenic (Prusiner et al., 1993) and due to the nature of the 
infectious agent being an altered form of a normal protein, there are few antibodies 
produced which claim to preferentially recognise the disease associated form of the protein 
(Korth et ah, 1997; Moroncini et al., 2004). Given the number of decontamination 
methodologies currently being developed (Baxter et al., 2005; Fichet et al., 2007; Heindl et
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al.,(in press); Jackson et al., 2005; McLeod et al., 2004; Whittaker et al., 2004) there is 
clearly an urgent requirement for validation of these processes other than by bioassay. It 
was decided that due to the lack of available sensitive and specific antibodies, that the 
priority was to focus on the detection end of the assay to enhance the overall sensitivity as 
far as possible.
The ultimate goal was to develop an assay that could be routinely adopted within a hospital 
setting and therefore it had to be relatively cost effective and applicable to standard 
hospital laboratories. Adenylate kinases (AKs) have been previously discussed as potential 
enzymatic reporters for conjugation to antibodies for immunoassay use (Gadow et al., 
1984). It was identified that the use o f AKs for this purpose would offer a number of 
advantages over conventional alkaline phosphatase or horseradish peroxidase conjugates 
due to the significant amplification of signal via generation of ATP, coupled to sensitive 
bioluminescence detection. This study looked at the use of mesophilic AKs for this 
purpose however had failed to generate enzymatically active antibody conjugates. For the 
purpose of this study therefore, it was decided to look at the possibility of using an 
alternative source of AKs isolated from thermophiles and hyperthermophiles for 
conjugation to antibodies, in the anticipation that the more inherently robust nature of these 
enzymes would overcome the problem of loss of enzyme activity on conjugation (Vieille 
& Zeikus 2001). Another advantage was that potential use of the inherent thermostability 
properties o f the enzymes to enable inclusion of thermal denaturation steps within the 
assay to effectively remove background signal resulting from AK present in contaminating 
tissue and therefore enable direct detection without requirement for pre-processing of the 
sample.
The use o f ATP bioluminescence has been described previously as a sensitive
methodology (reviewed by Kricka, 1995; Squirrell & Murphy, 1997). It also had the
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advantage that reagents and instrumentation are commercially available and in formats 
suitable for high throughput laboratory use or more portable applications. Many of these 
would support rapid read-out of results, perhaps suitable for use within sterile service 
departments to validate decontamination processes. The use of ATP bioluminescence has 
been extensively applied for hygiene monitoring (Stanley, 1989) and subsequently further 
refined to utilise the amplification step available by the use of recycling of ATP by AK and 
to enable specific detection of bacteria by release of internal AK from cells by bacterial 
phages (Blasco et al., 1998; Squirrell, Price & Murphy, 2002).
The use o f a thermostable AK as an enzyme reporter has not been described in the 
scientific literature; however there was clear potential for sensitive detection using the 
proposed assay format. The development of a model assay was important because it 
demonstrated the feasibility of the assay particularly that successful conjugation of an 
antibody to a thermostable AK was possible, without loss of biological activity of the 
enzyme. It also enabled establishment o f other assay parameters to overcome some of the 
practical difficulties of detection taking place on the surface of surgical instruments. This 
necessitated the development of a method to separate initial detection with generation of 
signal and therefore a method of cleavage of the AK from the bound antibody was 
developed. In addition establishment of whether it was possible to create conditions 
required to generate ATP from the enzyme reporter within this novel use of AK.
Therefore development of the model assay, using B. stearothermophilus AK was 
successful in establishing ‘proof of principle’. It also highlighted that although the 
parameters o f the assay were established in principle that in order for the proposed method 
to be used for the purpose of detection of prion protein that a number of changes to the 
format would be required. Particularly sourcing of a more thermostable AK, identification
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of a suitable anti-prion antibody, alongside optimisation of the methodology to maximise 
sensitivity.
7.4 Selection of improved thermostable adenylate kinases
The development of a model system demonstrated that the proposed assay methodology 
was possible and therefore the focus became to adapt the system to enable sensitive 
detection of infective prion material. One of the main achievements within development of 
the model assay was the successful conjugation of Bacillus stearothermophilus AK 
without loss of the enzyme activity, seen previously using mesophilic AK (Gadow et al., 
1984). It had been identified however, that the continued use of this enzyme for further 
development of the assay was not desirable, as results of heat stability studies showed that 
there was considerable loss of activity on heat steps up to 70 °C. The use of thermostable 
properties of the enzyme was crucial to enable direct detection of PrP within a potential 
excess of biological material as found on surgical instruments. This is due to the presence 
of thermolabile AK which is ubiquitous throughout cell types and therefore inclusion of 
sufficient heat steps would be a requirement of the assay. The next stage was to further 
progress the assay by identification of an alternative AK with superior qualities of 
thermostability and which could be produced recombinantly in order to enable production 
of sufficient quantities to enable development of the assay.
This was accomplished using a couple of different approaches, as the availability of a 
thermophile culture collection (CEPR Thermophile Culture Collection) meant that a 
number of thermophilic microorganisms could be screened for potential candidate AKs 
and in addition a source of recombinant Sulfolobus acidocaldarius AK in the form of a 
plasmid DNA was kindly donated by Professor G Schaeffer (Vonrhein et al., 1998). This
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was successfully transformed and over-expressed in E. coli and subsequently purified and 
provided an initial stock of AK for use in the assay development. However, it was 
identified that there was a low yield upon over-expression of 0.5 mg per Litre of culture 
meant that this was not ideal for continued use and it was also hoped that AKs with more 
desirable properties would be identified from the screening process. The results of the 
screening procedure identified some potential candidates with the desired thermostability 
and two o f these were successfully produced recombinantly, which were Sulfolobus 
acidocaldarius AK and Sulfolobus solfataricus AK and subsequently purified AK was 
conjugated successfully to anti-prion antibodies as described in Chapter 6.
The reason why thermostable AKs were able to be conjugated to antibody without
inactivation compared to mesophilic AK is not entirely clear. It is known that enzymes
isolated from thermophilic and hyperthermophilic microorganisms tend to be more
compact and denaturation resistant than mesophilic enzymes (Vieille & Zeikus, 2001). The
extreme thermostability exhibited by some AKs has resulted in studies which have aimed
to elucidate the structural and biochemical properties which confer this property (Bae,
Phillips, 2004; Bae & Phillips, 2006; Vieille & Zeikus, 2001). One of the main factors is
thought to be maintenance of flexibility of the protein molecule at the required
environmental temperatures and this is influenced by intramolecular interactions. However
even within classes of AKs that have the ability to survive at extreme temperatures there is
considerable variation. The biochemical composition and structure of AKs isolated from
the extremophiles S. acidocaldarius and S. solfataricus have been shown to be trimeric in
structure with an internal hydrophobic core and it was subsequently identified that they
belong to a novel class o f AKs (Kath, Schmid & Schafer, 1993; Okajima et al., 2002;
Vonrhein et al., 1998). It has been hypothesised that the trimeric nature of the structure
could be responsible for conferring the thermostability of the protein (Vonrhein et al.,
1998). It is tempting to postulate that it is the robustness of the protein structure as a result
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of the trimeric conformation that resulted in successful conjugation to antibodies without 
loss of biological activity. However on analysis of structural composition of B. 
stearothermophilus AK which was also conjugated successfully to antibody has revealed 
that this AK is monomeric in structure and although it is clear that this AK is less 
thermostable than S. acidocaldarius AK, conjugation to antibody was achieved without 
loss of enzyme activity (Berry, Phillips, 1998; Glaser et a l, 1992). Additional analysis of 
the structure of B. stearothermophilus AK has identified that it has a structural zinc atom 
unlike that of the AK from the mesophile Bacillus subtilis with which it has a high 
sequence identity (Glaser et al., 1992) and it has been hypothesised that it is the presence 
of this zinc atom that confers the thermostability. This has been further substantiated by a 
study of an AK from a different thermophile Thermotoga maritima which also contains a 
structural zinc, which demonstrates some suggestion that its removal results in loss of 
thermostability (Vieille et al., 2003). This is interesting, however since not all thermophilic 
AKs have this structural zinc atom; it is obviously not the only explanation in terms of 
conferring thermostability. Further investigation suggests that the balance between stability 
and flexibility is crucial for proteins to operate at their environmental temperatures and the 
differences are at the level of intramolecular interaction level (Bae & Phillips, 2004). 
Therefore there does not appear to be one common or distinct feature responsible for 
conferring thermostability or clarifying the reasons that enabled successful conjugation to 
take place for the AKs used within this study, without loss of activity in comparison 
mesophilic AKs.
The production of recombinant AKs was hampered by the comparative scarcity of known
genomic sequence for the thermophiles, however a few were available including
Pyrococcus abyssi, Thermatoga maritima, Sulfolobus acidocaldarius and Sulfolobus
solfataricus. Evaluation o f over-expression in E. coli and heat stability studies revealed
recombinant AKs produced from Sulfolobus acidocaldarius and Sulfolobus solfataricus
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AKs were the most thermostable and active enzymes and therefore work concentrated on 
these AKs for the purpose of production and purification of sufficient quantities for 
development of the assay. The thermostable nature of the proteins was able to be utilised 
within the purification process and established as a very efficient first stage of purification 
for removing a large proportion of the thermolabile proteins resulting from E. coli host 
strain and achieving approximately 80% purity before affinity purification.
One rather surprising result from the characterisation of S. acidocaldarius AK was that it 
was as active at 37 °C as at 80 °C. This has been described previously for AK isolated 
from the hyperthermophile Thermotoga neapolitana (Vieille et al., 2003). This unusual 
ability demonstrated further the suitability of the use of this enzyme for use in the 
development of an ultra-sensitive assay format as the enzyme was clearly robust and 
unlikely to be affected by all the various assay conditions encountered with a potential to 
reach very sensitive detection limits. Furthermore the enzyme activity was shown to be 
linear over greater than 8 logs and has shown considerable potential for sensitive detection 
to less than 100 attomoles.
7.5 Production of anti-prion polyclonal antisera
One of the key components for the development of an ultra-sensitive prion ELISA was the 
availability of anti-prion antibodies capable of recognising the putative disease associated 
form of PrP (PrPSc), however this remains a significant issue for the development of 
immunoassays (Gilch et al., 2003). A decision was taken that in house polyclonal 
antibodies would be produced based on a novel approach. The approach which was 
adopted within this study was to attempt to increase the antibody response to prion mimetic 
peptides by combining a method using cyclic peptides to potentially mimic native
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conformational structure of the proteins (van der Werf et al., 1994) with the use of an 
alternative carrier protein using purified protein derivative (PPD) in conjunction with pre­
immunisation with BCG which has been previously shown to boost the serum response 
(De Silva, Egodage & Wilson, 1999). For the purposes for detection on the surface of 
surgical instruments, it was not considered necessary to differentiate between the normal 
form of prion protein (PrPc) and the protease resistant form (PrPSc) because the presence of 
either isoform would indicate that the decontamination process had been inadequate. 
However for the developed assay to be suitable for other purposes such as a diagnostic or 
for screening of blood donations then preferential recognition of the putative disease 
isoform would be desirable.
Characterisation of the anti-prion polyclonal sera produced using these strategies showed 
reasonably good reactivity to the recombinant version of normal PrPc in both ELISA and 
Western blots, however the commercial antibody 6H4 showed significantly better 
detection o f rec PrP and additionally showed detection of the characteristic PrPSc bands 
within protease digested iMBH. It was therefore apparent that despite the use of strategies 
to attempt to increase the success of production of specific anti-prion polyclonal antibodies 
that the antisera produced were of limited use for the further development of the assay.
It was decided therefore that work would focus on the use of the commercially available 
monoclonal antibody 6H4, with the advantage that it would enable comparison of the assay 
results with other published material (Barletta et al., 2005; Biffiger et al., 2002; Lourenco 
et al., 2006).
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7.6 Development of an ultra-sensitive prion ELISA
7.6.1 Detection on the surface of surgical instruments
During the timescale of this project, there was significant progress in optimisation of this 
assay format for rec PrP and to some extent infectious MBH (iMBH) with some limits of 
detection established on the surface of surgical steel disks as a model for surgical 
instruments.
Surgical grade stainless steel coupons were used as model for surgical instruments for 
evaluation o f detection directly on this type o f surface. A number of unexpected problems 
were encountered specifically for detection on stainless steel disks with both the rec PrP 
and iMBH. When the assay was evaluated for detection of rec PrP on the surface of 
surgical steel coupons, the results were not as sensitive as those using a microtitre plate 
format and it was thought that this may be due to the surface of the steel not being 
designed to support binding of proteins. It was anticipated at this stage that this may be 
solved in part when detecting infectious material as the altered protein form of the 
infectious prion are known to adhere to stainless steel more readily. However on evaluation 
of the results with iMBH on the surface of surgical steel disks, it was found that there were 
similar problems as seen previously and there was evidently a high degree background 
signal that was not solved by the methods investigated. One hypothesis was that the 
relatively poor results combined with the high background signal may be due in part to the 
extremely tight adherence of the disease-associated prion material to stainless steel 
surfaces and the lack of availability of suitable epitopes for antibody binding. However, it 
was clear also that the results were also hampered by binding of the S. acidocaldarius AK 
to stainless steel surfaces in their own right, giving rise to relatively high background
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signal. This property of the thermostable S. acidocaldarius AK to bind tightly to stainless 
steel was clearly a disadvantage for the purposes of development of an assay for detection 
of prion infectivity on the surface of surgical grade steel. However, it may have potential 
use as an indicator for decontamination or cleaning processes relevant to prion 
inactivation.
The properties of adherence to surfaces like stainless steel was strangely reminiscent o f the 
prion infectious agent itself and may have something to do with the structure of the S. 
acidocaldarius AK with its trimeric structure with central (3-sheet region and highly 
condensed hydrophobic nature (Vonrhein et a l,  1998). The AKs from Sulfolobus 
acidocaldarius and Sulfolobus solfataricus which have also been shown to be trimeric 
structure may represent a separate class of AKs (Kath, Schmid & Schafer, 1993; Okajima 
et al., 2002). This raised the possibility that alternative thermostable AKs which differ in 
structure and are perhaps monomeric may have the desired thermostability and activity for 
use in the assay but without the characteristic adherence to surfaces such as stainless steel. 
Related immunoassay projects have subsequently made some progress on reducing the 
background binding to surfaces by using alternative thermostable AKs (results not shown) 
however this was after the completion of this project.
7.6.2 Detection of rec PrP
Results of detection of prion infective material on the surface of surgical steel coupons, 
was rather disappointing as although detection of rec PrP and iMBH was achieved, the 
sensitivity was rather low and the detection limits were not as sensitive as seen when using 
the traditional microtitre plate format.
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It was clear however that the developed AK-ELISA within a traditional microtitre plate 
format was capable of very sensitive levels of detection comparable with most current 
published studies. With detection limits optimised to approximately 0.6 pM (15 pg.ml'1) of 
rec PrP the assay compares favourably with other published immunoassays for PrP. 
(Grathwohl et al., 1997) report that detection of scrapie infected murine brain material by 
ELISA was as sensitive as Western blotting with detection limits in the region of 5- 20 
pg.ml'1, however additional steps were required to effectively remove the contaminating 
background biological material by detergent and protease digestion prior to detection. 
Another study (Yamamoto et al; .in press) reports detection limits for rec PrP of 20-65 
pg.ml'1 and again this assay involved a protease and detergent pre-step before detection. In 
a more direct comparison, (Biffiger et al., 2002) shows a detection limit of 30 pg.m l1 PrPSc 
using the antibody 6H4 in a luminescence-based assay. The use of a method of 
immunocapillary electrophoresis has also been evaluated for detection of abnormal prion 
protein in blood samples of CJD patients. (Lourenco et a l, 2006) however the results 
demonstrated a relatively low sensitivity of detection of rec PrP within the nM range. 
Another published study (Barletta et al., 2005) describes an unusual and rather nice 
approach which utilises a PCR reaction to amplify the signal subsequent to standard 
ELISA detection termed immuno-polymerase chain reaction (IPCR). Very sensitive 
detection has been shown using this method with detection of 1 fg.m L1 of rec PrP and 
detection of 10-100 infectious units within scrapie infected hamster brains. The researchers 
within this study have used a similar approach to that reported within this study in that the 
focus is to improve the detection end of the assay because of a lack of disease specific 
antibodies. This is clearly a novel approach with a great deal of potential, however it is 
perhaps too complex to be applied to general clinical use and there is an additional 
reported problem of false positives which it is thought to be due to inadequate proteinase K 
digestion prior to detection.
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As with any antibody based assay system, the detection limits achieved are dependant on 
the quality of the antibody used. The commercially available anti-prion antibodies, 
including 6H4 are relatively poor compared to antibodies developed for detection of other 
diseases which tend to have a better specificities and sensitivities. This has therefore been a 
.limiting factor on the ultimate sensitivity of the developed assay and availability of an 
improved antibody such as a higher affinity disease specific monoclonal antibody would be 
desirable and would provide a boost to the sensitivity.
One example would be the use of the conformation dependant specific antibody described 
in published studies (Safar et al., 2002; Safar et al., 2005). The use of this approach 
reportedly recognises the protease sensitive as well as the protease resistant forms of 
disease associated isoform PrPSc. This may be important given the recent reports of 
efficient transmission of disease despite the absence of significant levels of PrPSc 
immunoreactivity following proteinase K digestion and Western blotting (Barron et al., 
2007). However the reported detection limits of infectious prion material using this using 
this conformation specific immunoassay approach (Safar et al., 2002) is in the region of 
approximately 1 ng.mg'1 and this raises the possibility that the combination of AK-ELISA 
detection, with limits in the pg.ml''range, and a conformation specific antibody may enable 
a significant increase in sensitivity.
7.6.3 Detection in blood
During the course and subsequent to this study, three cases of vCJD attributed to blood 
transfusion have been published (Llewelyn et al., 2004; Peden et al., 2004; Wroe et al., 
2006) and a fourth announced via a press release by HPA.
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Given the current concern o f transmission o f vCJD through blood transfusion, it seemed 
prudent to look at the use o f the assay format to see if the required levels of sensitivity 
could be achieved using the AK ELISA. In order to assess the potential for this purpose, 
the assay was assessed for detection of rec PrP within whole blood and sera and the results 
reported in Chapter 6. The current estimate o f levels o f infectivity in blood used by the 
National Blood Service and others, is approximately 1-100 infectious units of vCJD prion 
agent per mL of blood which equates to around 0.1-10 pg.m L '1 prion (reviewed Brown, 
2005; Cervenakova et al., 2003). Therefore the current limits o f detection for rec PrP o f 15 
pg.m L'1 is approaching the required sensitivity for prion infectivity in blood and with some 
further optimisation it may be possible to reach the desired levels o f sensitivity. These 
results were very heartening, however caution is required when interpreting results o f an 
assay using a recombinant PrP and indeed spiked infectious brain material as the actual 
form that infective prions present in blood is as yet unknown and there is suggestion that 
the conformation within circulating blood may differ to that within brain material (Brown, 
2005).
The detection limit for non-proteinase K digested iMBH using the ultra-sensitive AK- 
ELISA was calculated as 320 ng.m L'1, which equates to approximately 16 infectious units 
if it is assumed that the majority of the signal is due to disease-associated PrP. It should be 
noted, however that these results were obtained on standard microtitre plates and the assay 
did not perform as effectively on stainless steel surfaces due to problems associated with 
the currently used S. acidocaldarius.
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7.6.4 Other applications
The AK ELISA methodology developed here for the detection of PrP is, broadly applicable 
to other assays where sensitive detection is required in complex biological mixtures. After 
the end of the period of this study, the use of the AK-ELISA format was explored further 
for other uses and the results showed exceptional levels of sensitivity. The increases in 
sensitivity were demonstrated by the substitution of the antibody labelled HRP detection 
with an AK labelled antibody. The use of this method for detection of rotavirus antigen 
showed a detection limit of 10 fg.mL'1 which was 100-fold more sensitive than the 
available kit format.
In addition, the use of the AK-ELISA for assessment of improvement of detection of 
Clostridium botulinum type B neurotoxin within an endopeptidase cleavage assay (Hallis, 
James & Shone, 1996; Shone et al., 1993; Wictome et al., 1999) demonstrated 10,000 fold 
improvement on the traditional assay (all results Murdoch, Sutton et al unpublished). 
These results show the potential of the developed novel AK-ELISA for ultra-sensitive 
detection of alternative targets with superior available antibodies.
As the novel assay format was developed during the period of study and to some extent 
subsequently afterwards, it became apparent that the uses of the assay could be varied to 
some extent depending on whether it was to be utilised for detection e.g. on the surface of 
surgical instruments; of antigen within a vast excess of biological material; or for direct 
ultra-sensitive detection using a straight forward microtitre plate format.
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7.7 Future work
Due to the fact that the period of study ended some time ago, a few of the desired future 
work goals have already been explored further. These have included further optimisation 
of the assay format, which have included modifications in the equipment used to make the 
process more stream-lined and more applicable to high throughput use.
The results of the research identified that the use of a thermostable AK within this novel 
immunoassay format was capable of very sensitive detection. This was particularly shown 
in the case of detection of rec PrP alone and within a background of biological tissue, 
blood or sera. Indeed the results of detection of rec PrP in blood approached the levels of 
sensitivity required for use for this purpose. Ideally therefore, future work would focus on 
the further development of the assay to improve the sensitivity 10-100-fold as indicated by 
current estimates of levels of prion infectivity in blood. This could be approached in a 
number of ways. Firstly the substitution of an alternative antibody to 6H4 with disease 
specific specificity would provide an immediate increase in sensitivity and applicability of 
the assay (Korth et a l, 1997; Paramithiotis et a l, 2003; Safar et a l, 2005).
The structure of the AKs isolated from thermophiles is of interest to determine and 
compare their suitability for the purpose within the assay format. This would be desirable 
to increase understanding and enable easier identification of alternative AKs with superior 
properties for this purpose. Investigation into the biochemical and protein structure of 
thermostable AKs has revealed that the reasons for thermostability of AKs is varied and 
probably multi-factorial. The choice of thermostable AK for use in the assay was limited to 
some extent by the lack of published sequence data for production of recombinant versions
148
and more suitable AKs may yet be identified which would further boost the sensitivity of 
the assay. There have been a number of studies which have shown that protein engineering 
can successfully be used to promote stability and enhanced activity of enzymes using a 
technique called directed evolution (Crameri et al., 1998; Giver et a l, 1998; Van den Burg 
et al., 1998; Zhang, Dawes & Stemmer, 1997). This is an in vitro technique which mimics 
natural evolution and has been shown to successfully increase enzyme activity or 
thermostability. One method involves the use of error prone PCR. The use o f this 
technique was shown to successfully confer thermostability and improve the activity more 
than 200 fold of an enzyme subtilisin (Zhao & Arnold, 1999). This use of this type of 
approach would seem to offer real possibilities for the production of a more active 
thermostable AK and with perhaps the desired properties of lack of surface adhesion.
Therefore in conclusion, the developed assay has demonstrated considerable potential for 
ultra-sensitive detection of prion protein and other antigens particularly for direct detection 
of antigens within biological materials such as tissue, blood or sera. There are possibilities, 
however for further improvement of sensitivity of the assay in terms of improvement of 
antibodies used and also use of potentially superior AKs either identified by further 
screening or by the use o f protein engineering techniques. The further development of this 
assay format for the specific detection of prions in blood would ideally be the main focus.
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